

RESEARCH ARTICLE

A Multicenter, Open-Label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA Smallpox Vaccine (IMVAMUNE) in 18–40 Year Old Subjects with Diagnosed Atopic Dermatitis



Richard N Greenberg^{1*}, Yadira Hurley², Dinh V. Dinh³, Serena Mraz⁴, Javier Gomez Vera⁵, Dorothea von Bredow⁶, Alfred von Krempelhuber^{6aa}, Siegfried Roesch⁶, Garth Virgin^{6ab}, Nathaly Arndtz-Wiedemann⁶, Thomas Peter Meyer⁶, Darja Schmidt⁶, Richard Nichols^{6ac}, Philip Young⁶, Paul Chaplin⁶

1 University of Kentucky School of Medicine, Lexington, KY, United States of America, **2** Saint Louis University, Department of Dermatology, Saint Louis, MO, United States of America, **3** Rx Clinical Research, Inc., Garden Grove, CA, United States of America, **4** Vallejo Dermatology Office, Vallejo, CA, United States of America, **5** Hospital Regional Lic. Adolfo Lopez Mateos, ISSSTE, Mexico City, Mexico, **6** Bavarian Nordic GmbH, Martinsried, Germany

OPEN ACCESS

Citation: Greenberg RN, Hurley Y, Dinh DV, Mraz S, Vera JG, von Bredow D, et al. (2015) A Multicenter, Open-Label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA Smallpox Vaccine (IMVAMUNE) in 18–40 Year Old Subjects with Diagnosed Atopic Dermatitis. PLoS ONE 10(10): e0138348. doi:10.1371/journal.pone.0138348

Editor: David Joseph Diemert, The George Washington University School of Medicine and Health Sciences, UNITED STATES

Received: March 30, 2015

Accepted: August 26, 2015

Published: October 6, 2015

Copyright: © 2015 Greenberg et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the paper and its Supporting Information files.

Funding: The study was funded by Bavarian Nordic through NIAID contract #N01-AI-40072 (<http://www.niaid.nih.gov/Pages/default.aspx>), and The National Institute of Allergy and Infectious Diseases (NIAID). These funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. Bavarian Nordic provided grants to Rx Clinical Research, Inc. Rx

^{aa} Current address: GlaxoSmithKline GmbH & Co., München, Germany

^{ab} Current address: Vifor Pharma Ltd, Glattbrugg, Switzerland

^{ac} Current address: NewLink Genetics / BioProtection Systems, München, Germany

* Rngree01@uky.edu

Abstract

Background

Replicating smallpox vaccines can cause severe complications in individuals with atopic dermatitis (AD). Prior studies evaluating Modified Vaccinia Ankara virus (MVA), a non-replicating vaccine in humans, showed a favorable safety and immunogenicity profile in healthy volunteers.

Objective

This Phase II study compared the safety and immunogenicity of MVA enrolling groups of 350 subjects with AD (SCORAD $\leq$ 30) and 282 healthy subjects.

Methods

Subjects were vaccinated twice with MVA, each dose given subcutaneously 4 weeks apart. Adverse events, cardiac parameters, and the development of vaccinia virus humoral immune responses were monitored.

Results

The overall safety of the vaccine was similar in both groups. Adverse events affecting skin were experienced significantly more often in subjects with AD, but the majority of these

Clinical Research, Inc. provided support in the form of salary for author DVD but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific role of this author is articulated in the 'author contributions' section. Bavarian Nordic provided support in the form of salaries for several authors (DB, AK, SR, GV, NA, TM, DS, RN, PY and PC), but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.

Competing Interests: This study was funded by Bavarian Nordic through NIAID contract #N01-AI-40072. Rx Clinical Research, Inc. received grants from Bavarian Nordic. DVD is employed by Rx Clinical Research, Inc. DB, AK, RS, GV, NA, TM, DS, RN, PY and PC were employed by Bavarian Nordic at the time of this study. The current employment is found on the title page of the submission. PC is holding patents in relation to MVA-BN (Modified Vaccinia Ankara Virus Variant, International Publication Number WO 02/42480 A2). Additional MVA-BN patents based on this patent and other MVA patents are listed in a Supporting Information file. There are no further patents, products in development or marketed products to declare. This does not alter the authors' adherence to all PLOS ONE policies on sharing data and materials.

events were mild to moderate in intensity. Seroconversion rates and geometric mean titers for total and neutralizing vaccinia-specific antibodies in the AD group were non-inferior compared to the healthy subjects.

Limitations

The size of the study population limited the detection of serious adverse events occurring at a frequency less than 1%.

Conclusion

MVA has a favorable safety profile and the ability to elicit vaccinia-specific immune responses in subjects with AD.

Trial Registration

ClinicalTrials.gov [NCT00316602](https://clinicaltrials.gov/ct2/show/study/NCT00316602)

Introduction

Smallpox is caused by Variola virus (VARV), an orthopoxvirus of the *Poxviridae* family. The disease was declared eradicated in 1980 by the World Health Organization (WHO). Serious concerns about the re-emergence of VARV persist and have led the US government to assess the potential reoccurrence of smallpox as a major bioterrorism threat [1,2].

Traditional smallpox vaccines contain replication-competent vaccinia virus (VACV), an orthopoxvirus related to VARV [1,2]. These vaccines are administered via scarification to the skin, causing a localized VACV infection that elicits a protective immune response to VARV. Although these vaccines are highly effective, their replication-competent nature can cause morbidity or even mortality. Skin complications include progressive vaccinia, eczema vaccinatum (EV), generalized vaccinia and autoinoculation [3–5].

Individuals with eczema, Atopic Dermatitis (AD) or a history of these conditions are at an increased risk of developing EV [6–8]. Historically, EV occurred at a rate of 39 cases per million vaccinations in the general population and was not limited to the vaccine recipients as contact transmission of VACV is possible [4,5]. Virus shedding following vaccination places individuals in contact with vaccine recipients at risk; there is evidence that EV may be more severe in contacts compared to vaccine recipients [4,9–11]. These observations led the Centers for Disease Control and Prevention Advisory Committee on Immunization Practices to advise against the use of traditional smallpox vaccines in individuals with skin disorders including eczema, active AD, a history of eczema or AD, and individuals who have household contacts with skin disorders.

The prevalence of skin disorders like AD or eczema could pose a serious challenge to any large-scale vaccination program that relies upon traditional smallpox vaccines. A recent survey of eczema prevalence in the USA found that as many as 31.6 million individuals met the empirical definition of eczema (i.e., itching and inflamed rash, excessive dryness, skin fold location, symptoms lasting ≥ 14 days, or associated with a physician diagnosis of asthma or of allergic rhinitis or hay fever) and 17.8 million met the more rigorous criteria for AD [12]. Further complicating any smallpox vaccination program is the observation that individual recollections regarding a history of eczema or AD are unreliable. Studies suggest that 20–40% of individuals

do not report that they or a close contact suffered from eczema or AD, even when medical records confirm the contrary [13,14]. Given the various contraindications (e.g. AD, HIV infection), up to 25% of the population would have to be excluded from vaccination [15]. Therefore there remains a need for a vaccine that can be used in individuals at increased risk of developing severe vaccine related complications.

MVA was used during the 1970s in more than 120,000 people for priming prior to administration with a traditional smallpox vaccine [16,17]. MVA was derived from the parental VACV, chorioallantois vaccinia Ankara, and essentially became replication restricted to avian and certain non-human mammalian cells [18]. MVA is being developed as a safer stand-alone smallpox vaccine. Clinical studies so far have shown that MVA is well tolerated in healthy adults and those with HIV and induces immune responses comparable to traditional smallpox vaccines [19–23]. These clinical data are supported by similar findings in animal models [24–27]. Sera from MVA vaccinated subjects neutralize VARV [28]. In a phase I clinical trial, subjects with mild AD tolerated MVA well and had humoral immune responses comparable to responses in healthy individuals [23]. We report the results of a Phase II clinical trial more thoroughly investigating the safety and immunogenicity of MVA in individuals with mild to moderate AD or a history of AD. The primary objective of the trial was to assess the humoral immune response induced by MVA in subjects with diagnosed atopic dermatitis compared to healthy subjects measured by an enzyme-linked immunosorbent assay (ELISA). The primary hypothesis is that the humoral immune response of the group with diagnosed atopic dermatitis was not statistically inferior compared to the group with healthy subjects, using the seroconversion rate measured with ELISA 2 weeks after the second vaccination with MVA as the primary endpoint. The main secondary safety objective was to detect all adverse events in the atopic dermatitis group with an incidence of at least 1:100 with at least 95% probability. Other secondary objectives were the comparison of safety and reactogenicity in both groups.

Methods

Study design and subjects

MVA smallpox vaccine (IMVAMUNE) was produced by IDT Biologika GmbH (Dessau-Roßlau, Germany) according to GMP and provided by Bavarian Nordic A/S (Kvistgaard, Denmark) in aliquots of 0.5 ml liquid-frozen vaccine containing at least 1×10^8 TCID₅₀/ml. Subjects were immunized at Weeks 0 and 4 by subcutaneous injection of a 0.5 ml dose.

This controlled, open-label Phase II study was conducted under an FDA IND. Enrollment of 18–40 year old vaccinia-naïve volunteers took place at 17 sites in the USA and 7 sites in Mexico, all according to Good Clinical Practice and the principles of the Declaration of Helsinki.

Subjects enrolled in the control group were healthy without any history of atopy; subjects enrolled for the group under investigation were diagnosed with AD. The latter included subjects with a documented history of AD with no symptoms for at least one year prior to enrollment, as well as subjects with active AD having a SCORAD ≤ 30 [29]. The first subject was screened in July 2006. The last screening took place in January 2009, the last regular study visit in April 2009 and the last follow up visit in October 2009.

The protocol was approved by independent ethics committees for each site and all volunteers provided written informed consent prior to participation in the clinical trial. Approval was granted by the following committees: Comité de Investigación. para Estudios en Humanos, Puente de Piedra No.150, Col. Toriello Guerra, Tlalpan Mexico City, Mexico 14050; Comité de Ética del Instituto Dermatológico de Jalisco, Avenida Federalismo Norte 3120 Col. Atemajac del Valle Zapopan, Jalisco, Mexico 45190; Comité de Ética de la Unidad de Investigación en

Salud de Chihuahua, Ortiz Mena 2200, Fracc. Las Palmas, Chihuahua, Chih. Chihuahua 31205; Comité de Investigación y Bioética del Hospital Adolfo López Mateos, Av. Universidad No. 1321, Col. Florida Mexico City, Mexico City 01030; Comité de Investigación y Ética de la Facultad de Medicina y Hospital Universitario "Dr. José Eleuterio González" Universidad Autónoma de Nuevo León, Av. Francisco I. Madero Pte s/n y Av. Gonzalitos s/n. Col. Mitras Centro Monterrey, Nuevo León 64460; Comité de Ética e Investigación del Hospital Juárez de México, Av. Instituto Politécnico Nacional #5160, Col. Magdalena de las Salinas, Mexico DF, CP 07760; Comité de Ética del Hospital "Doctor Ángel Leaño", Av. Dr. Ángel Leaño #500 Esq. Av. Juan Gil, Col. Los Robles, Zapopan, Jalisco, CP 45200; University of Kentucky Office of Research Integrity and Institutional Review Board, 315 Kinkead Hall, University of Kentucky; Lexington, KY 40506; IntegReview IRB, 3001 S. Lamar Blvd., Suite 210 Austin, TX 78704; Saint Louis University IRB, 3556 Caroline Street; Caroline Bldg C110, St. Louis, MO 63104; and the Northwestern University IRB, Rubloff Hall, 7th Floor; 750 N. Lake Shore Dr., Chicago, IL 60611.

Safety assessments

Safety assessments were conducted upon screening and at each of five visits during an 8 week active study period: study visits at weeks 0 (vaccination 1), 1, 4 (vaccination 2), 6 and 8. A follow-up (FU) visit or phone call was performed 28 weeks after the second vaccination. Solicited adverse events (AEs) constituted a set of pre-defined, expected local reactions and systemic symptoms. Solicited AEs were recorded on a diary card for the 8-day period following each vaccination. Unsolicited AEs were all events reported by the subject within a 29-day period after each vaccination but not already solicited in the diary card. Any cardiac symptom or electrocardiogram (ECG) change which was determined to be clinically significant and any cardiac enzyme elevation above normal were defined as AEs of special interest (AESI); cardiac enzymes were measured routinely two weeks after each vaccination. ECG assessments were performed at screening, week 1 and week 6. Any AEs that prevented daily activities or body temperatures $\geq 39^{\circ}\text{C}$ were defined as Grade ≥ 3 .

Immunogenicity assays

Blood was drawn at baseline prior to the first vaccination, 1 week and 4 weeks after the first, as well as 2 weeks and 4 weeks after the second vaccination. A sub-group of subjects had a follow-up sample drawn at least 26 weeks after their first vaccination.

Assays for ELISA and plaque reduction neutralization test (PRNT) are described in detail by Overton et al [30]. For the PRNT a different the detection limit (15) than described by Overton et al [30] was used.

Statistical methods

The safety analysis was based on the full analysis set (FAS) consisting of all subjects who received at least one vaccine dose. The immunogenicity analysis was performed on the per-protocol analysis set (PPS) comprising all subjects without major protocol violations. All protocol violations were carefully reviewed on a case-by-case basis; major violations included missed visits, missed vaccinations, missing ELISA titer data, immunosuppressive conditions or severity of illness that were exclusion criteria in the protocol, other vaccinations within 14 days of study vaccination, errors in vaccine preparation, or participation in other studies.

All statistical analyses were performed using SAS. AEs were summarized using frequency tables and differences between groups were tested using Fisher's exact test. For the primary endpoint analysis an exact 95% confidence interval for the difference in ELISA seroconversion

rates between healthy and AD subjects was calculated. If the lower limit of the interval was above -5%, then non-inferiority was concluded. A similar secondary analysis was conducted on the PRNT seroconversion rate differences. Differences in GMT were also tested using a homoscedastic t-test based on the $\log_{10}$ titers. If the lower limit of the confidence interval was above -0.176 (corresponding to a factor 1.5) for ELISA, or -0.301 (corresponding to a factor 2) for PRNT, then non-inferiority of the AD subjects to the healthy subjects was concluded.

The sample size calculation was based on the primary immunogenicity endpoint MVA-specific seroconversion rate. Assuming a significance level of 5%, a power of >80%, and an expected seroconversion rates of 99% in both groups, a sample size of 124 per group (248 in total) was estimated. In order to account for about 5% drop out rate, a total of 130 subjects per group (260 in total) were planned to be treated. However, in order to meet the safety objective of the trial, i.e. to detect adverse events with an incidence of at least 1:100 with 95% probability, a total of 350 subjects were recruited in the AD group. In order to then best compare the safety profile of the AD group to the healthy group, it was intended to recruit a roughly equal amount of healthy subjects; however, it was also planned that the recruitment would stop once 350 subjects had been recruited into the AD group.

Results

Study population

Three hundred and fifty AD subjects and 282 healthy subjects who had not been previously vaccinated against smallpox were enrolled ([Table 1](#)). 222 subjects in the AD group (63.4%) had active disease at the time of screening ([Table 2](#)). All 632 subjects received at least one dose of the MVA smallpox vaccine. [Fig 1](#) displays the disposition of subjects. Follow-up data were collected by a telephone contact 28 weeks after the second vaccination for 321 AD and 272 healthy subjects. For a subset of 76 AD and 94 healthy subjects there was an on-site visit to collect serum for immunogenicity studies.

Subject demographics and SCORAD status

Mean age, height and weight were similar in both groups. Some differences between the groups were observed in ethnic origin and gender distribution ([Table 1](#)). The mean SCORAD value of subjects with a SCORAD >0 was 18.6 ± 8.29 at screening, i.e. mild to moderate disease ([Table 2](#)). At Week 8 the number of subjects with a SCORAD > 0 was lower and their mean SCORAD was 15.7 ± 8.61 , suggesting that MVA did not exacerbate the underlying disease.

Safety and reactogenicity

Overview of adverse events (AEs). An overview of the incidence of all AEs is presented in [Table 3](#). No case of death, EV or myopericarditis occurred. There was no statistically significant difference in the frequency of AESI in both groups. The trial had been designed to detect, with a 95% probability, any safety signal occurring with a frequency of at least 1%. During the active study period, three subjects experienced a total of four serious AEs. Only one event, extraocular muscle paresis in a healthy subject, was considered as probably related to the study vaccine. One healthy subject was withdrawn from the study due to several AEs (arthralgia, nausea, abdominal pain) considered unlikely related to the study vaccine. AD subjects experienced causally related AEs more frequently than healthy subjects (67.4% vs 59.6%; $p = 0.046$, [Table 3](#)). However, this difference was mostly due to events of mild and moderate intensity. There was no statistically significant difference between the two groups in the proportion of subjects with Grade ≥ 3 causally related AEs (7.7% vs 5.7%; $p = 0.343$; AD vs healthy).

Table 1. Demographic data.

(FAS, N = 632)		Diagnosed AD (N = 350)	Healthy (N = 282)	p-Value
Age [years]	Mean ± SD	27.9 ± 6.33	27.4 ± 5.81	0.3095
	Median	27.0	26.6	
	Range	18–42	18–41	
Gender [n (%)]	Female	223 (63.7)	150 (53.2)	0.0092
	Male	127 (36.3)	132 (46.8)	
Height [cm]	Mean ± SD	166.9 ± 10.06	169.6 ± 9.72	0.0005
	Median	166.0	169.0	
	Range	137–201	145–195	
Weight [kg] ^a	Mean ± SD	73.19 ± 17.950	77.49 ± 19.779	0.0044
	Median	70.30	74.80	
	Range	40.9–138.8	40.9–175.0	
Body mass index [kg/m ²] ^a	Mean ± SD	26.20 ± 5.850	26.82 ± 6.132	0.1988
	Median	25.00	25.35	
	Range	15.9–55.3	15.7–64.3	
Ethnic origin [n (%)]	Black	33 (9.4)	24 (8.5)	0.0036
	Caucasian	125 (35.7)	124 (44.0)	
	Hispanic	134 (38.3)	109 (38.7)	
	Oriental/ Asian	49 (14.0)	20 (7.1)	
	Other	9 (2.6)	5 (1.8)	
(PPS, N = 451)		Diagnosed AD (N = 257)	Healthy (N = 194)	p-Value
Age [years]	Mean ± SD	27.6 ± 6.20	27.2 ± 5.96	0.4618
	Median	26.5	26.2	
	Range	18–42	18–41	
Gender [n (%)]	Female	165 (64.2)	101 (52.1)	0.0119
	Male	92 (35.8)	93 (47.4)	
Height [cm]	Mean ± SD	167.3 ± 10.18	170.3 ± 10.12	0.0023
	Median	166.0	170.0	
	Range	138–201	145–195	
Weight [kg] ^a	Mean ± SD	74.25 ± 18.24	76.92 ± 18.792	0.1370
	Median	72.00	74.80	
	Range	40.9–138.8	43.7–175.0	
Body mass index [kg/m ²] ^a	Mean ± SD	26.43 ± 5.913	26.44 ± 5.854	0.9960
	Median	25.30	25.15	
	Range	15.9–55.3	15.7–64.3	
Ethnic origin [n (%)]	Black	26 (10.1)	15 (7.7)	0.0010
	Caucasian	97 (37.7)	79 (40.7)	
	Hispanic	86 (33.5)	85 (43.8)	
	Oriental/ Asian	40 (15.6)	12 (6.2)	
	Other	8 (3.1)	3 (1.5)	

N = number of subjects in the specified group; n = number of subjects in the specified category; % = percentages of n based on N; AD = atopic dermatitis; FAS = full analysis set; SD = standard deviation

^a: weight determined at screening visit. PPS = Per Protocol analysis set.

doi:10.1371/journal.pone.0138348.t001

Solicited adverse events. As expected, most subjects in both groups experienced at least one solicited local AE (injection site pain, injection site erythema or injection site swelling, [Table 4](#)). Local AEs were most often of Grade 1 intensity except for injection site pain, which

Table 2. Atopic dermatitis status.

		Screening N = 350	Week 8 N = 325	P-value
AD currently active	n (%)	222 (63.4)	139 (42.8)	< 0.001
SCORAD (subjects with SCORAD >0 only)	n	220 (62.9)	136 (41.2)	< 0.001
	Mean $\pm$ SD	18.6 $\pm$ 8.29	15.7 $\pm$ 8.61	< 0.001
	Median	19.0	15.0	
	Range	0-70 ^a	0-45 ^a	

N = number of subjects in the specified group; n = number of subjects in the specified category; % = percentages of n based on N; AD = atopic dermatitis; SD = standard deviation; SCORAD = Scoring Atopic Dermatitis; ^a: 10 subjects with currently active AD had a SCORAD >30 at screening. The SCORAD is a rather subjective assessment tool. A baseline SCORAD up to 39 was considered as a minor and a baseline SCORAD > 39 as a major protocol violation. This allows for a variability of 30% in SCORAD assessment. 2 of these subjects had a SCORAD >39 and were excluded from PPS as major protocol violations. P-value is Fisher's exact test of the differences in proportions between groups or a t-test of difference in the mean SCORAD values.

doi:10.1371/journal.pone.0138348.t002

was experienced by most individuals with Grade 2 or 3 intensity. Statistically significant differences between the groups were seen for injection site erythema ($p = 0.004$) and injection site swelling ($p = 0.005$). Solicited systemic AEs (Table 5) were more frequent in subjects diagnosed with AD (70.1%) compared to healthy subjects (56.4%), a statistically significant difference ($p < 0.001$). The majority of solicited systemic AEs were considered to be causally related to the study vaccine. The duration of both solicited systemic and local AEs was similar in both groups. Taken together, the data indicate that AD subjects have slightly more solicited AEs with more intense reactions towards MVA than healthy subjects.

Unsolicited adverse events. Unsolicited AEs experienced by $\geq 2\%$ of subjects in any study group are presented in Table 6. A similar percentage of subjects reported at least one unsolicited AE (68.6% in subjects with diagnosed AD and 64.5% in healthy subjects), with most events being classified as 'systemic disorders and administration site conditions'. This was mostly due to a high rate of 'injection site pruritus', which was reported by 28.6% of the subjects in the AD group and by 17.0% of the healthy subjects, a statistically significant difference ($p < 0.001$). Rashes were observed only in isolated cases, with no trend towards a specific treatment group. In addition, AEs classified as 'skin and subcutaneous tissue disorders' were reported more frequently by AD than by healthy subjects ($p = 0.002$). Overall, more than two thirds of all unsolicited AEs in both groups were of Grade 1 intensity and Grade 3 AEs were reported in both groups with a similar frequency. Unsolicited AEs assessed as being probably or definitely related to the study vaccine occurred in 31.8% of the AD and 22.5% of the healthy subjects ($p = 0.007$) and they were usually associated with direct injection site reactions. Overall AD subjects had more skin reactions possibly, probable or definite related to the vaccine than healthy subjects, but these reactions were mostly mild or moderate and did not prevent daily activities.

Cardiac events. To determine the cardiac risk, any cardiac symptom, ECG change determined to be clinically significant, cardiac enzyme or troponin I level elevated above normal, was noted as an AESI. When AESI persisted, or if clinically indicated, the subjects were referred to a cardiologist. A transient increase in troponin I was measured for about the same percentage of subjects diagnosed with AD (15.4%) as for healthy subjects (13.1%, Table 6).

In the AD group, four subjects presented with one AESI each other than an increased Troponin I: Tachycardia and QTc prolongation of >440 msec, both assessed as unlikely related, and T wave inversion and palpitations, both considered possibly related to the study vaccine. The case of palpitations was assessed as benign by a cardiologist and symptoms resolved successfully after treatment with atenolol. A precise cause for the palpitations was not identified;




Fig 1. Disposition of subjects. AD = atopic dermatitis; n = number of subjects in the specified category; FAS = full analysis set; PPS = per-protocol analysis set. ^a: There was one subject that did not receive the second vaccination but did not terminate the study prematurely, i.e. returned for the final visit. ^b: more than one reason per subject possible. ^c: 10 subjects with currently active AD had a SCORAD >30 at screening; 2 of these subjects had a SCORAD >39 and

were excluded from PPS as major protocol violations. For the volunteers that were excluded from the PPS but had samples available, immunogenicity results were similar to those of the PPS subjects.

doi:10.1371/journal.pone.0138348.g001

however tests indicated that the subject's thyroid values were at the upper limit of normal and the ongoing concomitant medication with albuterol may have contributed. A second case of tachycardia, assessed as unrelated to the study vaccine, was recorded for one healthy subject at a follow-up visit. The heart rate had returned to normal at an additional visit. In total, four subjects were referred to a cardiologist, but with the exception of the case mentioned above, no cardiac treatment was prescribed. All events resolved without sequelae.

Serious adverse events (SAEs). During the active study period, one subject with active AD and two healthy subjects experienced a total of four SAEs. Three of them (head injury, loss of consciousness, panic attack) were assessed as not related to the study vaccine. One SAE (extraocular muscle paresis) occurring 8 days after the second vaccination was noted as probably related to the vaccine. The subject was a 28 year old healthy woman who complained of constant mixed horizontal and vertical diplopia. The ophthalmologist treated her with carbamazepine and vitamin B complex and the event resolved without sequelae. After Week 8, one healthy subject and two subjects with active AD experienced a total of four SAEs (pneumonia, asthma attack in a subject with a history of asthma, and two events of psychoneurotic disorder in one subject); all were assessed as not related to the study vaccine.

Immunogenicity

ELISA and PRNT seroconversion rates were similar for both groups at all time points (Fig 2A and 2B, Table 7). ELISA seroconversion rates peaked two weeks post second vaccination when 97.2% of AD subjects and 98.1% of healthy subjects had seroconverted. The primary endpoint of the trial was met because the ELISA seroconversion rate for AD subjects two weeks post second vaccination was non-inferior compared to that for healthy subjects. PRNT seroconversion rates peaked two weeks post second vaccination with 88.0% of the AD group and 86.0% of the healthy group seroconverting. The PRNT seroconversion rate for AD subjects two weeks post second vaccination was also non-inferior compared to that for healthy subjects.

GMTs determined by ELISA were similar for both groups at all visits, reaching a peak of 516.0 at Week 6 for the AD group, which was non-inferior to the peak of 508.8 for the healthy group (Fig 3A, Table 8) ($p < 0.0001$). The peak GMT determined by PRNT for the AD group was non-inferior compared to that of the healthy group at Week 6 (GMT of 43.0 and 38.5 in

Table 3. Subjects Experiencing at Least One Unsolicited or Solicited Adverse Events (FAS, N = 632).

Subject based	Diagnosed AD (N = 350) n (%)	Healthy (N = 282) n (%)	P-value
At least one AE documented	331 (94.6)	268 (95.0)	0.858
SAE in active study period	1 (0.3)	2 (0.7)	0.589
AESI	58 (16.6)	38 (13.5)	0.316
AE leading to withdrawal from study	0 (0.0)	1 (0.4)	0.446
Causally related AE	236 (67.4)	168 (59.6)	0.046
Causally related AE graded ≥ 3	27 (7.7)	16 (5.7)	0.343

N = number of subjects in the specified group; n = number of subjects in the specified category (with at least one adverse event); % = percentages of n based on N; AD = atopic dermatitis; AE = adverse event; AESI = adverse event of special interest; SAE = serious adverse event; related AE = AE considered by the investigator to have a possible, probable, definite or missing relationship to study medication; Grade ≥ 3 = AE which prevented normal everyday activities or body temperature $\geq 39^\circ\text{C}$; FAS = full analysis set. P-value is Fisher's exact test of the differences in proportions between groups.

doi:10.1371/journal.pone.0138348.t003

Table 4. Subjects Experiencing at Least One Solicited Local Adverse Event (8-Day Follow-Up Period after Vaccination, FAS, N = 632).

Solicited Local Event	Intensity/Size	Diagnosed AD N = 345 n (%)	Healthy N = 282 n (%)	P-value
Injection Site Pain	Total	283 (82.0)	233 (82.6)	0.916
	Grade $\geq 2^a$	152 (44.1)	117 (41.5)	0.570
	Grade $\geq 3^b$	53 (15.4)	31 (11.0)	0.126
Injection Site Erythema	Total	211 (61.2)	139 (49.3)	0.004
	≥ 30 mm (Grade 2)	66 (19.1)	35 (12.4)	0.029
	≥ 100 mm (Grade 3)	3 (0.9)	3 (1.1)	1.000
Injection Site Swelling	Total	180 (52.2)	115 (40.8)	0.005
	≥ 30 mm (Grade 2)	45 (13.0)	21 (7.4)	0.026
	≥ 100 mm (Grade 3)	1 (0.3)	2 (0.7)	0.591

N = number of subjects in the specified group; n = number of subjects in the specified category (with at least one report of a local adverse event); % = percentages of n based on N; AD = atopic dermatitis; AE = adverse event. FAS = full analysis set

^a: Injection Site Pain grade 2: pain when moving the limb

^b: Injection Site Pain grade 3: spontaneously painful. P-value is Fisher's exact test of the differences in proportions between groups.

doi:10.1371/journal.pone.0138348.t004

the AD and healthy groups respectively, ($p < 0.0001$)). Again, the GMTs on all other visits were similar for both groups. Combining both groups, there was a statistically significant correlation between ELISA and PRNT results (Fig 3B) at all time points, with Spearman correlation coefficients ranging from between 0.40 to 0.65 at the different time points. Maximum correlation was at the peak visit two weeks after the second vaccination.

Table 5. Subjects Experiencing at Least One Solicited Systemic Adverse Events (8-Day Follow-Up period After Vaccination, FAS, N = 632).

Solicited Systemic Adverse Event	Intensity	Diagnosed AD N = 345 n (%)	Healthy N = 282 n (%)	P-value
Any Solicited AE		242 (70.1)	159 (56.4)	0.001
Body temperature increase	Total number	28 (8.1)	23 (8.2)	1.000
	$\geq 39.0^\circ\text{C}$	1 (0.3)	1 (0.4)	1.000
	Grade ≥ 3 (related)	1 (0.3)	1 (0.4)	1.000
Headache	Total number	163 (47.2)	98 (34.8)	0.002
	Grade ≥ 3	26 (7.5)	9 (3.2)	0.022
	Grade ≥ 3 (related)	18 (5.2)	5 (1.8)	0.031
Myalgia	Total number	153 (44.3)	98 (34.8)	0.018
	Grade ≥ 3	14 (4.1)	9 (3.2)	0.671
	Grade ≥ 3 (related)	9 (2.6)	8 (2.8)	1.000
Chills	Total number	55 (15.9)	22 (7.8)	0.002
	Grade ≥ 3	7 (2.0)	4 (1.4)	0.762
	Grade ≥ 3 (related)	3 (0.9)	4 (1.4)	0.707
Nausea	Total number	80 (23.2)	41 (14.5)	0.008
	Grade ≥ 3	8 (2.3)	6 (2.1)	1.000
	Grade ≥ 3 (related)	5 (1.4)	4 (1.4)	1.000
Fatigue	Total number	124 (35.9)	75 (26.6)	0.013
	Grade ≥ 3	16 (4.6)	9 (3.2)	0.416
	Grade ≥ 3 (related)	9 (2.6)	5 (1.8)	0.592

N = number of subjects in the specified group; n = number of subjects in the specified category (with at least one report of a solicited systemic AE); % = percentages of n based on N; AD = atopic dermatitis; AE = adverse event; Grade ≥ 3 = AE which prevented normal everyday activities or body temperature $\geq 39^\circ\text{C}$; related AE = AE considered by the investigator to have a possible, probable or definite relationship to study medication.

doi:10.1371/journal.pone.0138348.t005

Discussion

This Phase II trial confirmed the observations from a Phase I trial that the safety and immunogenicity of MVA in individuals with active AD or a history of AD is similar to healthy individuals [23]. Unsolicited and solicited AEs reported during the study were consistent with results obtained from previously completed clinical trials with MVA [19–23].

The number of serious AEs was low, just one serious AE involving transitory ocular paralysis was assessed as probably related to the study vaccine. The impairment was limited to the extraocular inferior rectal muscle which recovered without sequelae. To date, no other similar event has been observed following administration of MVA. No other serious AE with a possible, probable or definite causal relationship occurred in the AD group, indicating with a 95% certainty that the rate of such events in subjects with AD is less than 1%.

Table 6. Subjects Experiencing at Least One Unsolicited Adverse Events (Occurring in $\geq 2\%$ of Subjects in any Study Group, FAS, N = 632).

System organ class Preferred term (MedDRA 9.0)	Diagnosed AD (N = 350) n (%)	Healthy (N = 282) n (%)	p-Value
At least one unsolicited AE	240 (68.6)	182 (64.5)	0.3083
Unsolicited AE Grade 1	298 (68.5)	432 (80.1)	0.1108
Unsolicited AE Grade 3	29 (6.7)	21 (3.9)	0.7627
Systemic disorders and administration site conditions	119 (34.0)	65 (23.0)	0.0027
Injection site pruritus	100 (28.6)	48 (17.0)	0.0007
Injection site bruising	7 (2.0)	2 (0.7)	0.3114
Injection site induration	3 (0.9)	6 (2.1)	0.1977
Investigations	63 (18.0)	46 (16.3)	0.5979
Troponin I increased	54 (15.4)	37 (13.1)	0.4273
Infections and infestations	56 (16.0)	55 (19.5)	0.2930
Nasopharyngitis	23 (6.6)	11 (3.9)	0.1582
Influenza	11 (3.1)	8 (2.8)	1.0000
Upper respiratory tract infection	6 (1.7)	9 (3.2)	0.2946
Pharyngitis	4 (1.1)	9 (3.2)	0.0916
Pharyngotonsillitis	3 (0.9)	7 (2.5)	0.1196
Gastrointestinal disorders	30 (8.6)	29 (10.3)	0.4933
Diarrhoea	9 (2.6)	7 (2.5)	1.0000
Nervous system disorders	29 (8.3)	27 (9.6)	0.5766
Headache	16 (4.6)	19 (6.7)	0.2940
Dizziness	11 (3.1)	7 (2.5)	0.8107
Skin and subcutaneous tissue disorders	35 (10.0)	10 (3.5)	0.0017
Dermatitis atopica	15 (4.3)	0 (0.0)	0.0002
Respiratory, thoracic and mediastinal disorders	16 (4.6)	25 (8.9)	0.0345
Cough	3 (0.9)	8 (2.8)	0.0705
Pharyngolaryngeal pain	2 (0.6)	8 (2.8)	0.0275
Rhinorrhoea	3 (0.9)	6 (2.1)	0.1977
Musculoskeletal and connective tissue disorders	13 (3.7)	19 (6.7)	0.1008
Injury, poisoning and procedural procedures	9 (2.6)	15 (5.3)	0.0932
Reproductive system and breast disorders	9 (2.6)	11 (3.9)	0.3683
Dysmenorrhoea	8 (2.3)	7 (2.5)	1.0000
Psychiatric disorders	7 (2.0)	9 (3.2)	0.4464
Eye disorders	7 (2.0)	3 (1.1)	0.5243

N = number of subjects in the specified group; n = number of subjects in the specified category (with at least one report of a unsolicited AE); % = percentages of n based on N; AD = atopic dermatitis; AE = adverse event; MedDRA = Medical Dictionary for Regulatory Activities; FAS = full analysis set.

doi:10.1371/journal.pone.0138348.t006




Fig 2. Seroconversion. Seroconversion rates were determined by vaccinia-specific ELISA (A) and PRNT (B). Data set is FAS (full analysis set), N = 632 (for Week 32 N = 235). Error bars represent upper and lower confidence intervals. Vaccinations were given at Week 0 and Week 4. AD = atopic dermatitis.

doi:10.1371/journal.pone.0138348.g002

Not surprisingly, AD subjects were more likely to develop 'injection site erythema' and 'injection site swelling'. However, there was no indication that vaccination with MVA worsened the intensity of AD. Some subjects in the AD group experienced a flare-up or worsening of their disease during the study, while others with active AD at screening did not show any active AD at the end of the study. This may reflect the nature of the underlying disease, which shows episodes of exacerbations as well as periods of remission [31].

While the burden of AD in the adult population is not as well characterized as in pediatric populations, based on SCORAD the population enrolled in this study was similar to the distribution of AD reported in pediatric populations [32,33]. Although individuals with severe AD (SCORAD >30) were per protocol excluded from this trial, there was no signal in this trial to suggest that MVA would not be safe for them. Historically, the severity of AD has not been associated with increased occurrence or greater severity of complications resulting from smallpox vaccination. Both persons with a history of active disease or with active disease are at risk of developing EV, suggesting an underlying "genetic" susceptibility might be the most important factor for vaccination side-effects [6]. As MVA does not replicate in human cells and is administered subcutaneously rather than by scarification, MVA vaccination should not result in any of the other adverse events associated with virus replication. While the trial was not large enough to draw definitive conclusions, it is reassuring that no case of EV or any other replication-associated adverse event occurred.

Smallpox vaccination using replicating vaccines conducted in recent years resulted in cases of myopericarditis that clustered during the second week after vaccination. The occurrence of vaccine associated myopericarditis was confirmed at a rate of 5.73 per 1,000 vaccinia-naïve vaccinees who received ACAM2000 [34,35]. Cardiac monitoring during the present trial revealed no cardiac risks related to the use of MVA, consistent with published data on cardiac monitoring following administration of MVA [36]. The vast majority of cardiac related events were Grade 1 events ('troponin I increased') that were transient and not connected to abnormal ECG findings or any cardiac symptom [37].

Table 7. Seroconversion rates for ELISA and PRNT at all post-baseline visits (FAS, N = 632).

Week	Diagnosed AD (N = 350) n SC (%)	Healthy (N = 282) n SC (%)	Difference in SC rates (95% CI) (AD–Healthy)
ELISA			
Week 1	333 74 (22.2)	267 39 (14.6)	7.6 (1.4, 13.8)
Week 4	328 276 (84.1)	273 233 (85.3)	-1.2 (-7.0, 4.7)
Week 6	325 316 (97.2)	265 260 (98.1)	-0.9 (-3.7, 1.9)
Week 8	325 311 (95.7)	264 254 (96.2)	-0.5 (-3.9, 2.9)
Week 32	111 80 (72.1)	124 87 (70.2)	1.9 (-9.9, 13.7)
PRNT			
Week 1	333 20 (6.0)	267 13 (4.9)	1.1 (-2.7, 4.9)
Week 4	327 81 (24.8)	273 64 (23.4)	1.3 (-5.6, 8.2)
Week 6	325 286 (88.0)	265 228 (86.0)	2.0 (-3.5, 7.6)
Week 8	325 253 (77.8)	264 197 (74.6)	3.2 (-3.7, 10.2)
Week 32	111 27 (24.3)	124 30 (24.2)	0.1 (-11.0, 11.3)

N = number of subjects in the specified group; n = number of subjects who had a titer available at the specified visit; SC is the number of subjects who had seroconverted.

doi:10.1371/journal.pone.0138348.t007




Fig 3. Antibody Titers. Geometric mean titers determined by vaccinia-specific ELISA (A) or PRNT (B). Data set is FAS (full analysis set), N = 632 (for Week 32 N = 235). Error bars represent upper and lower confidence intervals. Vaccinations were given at Week 0 and Week 4. AD = atopic dermatitis.

doi:10.1371/journal.pone.0138348.g003

Table 8. GMT for ELISA and PRNT at all post-baseline visits (FAS, N = 632).

Week	Diagnosed AD (N = 350) GMT (95% CI)	Healthy (N = 282) GMT (95% CI)	Ratio of GMTs (95% CI) (AD / Healthy)
ELISA			
Week 0	1.7 (1.5, 2.0)	1.4 (1.2, 1.6)	1.211 (0.984, 1.489)
Week 1	3.4 (2.7, 4.3)	2.5 (2.0, 3.1)	1.387 (1.004, 1.916)
Week 4	59.7 (49.2, 72.4)	59.7 (48.8, 73.1)	0.999 (0.755, 1.324)
Week 6	516.0 (449.7, 592.0)	508.8 (432.2, 598.9)	1.014 (0.821, 1.253)
Week 8	285.8 (247.6, 329.8)	283.8 (240.8, 334.6)	1.007 (0.811, 1.251)
Week 32	30.0 (21.0, 42.7)	22.8 (16.0, 32.4)	1.314 (0.798, 2.163)
PRNT			
Week 0	1.2 (1.1, 1.3)	1.1 (1.0, 1.2)	1.103 (0.982, 1.238)
Week 1	1.4 (1.2, 1.7)	1.3 (1.1, 1.5)	1.121 (0.924, 1.359)
Week 4	2.6 (2.1, 3.1)	2.2 (1.9, 2.7)	1.444 (0.868, 1.508)
Week 6	43.0 (35.0, 52.8)	35.5 (28.1, 44.7)	1.213 (0.890, 1.653)
Week 8	19.7 (15.9, 24.3)	14.8 (11.8, 18.6)	1.329 (0.971, 1.819)
Week 32	2.4 (1.8, 3.3)	2.3 (1.7, 3.0)	1.074 (0.713, 1.618)

N = number of subjects in the specified group.

doi:10.1371/journal.pone.0138348.t008

The trial confirmed that AD subjects were able to generate humoral vaccinia-specific immune responses at levels similar to healthy subjects, confirming earlier results in subjects with mild AD [31]. Although individuals with severe AD (SCORAD >30) were not under investigation in this the trial, it is likely that they would mount a comparable immunological response, as there is little evidence suggesting that AD has any measurable impact on immunological responses to vaccines delivered subcutaneously [38].

In summary, vaccination with MVA was equally well tolerated in both populations and elicited a robust vaccinia-specific immune response. The observation that vaccination does not have any discernible impact on the status or severity of AD suggests that MVA may represent a safer alternative to replication-competent vaccinia vaccines for individuals with AD.

Supporting Information

S1 Checklist.

(DOCX)

S1 Fig. This is the Seroconversion ELISA PPS.

(TIF)

S2 Fig. This is the Seroconversion PRNT PPS.

(TIF)

S3 Fig. This is the GMT ELISA PPS.

(TIF)

S4 Fig. This is the GMT PRNT PPS.
(TIF)

S5 Fig. These are the figure legends for the supplemental figures.
(DOCX)

S1 IRB. These are the IRB approvals for the sites in Mexico.
(DOC)

S2 IRB. These are the IRB listings.
(PDF)

S3 IRB. This is the IRB approval for Dr. Greenberg's site.
(PDF)

S1 Patents.
(DOCX)

S1 Protocol.
(PDF)

S1 Table. These are adverse events tables.
(DOCX)

S2 Table. This shows the PRNT and ELISA Titers of Subjects not in PPS.
(DOCX)

Acknowledgments

The following Investigators and Clinical Trials Sites recruited subjects for this trial: Richard N Greenberg, University of Kentucky, Lexington, KY, USA (RNG is grateful to Elizabeth Plummer, Dana Hargis, Heather Flynn, Debra Plummer, Malissia VanHook, Connie Gerardot, Stephen Sitzlar and the UK-CCTS clinic (the UK-CCTS clinic is supported by the National Center for Advancing Translational Sciences, National Institutes of Health, through grant number UL1TR000117) at the University of Kentucky for the recruitment and care of subjects.); Yadira Hurley, Saint Louis University, St Louis, MO, USA; Dinh V Dinh, Rx Clinical Research, Garden Grove, CA, USA; Serena Mraz, Solano Clinical Research, Petaluma, CA, USA; Javier Gomez Vera, Hospital Regional Lic. Adolfo Lopez Mateos, Mexico City, Mexico; Brandon Essink, Meridian Clinical Research, Omaha, NE, USA; Tyler Wadsworth, Sundance Clinical Research, St. Louis, MO, USA; Juan Galán Herrera, Operadora MSB CIF-BIOTEC, Ciudad de México, México; Dowling Stough, Burke Pharmaceutical Research, Hot Springs, AR, USA; Anne Laumann, Northwestern University, Chicago, IL, USA; Sandra González Diaz, Centro Regional de Alergia e Inmunología, Monterrey, México; Phoebe Rich, Oregon Dermatology and Research Center, Portland, OR, USA; Stefanie Lundell, Alta Clinical Research, Tucson, AZ, USA; Eduardo Tschen, Academic Dermatology Associates, Albuquerque, NM, USA; Araceli Hernandez Garcia, Unidad de Investigación en Salud de Chihuahua, Chihuahua, México; John Tu, Dermatology Associates of Rochester, Rochester, NY, USA; David Kaplan, Dr. Kaplan's Medspa Dermatology PC; Overland Park, KS, USA; Maria Mata Lara, Hospital Angel Leañol, Zapopan, Mexico; Steven Davis, Dermatology Clinical Research, San Antonio, TX, USA; Maria Rojo Gutiérrez, Hospital Juárez de México, Ciudad de México, México; Williams Abramovits, Dermatology Treatment & Research Center, Dallas, TX, USA;

Data collection, management and analyses were performed by Kendle International (Cincinnati, OH). Design and conduct of the trial were managed by Bavarian Nordic A/S. The

assistance of the following team members is appreciated: Gabriela Mancera (Kendle), Karla Guzman (Kendle), Monika Herrmann (Kendle), Petra Hanel (Kendle), Jane MacLennan (BN) and Eva Wagner (BN).

We thank Carol Ostrye and Steve Heyse from NIAID.

This study was funded by NIAID contract#N01-AI-40072.

We wish to gratefully acknowledge the trial participants that devoted their time and effort to this research endeavor.

Parts of the data have been presented at the following meetings:

69th Annual Meeting of the American Association of Dermatology in February 2011 (New Orleans): A new smallpox vaccine for people with atopic dermatitis (AD): protection for the unprotected?

2nd Israeli International Conference on Healthcare System Preparedness and Response to Emergencies and Disasters (IPRED) in January 2012 (Tel Aviv, Israel) Safety And Immunogenicity Of The Third Generation Smallpox Vaccine IMVAMUNE In Subjects With Atopic Dermatitis.

Author Contributions

Conceived and designed the experiments: DB AK NA TPM PY. Performed the experiments: RNG YH DVD SM JGV. Analyzed the data: PY. Contributed reagents/materials/analysis tools: TPM DS. Wrote the paper: RNG YH SR GV RN PC.

References

1. Henderson DA. Smallpox: Clinical and epidemiologic features. *Emerg Infect Dis* 1999 Jul; 5(4):537–9. PMID: [10458961](#)
2. Artenstein AW, Grabenstein JD. Smallpox vaccines for biodefense: need and feasibility. *Expert Rev Vaccines* 2008 Oct; 7(8):1225–37. doi: [10.1586/14760584.7.8.1225](#) PMID: [18844596](#)
3. Goldstein JA, Neff JM, Lane JM, Koplan JP. Smallpox vaccination reactions, prophylaxis, and therapy of complications. *Pediatrics* 1975 Mar; 55(3):342–7. PMID: [238178](#)
4. Lane JM, Frederick L, Ruben FL, Neff JM, Millar JD. Complications of smallpox vaccination, 1968. *N Engl J Med* 1969 Nov 27; 281(22):1201–8. PMID: [4186802](#)
5. Lane JM, Frederick L, Ruben FL, Neff JM, Millar JD. Complications of smallpox vaccination, 1968: Results of ten statewide surveys. *J Infect Dis* 1970 Oct; 122(4):303–9. PMID: [4396189](#)
6. Engler RJ, Kenner J, Leung DY. Smallpox vaccination: Risk considerations for patients with atopic dermatitis. *J Allergy Clin Immunol* 2002 Sep; 110(3):357–65. PMID: [12209080](#)
7. Vora S, Damon I, Fulginiti V, Weber SG, Kahana M, Stein SL, et al. Severe eczema vaccinatum in a household contact of a smallpox vaccinee. *Clin Infect Dis* 2008 May 15; 46(10):1555–61. doi: [10.1086/587668](#) PMID: [18419490](#)
8. Howell MD, Gallo RL, Boguniewicz M, Jones JF, Wong C, Streib JE, et al. Cytokine milieu of atopic dermatitis skin subverts the innate immune response to vaccinia virus. *Immunity* 2006 Mar; 24(3):341–8. PMID: [16546102](#)
9. Copeman P, Wallace HJ. Eczema Vaccinatum. *Br Med J* 1964;(5414):906–8. PMID: [14185655](#)
10. Waddington E, Bray P, Evans A, Richards I. Cutaneous complications of mass vaccination against smallpox in South Wales 1962. *Trans St Johns Hosp Dermatol Soc* 1964; 50:22–42.
11. Neff JM, Lane JM, Fulginiti VA, Henderson DA. Contact vaccinia-transmission of vaccinia from smallpox vaccination. *JAMA* 2002 Oct 16; 288(15):1901–5. PMID: [12377090](#)
12. Hanifin JM, Reed ML. A population-based survey of eczema prevalence in the United States. *Dermatitis* 2007 Jun; 18(2):82–91. PMID: [17498413](#)
13. Naleway AL, Belongia EA, Greenlee RT, Kieke BA Jr, Chen RT, Shay DK. Eczematous skin disease and recall of past diagnoses: implications for smallpox vaccination. *Ann Intern Med* 2003 Jul 1; 139(1):1–7. PMID: [12834312](#)
14. Moberg C, Meding B, Stenberg B, Svensson A, Lindberg M. Remembering childhood atopic dermatitis as an adult: factors that influence recollection. *Br J Dermatol* 2006 Sep; 155(3):557–60. PMID: [16911281](#)

15. Kemper AR, Davis MM, Freed GL. Expected adverse events in a mass smallpox vaccination campaign. *Eff Clin Pract* 2002 Mar; 5(2):84–90. PMID: [11990216](#)
16. Stickl H, Hochstein-Mintzel V, Mayr A, Huber HC, Schafer H, Holzner A. [MVA vaccination against smallpox: clinical tests with an attenuated live vaccinia virus strain (MVA) (author's transl)]. *Dtsch Med Wochenschr* 1974 Nov 22; 99(47):2386–92. PMID: [4426258](#)
17. Mayr A, Stickl H, Muller HK, Danner K, Singer H. [The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism (author's transl)]. *Zentralbl Bakteriol [B]* 1978 Dec; 167(5–6):375–90.
18. Mayr A, Hochstein-Mintzel V, Stickl H. Passage history, properties, and use of attenuated vaccinia virus strain MVA. *Infection* 1975; 3(1):6–14.
19. Frey SE, Newman FK, Kennedy JS, Sobek V, Ennis FA, Hill H, et al. Clinical and immunologic responses to multiple doses of IMVAMUNE (Modified Vaccinia Ankara) followed by Dryvax challenge. *Vaccine* 2007 Dec 12; 25(51):8562–73. PMID: [18036708](#)
20. Greenberg RN, Overton ET, Haas DW, Frank I, Goldman M, von KA, et al. Safety, Immunogenicity, and Surrogate Markers of Clinical Efficacy for Modified Vaccinia Ankara as a Smallpox Vaccine in HIV-Infected Subjects. *J Infect Dis* 2013 Mar; 207(5):749–58. doi: [10.1093/infdis/jis753](#) PMID: [23225902](#)
21. Vollmar J, Arndt N, Eckl KM, Thomsen T, Petzold B, Mateo L, et al. Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine. *Vaccine* 2006 Mar 15; 24(12):2065–70. PMID: [16337719](#)
22. von Krempelhuber A, Vollmar J, Pokorny R, Rapp P, Wulff N, Petzold B, et al. A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE. *Vaccine* 2010 Feb 3; 28(5):1209–16. doi: [10.1016/j.vaccine.2009.11.030](#) PMID: [19944151](#)
23. von Sonnenburg F, Perona P, Darsow U, Ring J, Krempelhuber A, Vollmer J, et al. Safety and Immunogenicity of Modified Vaccinia Ankara as a Smallpox Vaccine in People with atopic dermatitis. *Vaccine* 2014; 32: 5696–5702 doi: [10.1016/j.vaccine.2014.08.022](#) PMID: [25149431](#)
24. Stittelaar KJ, van AG, Kondova I, Kuiken T, van Lavieren RF, Pistor FH, et al. Modified vaccinia virus Ankara protects macaques against respiratory challenge with monkeypox virus. *J Virol* 2005 Jun; 79(12):7845–51. PMID: [15919938](#)
25. Earl PL, Americo JL, Wyatt LS, Eller LA, Whitbeck JC, Cohen GH, et al. Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox. *Nature* 2004 Mar 11; 428(6979):182–5. PMID: [15014500](#)
26. Samuelsson C, Hausmann J, Lauterbach H, Schmidt M, Akira S, Wagner H, et al. Survival of lethal pox-virus infection in mice depends on TLR9, and therapeutic vaccination provides protection. *J Clin Invest* 2008 May; 118(5):1776–84. doi: [10.1172/JCI33940](#) PMID: [18398511](#)
27. Earl PL, Americo JL, Wyatt LS, Espenshade O, Bassler J, Gong K, et al. Rapid protection in a monkey-pox model by a single injection of a replication-deficient vaccinia virus. *Proc Natl Acad Sci U S A* 2008 Aug 5; 105(31):10889–94. doi: [10.1073/pnas.0804985105](#) PMID: [18678911](#)
28. Damon IK, Davidson WB, Hughes CM, Olson VA, Smith SK, Holman RC, et al. Evaluation of smallpox vaccines using variola neutralization. *J Gen Virol* 2009 Apr 1.
29. Kunz B, Oranje AP, Labreze L, Stalder JF, Ring J, Taieb A. Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis. *Dermatology* 1997; 195(1):10–9. PMID: [9267730](#)
30. Overton E, Stapleton J, Frank I, Hassler S, Goepfert P, Barker D, et al. Immunogenicity of Modified Vaccinia Ankara-Bavarian Nordic Smallpox Vaccine in Vaccinia-Naive and Experienced Human Immunodeficiency Virus-Infected Individuals: An open-Label, Controlled Clinical Phase II Trial. *OFID* 2015 1–10.
31. Leung DY, Bieber T. Atopic Dermatitis. *Lancet* 2003 Jan 11; 361(9352):151–60. PMID: [12531593](#)
32. Boehme M, Svensson A, Kull I, Nordvall S, Wahlrgren C. Clinical features of atopic dermatitis at two years of age: a prospective, population-based case-control study. *Acta Derm Venereol* 2001; 81(3):193–7. PMID: [11558876](#)
33. Kim M, Kang T, Cho E, Kim H, Min J, Park H, et al. Prevalence of atopic dermatitis among Korean adults visiting health service center of the Catholic Medical Center in Seoul Metropolitan Area, Korea. *J Korean Med Sci* 2010; 25(12):1828–30. doi: [10.3346/jkms.2010.25.12.1828](#) PMID: [21165305](#)
34. Arness MK, Eckart RE, Love SS, Atwood JE, Wells TS, Engler RJ, et al. Myopericarditis following smallpox vaccination. *Am J Epidemiol* 2004 Oct 1; 160(7):642–51. PMID: [15383408](#)
35. Nalca A. ACAM2000: The new smallpox vaccine for United States Strategic National Stockpile. *Drug Design Development and Therapy* 2010; 4:71–9.

36. Elizaga ML, Vasan S, Marovich MA, Sato AH, Lawrence DN, Chaitman BR, et al. Prospective surveillance for cardiac adverse events in healthy adults receiving modified vaccinia ankara vaccines: a systematic review. PLoS ONE 2013; 8(1):e54407. doi: [10.1371/journal.pone.0054407](https://doi.org/10.1371/journal.pone.0054407) PMID: [23349878](https://pubmed.ncbi.nlm.nih.gov/23349878/)
37. Roongsritong C, Warraich I, Bradley C. Common causes of troponin elevations in the absence of acute myocardial infarction: incidence and clinical significance. Chest 2004; 125(5):1877–84. PMID: [15136402](https://pubmed.ncbi.nlm.nih.gov/15136402/)
38. Scott JE, Elkhail A, Freyschmidt EJ, MacArthur DH, McDonald D, Howell MD, et al. Impaired immune response to vaccinia virus inoculated at the site of cutaneous allergic inflammation. J Allergy Clin Immunol 2007 Dec; 120(6):1382–8. PMID: [17889291](https://pubmed.ncbi.nlm.nih.gov/17889291/)

readme.txt

S1_Checklist.docx
10.1371/journal.pone.0138348.s001

S1_Fig.tif
10.1371/journal.pone.0138348.s002

S2_Fig.tif
10.1371/journal.pone.0138348.s003

S3_Fig.tif
10.1371/journal.pone.0138348.s004

S4_Fig.tif
10.1371/journal.pone.0138348.s005

S5_Fig.docx
10.1371/journal.pone.0138348.s006

S1_IRB.doc
10.1371/journal.pone.0138348.s007

S2_IRB.pdf
10.1371/journal.pone.0138348.s008

S3_IRB.pdf
10.1371/journal.pone.0138348.s009

S1_Patents.docx
10.1371/journal.pone.0138348.s010

S1_Protocol.pdf
10.1371/journal.pone.0138348.s011

S1_Table.docx
10.1371/journal.pone.0138348.s012

S2_Table.docx
10.1371/journal.pone.0138348.s013

TREND Statement Checklist

Paper Section/ Topic	Item No	Descriptor	Reported?	
				Pg #
Title and Abstract				
Title and Abstract	1	Information on how unit were allocated to interventions	✓	1
		Structured abstract recommended	✓	3
		Information on target population or study sample	✓	3
Introduction				
Background	2	Scientific background and explanation of rationale	✓	4,5
		Theories used in designing behavioral interventions	n.a.	
Methods				
Participants	3	Eligibility criteria for participants, including criteria at different levels in recruitment/sampling plan (e.g., cities, clinics, subjects)	✓	6
		Method of recruitment (e.g., referral, self-selection), including the sampling method if a systematic sampling plan was implemented	✓	6
		Recruitment setting	✓	6
		Settings and locations where the data were collected	✓	Footnote Page
Interventions	4	Details of the interventions intended for each study condition and how and when they were actually administered, specifically including:		
		o Content: what was given?	✓	6
		o Delivery method: how was the content given?	✓	6
		o Unit of delivery: how were the subjects grouped during delivery?	✓	7
		o Deliverer: who delivered the intervention?	✓	6
		o Setting: where was the intervention delivered?	✓	6
		o Exposure quantity and duration: how many sessions or episodes or events were intended to be delivered? How long were they intended to last?	✓	6
		o Time span: how long was it intended to take to deliver the intervention to each unit?	✓	6
		o Activities to increase compliance or adherence (e.g., incentives)	n.a.	
Objectives	5	Specific objectives and hypotheses	✓	5
Outcomes	6	Clearly defined primary and secondary outcome measures	✓	7,8
		Methods used to collect data and any methods used to enhance the quality of measurements	✓	7,8
		Information on validated instruments such as psychometric and biometric properties	n.a.	
Sample Size	7	How sample size was determined and, when applicable, explanation of any interim analyses and stopping rules	✓	9
Assignment Method	8	Unit of assignment (the unit being assigned to study condition, e.g., individual, group, community)	✓	4
		Method used to assign units to study conditions, including details of any restriction (e.g., blocking, stratification, minimization)	n.a.	
		Inclusion of aspects employed to help minimize potential bias induced due to non-randomization (e.g., matching)	n.a.	


TREND Statement Checklist

Blinding (masking)	9	Whether or not participants, those administering the interventions, and those assessing the outcomes were blinded to study condition assignment; if so, statement regarding how the blinding was accomplished and how it was assessed.	n.a.	
Unit of Analysis	10	Description of the smallest unit that is being analyzed to assess intervention effects (e.g., individual, group, or community)	n.a.	
		If the unit of analysis differs from the unit of assignment, the analytical method used to account for this (e.g., adjusting the standard error estimates by the design effect or using multilevel analysis)	n.a.	
Statistical Methods	11	Statistical methods used to compare study groups for primary methods outcome(s), including complex methods of correlated data	✓	8,9
		Statistical methods used for additional analyses, such as a subgroup analyses and adjusted analysis	✓	8,9
		Methods for imputing missing data, if used	n.a.	
		Statistical software or programs used	✓	8,9
Results				
Participant flow	12	Flow of participants through each stage of the study: enrollment, assignment, allocation, and intervention exposure, follow-up, analysis (a diagram is strongly recommended)	✓	10, Figure 1
		o Enrollment: the numbers of participants screened for eligibility, found to be eligible or not eligible, declined to be enrolled, and enrolled in the study	✓	10, Figure 1
		o Assignment: the numbers of participants assigned to a study condition	✓	10, Figure 1
		o Allocation and intervention exposure: the number of participants assigned to each study condition and the number of participants who received each intervention	✓	10, Figure 1
		o Follow-up: the number of participants who completed the follow-up or did not complete the follow-up (i.e., lost to follow-up), by study condition	✓	10, Figure 1
		o Analysis: the number of participants included in or excluded from the main analysis, by study condition	✓	10, Figure 1
		Description of protocol deviations from study as planned, along with reasons	✓	10, Figure 1
Recruitment	13	Dates defining the periods of recruitment and follow-up	✓	7
Baseline Data	14	Baseline demographic and clinical characteristics of participants in each study condition	✓	10
		Baseline characteristics for each study condition relevant to specific disease prevention research	✓	10
		Baseline comparisons of those lost to follow-up and those retained, overall and by study condition	n.a.	
		Comparison between study population at baseline and target population of interest	n.a.	
Baseline equivalence	15	Data on study group equivalence at baseline and statistical methods used to control for baseline differences	n.a.	

TREND Statement Checklist

Numbers analyzed	16	Number of participants (denominator) included in each analysis for each study condition, particularly when the denominators change for different outcomes; statement of the results in absolute numbers when feasible	n.a.	
		Indication of whether the analysis strategy was “intention to treat” or, if not, description of how non-compliers were treated in the analyses	✓	8
Outcomes and estimation	17	For each primary and secondary outcome, a summary of results for each estimation study condition, and the estimated effect size and a confidence interval to indicate the precision	✓	19 figure 2 and 3
		Inclusion of null and negative findings	n.a.	
		Inclusion of results from testing pre-specified causal pathways through which the intervention was intended to operate, if any	n.a.	
Ancillary analyses	18	Summary of other analyses performed, including subgroup or restricted analyses, indicating which are pre-specified or exploratory	n.a.	
Adverse events	19	Summary of all important adverse events or unintended effects in each study condition (including summary measures, effect size estimates, and confidence intervals)	✓	18
DISCUSSION				
Interpretation	20	Interpretation of the results, taking into account study hypotheses, sources of potential bias, imprecision of measures, multiplicative analyses, and other limitations or weaknesses of the study	✓	20,21
		Discussion of results taking into account the mechanism by which the intervention was intended to work (causal pathways) or alternative mechanisms or explanations	✓	20,21
		Discussion of the success of and barriers to implementing the intervention, fidelity of implementation	✓	20,21
		Discussion of research, programmatic, or policy implications	n.a.	
Generalizability	21	Generalizability (external validity) of the trial findings, taking into account the study population, the characteristics of the intervention, length of follow-up, incentives, compliance rates, specific sites/settings involved in the study, and other contextual issues	✓	20,21
Overall Evidence	22	General interpretation of the results in the context of current evidence and current theory	✓	20,21

From: Des Jarlais, D. C., Lyles, C., Crepaz, N., & the Trend Group (2004). Improving the reporting quality of nonrandomized evaluations of behavioral and public health interventions: The TREND statement. *American Journal of Public Health*, 94, 361-366. For more information, visit: <http://www.cdc.gov/trendstatement/>



Translation from Spanish

(In the upper right-hand margin is found a logo with the inscription "Médica Sur")

Mexico City, March 10, 2006.

Dr. Juan Francisco Galán-Herrera
Main Researcher
Present
Very Dear Dr. Galán:

Regarding the research protocol titled: "A multicenter, open-label, controlled phase II study to evaluate safety and immunogenicity of MVA-BN[®] (IMVAMUNE[™]) smallpox vaccine in 18-40 year old subjects with diagnosed atopic dermatitis" Study Number: POX-MVA-008, Final Version 2.0 Dated January 20, 2006. Trial sponsored by Bavarian Nordic A/S. I am glad to inform you that the project has been Accepted to be carried out in this Institution.

With nothing further at this moment, we thank for your interest to carry out research studies in our hospital.

Kindly,

SIGNED:



Dr. Nahum Méndez-Sánchez
President of the Investigation Committee
for Research in Humans
and Coordinator of the Ethics, Biosecurity
and Research Commissions



The undersigned, SILVIA GLORIA VALDES GARCIA
Ave. Universidad No. 2014 Edificio Costa Rica
Entrada B-202 Unidad Integracion Latinoamericana
Col. Romero de Terreros Tel: 658-82-14 México 5
D.F. official Sworn translator before the Superior
Court of Justice of the Federal District, Mexico for
the Spanish and English languages, certifies that the
above is a true and exact translation of the
document attached

Mexico City,

JUL 14 2008

SILVIA GLORIA VALDES GARCIA

México, D.F., 10 de marzo, 2006.


Dr. Juan Francisco Galán Herrera
Investigador Principal
P r e s e n t e.

Muy estimado Dr. Galán:

En relación al protocolo de investigación intitulado: "Un estudio multicéntrico, abierto, controlado, de fase II para evaluar la seguridad e inmunogenicidad de MVA-BN® (IMVAMUNE™) vacuna contra la viruela en sujetos de 18-40 años de edad con diagnóstico de dermatitis atópica". Número de estudio: POX-MVA-008, Versión Final 2.0 del 20-Enero-2006. Estudio patrocinado por Bavarian Nordic A/S. Tengo el gusto de informarle que su proyecto ha sido Aceptado para llevarse a cabo en esta Institución.

Sin otro particular por el momento, le agradecemos el interés por llevar a cabo estudios de investigación en nuestro hospital.

Atentamente,


Dr. Nahum Méndez-Sánchez
Presidente del Comité de Investigación
para Estudios en Humanos
y Coordinador de las Comisiones de
Ética, Bioseguridad e Investigación

Translation from Spanish

(In the upper left-hand margin is found a logo)
(In the center margin is the inscription INSTITUTO
DERMATOLÓGICO DE JALISCO "Dr. Jose Barba Rubio")
(In the upper right-hand margin is found a logo)

Zapopan, Jalisco March 13, 2005.

Dr. José Fernando Barba-Gómez
Main Researcher
Instituto Dermatológico de Jalisco "Dr. José Barba Rubio"
Present

Dear Dr. Barba:

RE: "A multicenter, open-label, controlled phase II study
to evaluate safety and immunogenicity of MVA-BN®
(IMVAMUNE™) smallpox vaccine in 18-40 year old subjects
with diagnosed atopic dermatitis" Study Number: POX-MVA-
008, Final Version 2.0 Dated January 20, 2006. Sponsor:
Bavarian Nordic A/S.

By this mean I inform you that it has been reviewed and
approved by the Ethics Committee of the Instituto
Dermatológico of Jalisco "Dr. José Barba Rubio" the
following documentation:

- Protocol No. POX-MVA-008, mentioned above final
version 2.0 dated January 20, 2006.
- Informed Vaccination Consent Mexico POX-MVA-008
version 2.0 dated January 20, 2006.
- Investigator's Brochure version 08 dated November 22,
2005.



- Patient Diary Version 1.0 Final dated January 13, 2006.

Also, we make notice we are aware that all the study subjects will receive a Patient Diary, a thermometer to measure their corporal temperature and a ruler to measure the diameter of any reddening or swelling that may occur after the study vaccination application.

By the previous, you are authorized to make this study in the facilities of the Instituto Dermatológico de Jalisco "Dr. José Barba Rubio" as responsible researcher.

Kindly,

SIGNED:

Dr. Roberto Morales-Ortiz

President of the Ethics Committee of the


Instituto Dermatológico de Jalisco "Dr. José Barba Rubio"





The undersigned, SILVIA GLORIA VALDES GARCIA
Ave. Universidad No. 2014 Edificio Costa Rica
Entrada B-202 Unidad Integracion Latinoamericana
Col. Romero de Tixereros Tel: 658-82-14 México 5
D.F. official Sworn translator before the Superior
Court of Justice of the Federal District, Mexico for
the Spanish and English languages, certifies that the
above is a true and exact translation of the
document attached

Mexico City, JUL 14 2006


SILVIA GLORIA VALDES GARCIA



GOBIERNO DE JALISCO
SECRETARÍA DE SALUD

INSTITUTO DERMATOLÓGICO DE JALISCO

"DR. JOSE BARBA RUBIO"



Zapopan, Jalisco, a 13 de marzo de 2006

Dr. José Fernando Barba Gómez
Investigador Principal
Instituto Dermatológico de Jalisco "Dr. José Barba Rubio"
P r e s e n t e

Estimado Dr. Barba:

Re: "Un estudio multicéntrico, abierto, controlado, de fase II para evaluar la seguridad e inmunogenicidad de MVA-BN® (IMVAMUNE™) vacuna contra la viruela en sujetos de 18-40 años de edad con diagnóstico de dermatitis atópica" Número del Estudio: POX-MVA-008, Versión Final 2.0, Fechado el 20-Ene-2006, Patrocinador: Bavarian Nordic A/S


Por éste conducto le informo que ha sido revisada y aprobada por el Comité de Ética del Instituto Dermatológico de Jalisco "Dr. José Barba Rubio" la siguiente documentación:

- Protocolo No. POX-MVA-008, arriba mencionado versión final 2.0 del 20 de enero de 2006.
- Consentimiento Informado de Vacunación México POX-MVA-008 Versión 2.0 del 20 de enero de 2006.
- Folleto del Investigador, versión 08 del 22 de noviembre de 2005
- Diario del Paciente Versión 1.0 Final del 13 de enero de 2006

Así mismo, hacemos notar que estamos enterados de que todos los sujetos del estudio recibirán un Diario del Paciente, un termómetro para medir su temperatura corporal y una regla para medir el diámetro de cualquier enrojecimiento o hinchazón que se pudiera presentar después de la aplicación de la vacuna del estudio

Por lo anterior, queda usted autorizado para realizar dicho estudio en las instalaciones del Instituto Dermatológico de Jalisco "Dr. José Barba Rubio" como Investigador responsable.

Atentamente


Dr. Roberto Morales Ortiz
Presidente del Comité de Ética del
Instituto Dermatológico de Jalisco "Dr. José Barba Rubio"



Translation from Spanish

(In the upper right-hand margin is found a logo with the
Inscription Unidad de Investigación en Salud)

Chihuahua, Chih., February 14, 2006.


Dr. Araceli Hernández García
Main Researcher
Present

We had analyzed in detail the clinical research protocol titled "A multicenter, open-label, controlled phase II study to evaluate safety and immunogenicity of MVA-BN® (IMVAMUNE™) smallpox vaccine in 18-40 year old subjects with diagnosed atopic dermatitis" Study Number: POX-MVA-008, Final Version 2.0 Dated January 20, 2006. Sponsor: Bavarian Nordic A/S.

This Ethics Committee authorizes the accomplishment of the study before mentioned so that it is carried out in the Unidad de Investigación en Salud de Chihuahua, S.C and for which you will be Main Researcher.

In addition to the referred protocol, this committee has received and approved the following material:

- Protocol No. POX-MVA-008, mentioned above final version 2.0 dated January 20, 2006.
- Informed Vaccination Consent Mexico POX-MVA-008 Version 2.0 dated January 20, 2006.
- Investigator's Brochure version 08 dated November 22, 2005.



- Patient Diary Version 1.0 Final dated January 13, 2006.

Also, we make notice we are aware that all the study subjects will receive a Patient Diary, a thermometer to measure their corporal temperature and a ruler to measure the diameter of any reddening or swelling that may occur after the study vaccination application.

With nothing further at this moment, receive a warm greeting.

Kindly,

SIGNED:

Dr. Roberto I. Contreras
President of the Ethics Committee
Unidad de Investigación en Salud





The undersigned, SILVIA GLORIA VALDES GARCIA
Ave. Universidad No. 2014 Edificio Costa Rica
Entrada B-202 Unidad Integracion Latinoamericana
Col. Romero de Taveros Tel: 658-82-14 México 5
D.F. official Sworn translator before the Superior
Court of Justice of the Federal District, Mexico for
the Spanish and English languages, certifies that the
above is a true and exact translation of the
document attached

Mexico City, JUL 14 2006

SILVIA GLORIA VALDES GARCIA

Chihuahua, Chih., a 14 de Febrero de 2006

Dra. Araceli Hernández García
Investigadora Principal
Presente.-

Hemos analizado detalladamente el protocolo de investigación clínica titulado: **"Un estudio multicéntrico, abierto, controlado, de fase II para evaluar la seguridad e inmunogenicidad de MVA-BN® (IMVAMUNE™) vacuna contra la viruela en sujetos de 18-40 años de edad con diagnóstico de dermatitis atópica"** Número del Estudio: POX-MVA-008, Versión Final 2.0, Fechado el 20-Ene-2006, Patrocinador: Bavarian Nordic A/S.

Este Comité de Ética autoriza la realización del estudio antes citado, para que se lleve a cabo en la Unidad de Investigación en Salud de Chihuahua, SC. y para el cual usted fungirá como la Investigadora Principal.

Además del protocolo referido, este comité ha recibido y aprobado el siguiente material:

- Protocolo No. POX-MVA-008, arriba mencionado versión final 2.0 del 20-Enero-2006.
- Consentimiento Informado de Vacunación México POX-MVA-008 Versión 2.0 del 20 de Enero de 2006.
- Folleto del Investigador, versión 08 del 22 de Noviembre de 2005.
- Diario del Paciente Versión 1.0 Final del 13 de Enero de 2006.

Así mismo, hacemos notar que estamos enterados de que todos los sujetos del estudio recibirán un Diario del Paciente, un termómetro para medir su temperatura corporal y una regla para medir el diámetro de cualquier enrojecimiento o hinchazón que se pudiera presentar después de la aplicación de la vacuna del estudio

Sin otro particular por el momento, reciba un cordial saludo.

Atentamente



Dr. Roberto I. Contreras
Presidente del Comité de Ética
Unidad de Investigación en Salud

Translation from Spanish

(In the upper left-hand margin is found a logo)
(In the center margin is the inscription Hospital Regional
"Lic. Adolfo López Mateos")


Training, Research and
Development Coordination
Research Headquarters
Subject: Protocol approval

Mexico City, March 14, 2006.

Dr. Javier Gómez-Vera
Main Researcher
Hospital Regional "Lic. Adolfo López Mateos", ISSSTE
P r e s e n t

By this conduit I inform you that it has been reviewed and
approved by the Research and Bioethics Committee of the
Hospital "Lic. Adolfo López Mateos" the following
documentation:

RE: "A multicenter, open-label, controlled phase II study
to evaluate safety and immunogenicity of MVA-BN®
(IMVAMUNE™) smallpox vaccine in 18-40 year old subjects
with diagnosed atopic dermatitis" Study Number: POX-MVA-
008, Final Version 2.0 Dated January 20, 2006. Sponsor:
Bavarian Nordic A/S.



Protocol No. POX-MVA-008, mentioned above final
version 2.0 dated January 20, 2006.

• Informed Vaccination Consent Mexico POX-MVA-008
Version 2.0 dated January 20, 2006.

- Investigator's Brochure version 08 dated November 22, 2005.
- Patient Diary Version 1.0 Final dated January 13, 2006.

Also, we make notice we are aware that all the study subjects will receive a Patient Diary, a thermometer to measure their corporal temperature and a ruler to measure the diameter of any reddening or swelling that may occur after the study vaccination application.

By the previous, you are authorized to make this study in the facilities of the Hospital Regional "Lic. Adolfo López Mateos", ISSSTE as responsible researcher.

With nothing further at this moment, I remain of you.

Kindly,

SIGNED:

Dr. Carlos Lenin Pliego-Reyes

Chairman of Research and Bioethics of the
Hospital Regional "Lic. Adolfo López Mateos"

Copies

Dr. Arnulfo L'Gamiz-Matuk - Hospital Director

Dr. Sergio Barragán-Padilla - CAPADESI Coordinator






The undersigned, **SILVIA GLORIA VALDES GARCIA**
Ave. Universidad No. 2014 Edificio Costa Rica
Entrada B-202 Unidad Integracion Latinoamericana
Col. Romero de Terreros Tel: 658-82-14 México 5
D.F. official Sworn translator before the Superior
Court of Justice of the Federal District, Mexico for
the Spanish and English languages, certifies that the
above is a true and exact translation of the
document attached

Mexico City,

JUL 14 2006


SILVIA GLORIA VALDES GARCIA



Hospital Regional "Lic. Adolfo Lopez Mateos"

COORDINACION DE CAPACITACION
DESARROLLO E INVESTIGACION
Jefatura de Investigación

Asunto: Aprobación de Protocolo

Ciudad de México a 14 de Marzo de 2006

Dr. Javier Gómez Vera
Investigador Principal
Hospital Regional "Lic. Adolfo López Mateos", ISSSTE
Presente

Por éste conducto le informo que ha sido revisada y aprobada por el Comité de Investigación y Bioética del Hospital "Lic. Adolfo López Mateos" la siguiente documentación:

Re: "Un estudio multicéntrico, abierto, controlado, de fase II para evaluar la seguridad e inmunogenicidad de la vacuna contra la viruela MVA-BN® (IMVAMUNE™) en sujetos de 18-40 años de edad con diagnóstico de dermatitis atópica" Número del Estudio: POX-MVA-008, Versión Final 2.0, Fechado el 20-Ene-2006, Patrocinador: Bavarian Nordic A/S

- Protocolo No. POX-MVA-008, arriba mencionado versión final 2.0 del 20 de Enero de 2006.
- Consentimiento Informado de Vacunación México POX-MVA-008 Versión 2.0 del 20 de Enero de 2006.
- Folleto del Investigador, versión 08 del 22 de Noviembre de 2005
- Diario del Paciente Versión 1.0 Final del 13 de Enero de 2006

Así mismo, hacemos notar que estamos enterados de que todos los sujetos del estudio recibirán un Diario del Paciente, un termómetro para medir su temperatura corporal y una regla para medir el diámetro de cualquier enrojecimiento o hinchazón que se pudiera presentar después de la aplicación de la vacuna del estudio

Por lo anterior, queda usted autorizado para realizar dicho estudio en *las instalaciones del* Hospital Regional "Lic. Adolfo López Mateos", ISSSTE como investigador responsable.

Sin más por el momento, quedo de Usted.

Atentamente


Dr. Carlos Lenin Pliego Reyes
Jefe de Investigación y Bioética del
Hospital Regional "Lic. Adolfo Lopez Mateos"

Copias
Dr. Arnulfo L'Gamiz Matuk.-Director del Hospital
Dr. Sergio Barragan Padilla.- Coordinador de CAPADESI

CLPY/fce

Translation from Spanish

(In the upper left-hand margin is found a logo and the inscription Universidad Autónoma de Nuevo León)

(In the upper right margin is found a logo and the inscription Facultad de Medicina y Hospital Universitario)

Dra. Sandra N. González-Diáz
Main Researcher
Allergy and Immunology Service
Present


Dear Dr. González

RE: "A multicenter, open-label, controlled phase II study to evaluate safety and immunogenicity of MVA-BN® (IMVAMUNE™) smallpox vaccine in 18-40 year old subjects with diagnosed atopic dermatitis" Study Number: POX-MVA-008, Final Version 2.0 Dated January 20, 2006. Sponsor: Bavarian Nordic A/S.

By this conduit I inform you that it has been reviewed and approved by the Research and Ethics Committee of the Facultad de Medicina y Hospital Universitario "Dr. José Eleuterio González" the following documentation:

- Protocol No. POX-MVA-008, mentioned above final version 2.0 dated January 20, 2006.

- Informed Vaccination Consent Mexico POX-MVA-008 Version 2.0 dated January 20, 2006. Centro Regional de Alergia e Inmunología del Hospital Universitario "Dr. José Eleuterio González" Version dated March 08, 2006.



- Investigator's Brochure version 08 dated November 22, 2005.
- Patient Diary Version 1.0 Final dated January 13, 2006.

Also, we make notice we are aware that all the study subjects will receive a Patient Diary, a thermometer to measure their corporal temperature and a ruler to measure the diameter of any reddening or swelling that may occur after the study vaccination application.

Reason why, in my quality of President of the Research and Ethics Committee, **I give my authorization** so that you, who are the main researcher, take the responsibility in the **conduction of the study in this institution**, your protocol was registered in this subdivision with key **AL06-011**.

With nothing further at this moment, I reiterate to you the security of my kindest and distinguished consideration.

Kindly,
"Alere Flamman Veritatis"
Monterrey, Nuevo León, March 14, 2006.

SIGNED:
Dr. José Gerardo Garza-Leal
Secretary of Clinical Area Research
President of the Research and Ethics Committee





The undersigned, SILVIA GLORIA VALDES GARCIA
Ave. Universidad No. 2014 Edificio Costa Rica
Entrada B-202 Unidad Integracion Latinoamericana
Col. Romero de Terreros Tel: 658-82-14 México 5
D.F. official Sworn translator before the Superior
Court of Justice of the Federal District, Mexico for
the Spanish and English languages, certifies that the
above is a true and exact translation of the
document attached

Mexico City, JUL 14 2006

SILVIA GLORIA VALDES GARCIA

A handwritten signature in blue ink, appearing to read "Silvia", written over the printed name.



UANL

UNIVERSIDAD AUTÓNOMA DE NUEVO LEÓN



FACULTAD DE MEDICINA Y HOSPITAL UNIVERSITARIO

DRA. SANDRA N. GONZALEZ DIAZ

Investigador principal

Servicio de Alergias e Inmunología Clínica

Presente.-

Estimada Dra. González:

Re. "Un estudio multicéntrico, abierto, controlado, de fase II para evaluar la seguridad e inmunogenicidad de MVA-BN® (IMVAMUNE™) vacuna contra la viruela en sujetos de 18-40 años de edad con diagnóstico de dermatitis atópica" No. de Estudio: POX-MVA-008, Versión final 2.0, fechada el 20 enero de 2006, Patrocinador: Bavarian Nordic A/S.

Por este conducto le informo que ha sido revisado y aprobado por el Comité de Investigación y Ética de la Facultad de Medicina y Hospital Universitario "Dr. José Eleuterio González" la siguiente documentación:

- **Protocolo No. POX-MVA-008**, arriba mencionado Versión final 2.0 del 20 de Enero de 2006
- **Consentimiento Informado** de Vacunación México POX-MVA-008 Versión 2.0 del 20 de Enero de 2006 Centro Regional de Alergia e Inmunología Clínica del Hospital Universitario "Dr. José Eleuterio González" Versión 08 de Marzo de 2006.
- **Folleto del Investigador**, Versión 08 del 22 de Noviembre de 2005.
- **Diario del Paciente** Versión 1.0 Final del 13 de Enero de 2006.

Así mismo, hacemos notar que estamos enterados de que todos los sujetos del estudio recibirán un Diario del Paciente, un Termómetro para medir su temperatura corporal y una Regla para medir el diámetro de cualquier enrojecimiento o hinchazón que se pudiera presentar después de la aplicación de la vacuna del estudio.


Por lo que en mi calidad de Presidente del Comité de Investigación y Ética, **doy mi autorización** para que usted, quien es el Investigador principal, tome la responsabilidad en la **conducción del estudio en esta Institución**, su protocolo quedo registrado en esta Subdirección con la clave **AL06-011**.

Sin más por el momento, le reitero la seguridad de mi más atenta y distinguida consideración

Atentamente,

"Alere Flammas Veritatis"

Monterrey Nuevo León a 14 de Marzo del 2006


DR. JOSE GERARDO GARZA LEAL
Secretario de Investigación del Área Clínica
Presidente del Comité de Investigación y Ética



SUB-DIRECCION DE INVESTIGACION

SUBDIRECCIÓN DE INVESTIGACIÓN

Edificio de la Biblioteca Central de la Facultad de Medicina de la U.A.N.L. planta baja.

Av. Francisco I. Madero Pto. s/n y Dr. E. Aguirre Pequeño, Col. Mitras Centro, C.P. 64460 Monterrey, N.L. México

Tel./Fax (+52) 6329 4050 Ext. 2871 al 2874. Correo Electrónico: sinvestigacion@hu.uanl.mx

Patents by Inventor Paul Chaplin regarding MVA

RECOMBINANT MODIFIED VACCINIA VIRUS ANKARA (MVA) RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE

Application number: 20150209421

Inventors: Cédric Cheminay, Robin Steigerwald, Paul Chaplin

POXVIRAL VECTORS FOR LOW ANTIBODY RESPONSE AFTER A FIRST PRIMING IMMUNIZATION

Application number: 20150174238

Inventors: Robin Steigerwald, Kay Brinkmann, Ulrike Dirmeier, Paul Chaplin

USE OF A MODIFIED POXVIRUS FOR THE RAPID INDUCTION OF IMMUNITY AGAINST A POXVIRUS OR OTHER INFECTIOUS AGENTS

Application number: 20140341946

Inventors: Paul CHAPLIN, Luis MATEO

RECOMBINANT POXVIRUS VECTOR COMPRISING TETANUS TOXIN FRAGMENT C

Application number: 20140322265

Inventors: Paul Chaplin, Robin Steigerwald

Use of a modified poxvirus for the rapid induction of immunity against a poxvirus or other infectious agents

Patent number: 8808709

Inventors: Paul Chaplin, Luis Mateo

Modified Vaccinia Ankara virus variant and cultivation method

Patent number: 8470598

Inventors: Paul Chaplin, Paul Howley, Christine Meisinger-Henschel, Ingmar Rathe, Eva Felder, Karl Heller

Modified vaccinia virus ankara for the vaccination of neonates

Patent number: 8372622

Inventors: Mark Suter, Sabine Vollstedt, Paul Chaplin

MODIFIED VACCINIA ANKARA VIRUS VARIANT

Application number: 20120328650

Inventors: PAUL CHAPLIN, PAUL HOWLEY, CHRISTINE MEISINGER-HENSCHEL

Method for generating a stable recombinant modified vaccinia virus ankara (MVA) comprising human immunodeficiency virus (HIV) genes inserted into one or more intergenic regions (IGRs)

Patent number: 8323661

Inventors: Paul Howley, Sonja Leyrer, Paul Chaplin, Eva Felder

Recombinant modified vaccinia ankara (MVA) virus containing heterologous DNA inserts encoding human immunodeficiency virus (HIV) antigens inserted into one or more intergenic regions (IGRs)

Patent number: 8309098

Inventors: Paul Howley, Sonja Leyrer, Paul Chaplin, Eva Felder

MODIFIED VACCINIA ANKARA VIRUS VARIANT AND CULTIVATION METHOD

Application number: 20120276613

Inventors: PAUL CHAPLIN, PAUL HOWLEY, CHRISTINE MEISINGER-HENSCHEL, INGMAR RATHE, EVA FELDER, KARL HELLER

Modified Vaccinia Ankara virus variant

Patent number: 8268325

Inventors: Paul Chaplin, Paul Howley, Christine Meisinger-Henschel

Modified virus variant

Patent number: 8268329

Inventors: Paul Chaplin, Paul Howley, Christine Meisinger-Henschel

Modified Vaccinia Ankara virus variant and cultivation method

Patent number: 8236560

Inventors: Paul Chaplin, Paul Howley, Christine Meisinger-Henschel, Ingmar Rathe, Eva Felder, Karl Heller

MODIFIED VACCINIA VIRUS ANKARA FOR THE VACCINATION OF NEONATES

Application number: 20120183574

Inventor: Paul Chaplin

Method for introducing human immunodeficiency virus nucleotide sequences into a cell utilizing modified vaccinia virus Ankara (MVA) recombinants comprising HIV genes inserted into one or more intergenic regions (IGRs)

Patent number: 8198088

Inventors: Paul Howley, Sonja Leyrer, Paul Chaplin, Eva Felder

Method for the production of human immunodeficiency virus (HIV) proteins utilizing modified vaccinia virus ankara (MVA) recombinants comprising HIV genes inserted into one or more intergenic regions (IGRs)

Patent number: 8197822

Inventors: Paul Howley, Sonja Leyrer, Paul Chaplin, Eva Felder

GENERATION OF A BROAD T-CELL RESPONSE IN HUMANS AGAINST HIV

Application number: 20120135032

Inventors: Paul Chaplin, Richard Nichols

USE OF A MODIFIED POXVIRUS FOR THE RAPID INDUCTION OF IMMUNITY AGAINST A POXVIRUS OR OTHER INFECTIOUS AGENTS

Inventors: Paul CHAPLIN, Luis Mateo

Modified Vaccinia Virus Ankara for the vaccination of neonates

Patent number: 8163293

Inventor: Paul Chaplin

INTERGENIC REGIONS AS NOVEL SITES FOR INSERTION OF HIV DNA SEQUENCES IN THE GENOME OF MODIFIED VACCINIA VIRUS ANKARA

Application number: 20120014922

Inventors: Paul Howley, Sonja Leyrer, Paul Chaplin, Eva Felder

INTERGENIC REGIONS AS NOVEL SITES FOR INSERTION OF HIV DNA SEQUENCES IN THE GENOME OF MODIFIED VACCINIA VIRUS ANKARA

Application number: 20120015423

Inventors: Paul HOWLEY, Sonja Leyrer, Paul Chaplin, Eva Felder

INTERGENIC REGIONS AS NOVEL SITES FOR INSERTION OF HIV DNA SEQUENCES IN THE GENOME OF MODIFIED VACCINIA VIRUS ANKARA

Application number: 20120009214

Inventors: Paul HOWLEY, Sonja Leyrer, Paul Chaplin, Eva Felder

INTERGENIC REGIONS AS NOVEL SITES FOR INSERTION OF HIV DNA SEQUENCES IN THE GENOME OF MODIFIED VACCINIA VIRUS ANKARA

Inventors: PAUL HOWLEY, SONJA LEYRER, PAUL CHAPLIN, EVA FELDER

Recombinant modified vaccinia virus ankara (MVA) comprising human immunodeficiency virus (HIV) genes inserted into one or more intergenic regions (IGRs)

Patent number: 8029800

Inventors: Paul Howley, Sonja Leyrer, Paul Chaplin, Eva Felder

Methods for inducing an immune response in a host comprising administering modified vaccinia virus ankara (MVA) recombinants comprising human immunodeficiency virus (HIV) genes inserted into one or more intergenic regions (IGRs)

Inventors: Paul Howley, Sonja Leyrer, Paul Chaplin, Eva Felder

MODIFIED VACCINIA ANKARA VIRUS VARIANT AND CULTIVATION METHOD

Application number: 20110217757

Inventors: PAUL CHAPLIN, PAUL HOWLEY, CHRISTINE MEISINGER-HENSCHER, INGMAR RATHE, EVA FELDER, KARL HELLER

MODIFIED VACCINIA ANKARA VIRUS VARIANT

Application number: 20110182933

Inventors: PAUL CHAPLIN, PAUL HOWLEY, CHRISTINE MEISINGER

MODIFIED VACCINIA ANKARA VIRUS VARIANT

Application number: 20110182932

Inventors: PAUL CHAPLIN, PAUL HOWLEY, CHRISTINE MEISINGER

PHENOTYPIC AND GENOTYPIC DIFFERENCES OF MVA STRAINS

Application number: 20110172407

Inventor: PAUL CHAPLIN

MODIFIED VACCINIA VIRUS ANKARA FOR THE VACCINATION OF NEONATES

Application number: 20110159032

Inventors: Mark Suter, Sabine Vollstedt, Paul Chaplin

Modified vaccinia ankara virus variant and cultivation method

Patent number: 7964398

Inventors: Paul Chaplin, Paul Howley, Christine Meisinger-Henschel, Ingmar Rathe, Eva Felder, Karl Heller

Modified vaccinia ankara virus variant and cultivation method

Patent number: 7964395

Inventors: Paul Chaplin, Paul Howley, Christine Meisinger-Henschel, Ingmar Rathe, Eva Felder, Karl Heller

Modified vaccinia ankara virus variant and cultivation method

Patent number: 7964396

Inventors: Paul Chaplin, Paul Howley, Christine Meisinger-Henschel, Ingmar Rathe, Eva Felder, Karl Heller

Use of a modified poxvirus for the rapid induction of immunity against a poxvirus or other infectious agents

Inventors: Paul Chaplin, Luis Mateo

MODIFIED VACCINIA VIRUS ANKARA FOR THE VACCINATION OF NEONATES

Application number: 20110135683

Inventor: Paul Chaplin

Modified Vaccinia Ankara virus variant

Patent number: 7939086

Inventors: Paul Chaplin, Paul Howley, Christine Meisinger-Henschel

Modified Vaccinia Ankara virus variant

Inventors: Paul Chaplin, Paul Howley, Christine Meisinger-Henschel

RECOMBINANT MODIFIED VACCINIA VIRUS MEASLES VACCINE

Application number: 20110052627

Inventor: Paul Chaplin

Modified vaccinia virus ankara for the vaccination of neonates

Patent number: 7897156

Inventors: Mathias Ackermann, Mark Suter, Hans Peter Hefti, Ruth Hefti, legal representative, Marco Franchini, Sabine Vollstedt, Paul Chaplin

Modified vaccinia virus ankara for the vaccination of neonates

Patent number: 7892533

Inventors: Mark Suter, Sabine Vollstedt, Paul Chaplin

MODIFIED VACCINIA ANKARA VIRUS VARIANT AND CULTIVATION METHOD

Application number: 20100279386

Inventors: PAUL CHAPLIN, PAUL HOWLEY, CHRISTINE MEISINGER-HENSCHER, INGMAR RATHE, EVA FELDER, KARL HELLER

INTERGENIC REGIONS AS NOVEL SITES FOR INSERTION OF HIV DNA SEQUENCES IN THE GENOME OF MODIFIED VACCINIA VIRUS ANKARA

Application number: 20100196992

Inventors: PAUL HOWLEY, SONJA LEYRER, PAUL CHAPLIN, EVA FELDER

INTERGENIC REGIONS AS NOVEL SITES FOR INSERTION OF HIV DNA SEQUENCES IN THE GENOME OF MODIFIED VACCINIA VIRUS ANKARA

Application number: 20100183663

Inventors: PAUL HOWLEY, SONJA LEYRER, PAUL CHAPLIN, EVA FELDER

MODIFIED VACCINIA ANKARA VIRUS VARIANT

Application number: 20100119545

Abstract: The present invention provides an attenuated virus, which is derived from

Inventors: Paul Chaplin, Paul Howley, Christine Meisinger

MODIFIED VACCINIA VIRUS ANKARA FOR THE VACCINATION OF NEONATES

Application number: 20100048683

Inventors: Mark SUTER, Sabine Vollstedt, Paul Chaplin

PHENOTYPIC AND GENOTYPIC DIFFERENCES OF MVA STRAINS

Application number: 20100011451

Inventor: Paul Chaplin

Modified vaccinia virus ankara for the vaccination of neonates

Patent number: 7628980

Inventors: Mark Suter, Sabine Vollstedt, Paul Chaplin

Modified vaccinia Ankara virus variant

Application number: 20090169579

Inventors: Paul Chaplin, Paul Howley, Christine Meisinger

MODIFIED VACCINIA VIRUS ANKARA FOR THE VACCINATION OF NEONATES

Application number: 20090104224

Inventors: Mathias Ackermann, Mark Suter, Hans Peter Hefti, Marco Franchini, Sabine Vollstedt, Paul Chaplin

Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara

Patent number: 7501127

Inventors: Paul Howley, Sonja Leyrer, Paul Chaplin, Eva Felder

MODIFIED VACCINIA ANKARA VIRUS VARIANT AND CULTIVATION METHOD

Application number: 20090017536

Inventors: Paul Chaplin, Paul Howley, Christine Meisinger-Henschel, Ingmar Rathe, Eva Felder, Karl Heller

MODIFIED VACCINIA ANKARA VIRUS VARIANT AND CULTIVATION METHOD

Application number: 20080317778

Inventors: Paul Chaplin, Paul Howley, Christine Meisinger-Henschel, Ingmar Rathe, Eva Felder, Karl Heller

Modified Vaccinia Ankara virus variant

Patent number: 7459270

Inventors: Paul Chaplin, Paul Howley, Christine Meisinger-Henschel

Modified Vaccinia Ankara virus variant and cultivation method

Patent number: 7445924

Inventors: Paul Chaplin, Paul Howley, Christine Meisinger, Ingmar Rathe, Eva Felder, Karl Heller

Modified Vaccinia Ankara virus variant

Patent number: 7384644

Inventors: Paul Chaplin, Paul Howley, Christine Meisinger-Henschel

Modified vaccinia Ankara virus variant

Application number: 20080089907

Inventors: Paul Chaplin, Paul Howley, Christine Meisinger-Henschel

Modified Vaccinia Ankara virus variant

Patent number: 7335364

Inventors: Paul Chaplin, Paul Howley, Christine Meisinger-Henschel

Modified vaccinia ankara virus variant

Patent number: 7189536

Inventors: Paul Chaplin, Paul Howley, Christine Meisinger

Modified vaccinia ankara virus variant

Application number: 20060280758

Inventors: Paul Chaplin, Paul Howley, Christine Meisinger-Henschel

Modified vaccinia virus ankara for the vaccination of neonates

Patent number: 7097842

Inventors: Mark Suter, Sabine Vollstedt, Paul Chaplin

Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of modified vaccinia virus ankara

Application number: 20060188961

Inventors: Paul Howley, Sonja Leyrer, Paul Chaplin, Eva Felder

Modified Vaccinia virus Ankara for the vaccination of neonates

Application number: 20060127984

Inventors: Mathias Ackermann, Mark Suter, Hans Hefti, Marco Franchini, Sabine Vollstedt, Paul Chaplin

Modified vaccinia ankara virus variant

Application number: 20050271688

Inventors: Paul Chaplin, Paul Howley, Christine Meisinger-Henschel

Modified vaccinia virus ankara for the vaccination of neonates

Application number: 20050260156

Inventors: Mark Suter, Sabine Vollstedt, Paul Chaplin

Modified vaccinia ankara virus variant and cultivation method

Application number: 20050214323

Inventors: Paul Chaplin, Paul Howley, Christine Meisinger-Henschel, Ingmar Rathe, Eva Felder, Karl Heller

Modified Vaccinia Ankara virus variant

Patent number: 6913752

Inventors: Paul Chaplin, Paul Howley, Christine Meisinger

Modified vaccinia ankara virus variant

Patent number: 6761893

Inventors: Paul Chaplin, Paul Howley, Christine Meisinger

Modified Vaccinia Virus Ankara for the vaccination of neonates

Application number: 20030224018

Abstract: The invention concerns the use of a virus for the preparation of a

Inventors: Mathias Ackermann, Mark Suter, Hans Peter Hefti, Marco Franchini, Sabine Vollstedt, Paul Chaplin

Modified vaccinia ankara virus variant

Application number: 20030215466

Inventors: Paul Chaplin, Paul Howley, Christine Meisinger

Modified vaccinia ankara virus variant

Application number: 20030206926

Issued: November 6, 2003

Inventors: Paul Chaplin, Paul Howley, Christine Meisinger

Modified vaccinia ankara virus variant

Application number: 20030202988

Issued: October 30, 2003

Inventors: Paul Chaplin, Paul Howley, Christine Meisinger

POX-MVA-008

DMID 05-0133

A multicenter, open-label, controlled phase II study to evaluate safety and immunogenicity of MVA-BN[®] (IMVAMUNE[®]) smallpox vaccine in 18-40 year old subjects with diagnosed atopic dermatitis

RESTRICTED
BUSINESS PROPRIETARY

Revised Study Protocol #6, 03-Feb-2010

I. General Information

Site Signature Page

Site Signature Page for Revised Protocol #6

Herewith I agree that I have read and fully understood the Revised Protocol #6

POX-MVA-008

A multicenter, open-label, controlled phase II study to evaluate the safety and immunogenicity of MVA-BN[®] (IMVAMUNE[®]) smallpox vaccine in 18-40 year old subjects with diagnosed atopic dermatitis, Revised Protocol #6, dated 03-Feb-2010, DMID 05-0133

which reveals all the Information necessary to conduct the study. I agree that I will conduct the study according to the instructions given by this protocol. Furthermore I agree that I will conduct this study according to ICH GCP, the current version of the declaration of Helsinki, U.S. Code of Federal Regulations applicable to clinical studies and local legal and regulatory requirements.

I agree that all Information revealed in this protocol is handled strictly confidential.

Other than that I will permit trial related monitoring, audits, Ethics Committee review and regulatory inspections, providing direct access to source data/documents.

_____	_____
Date	[name] Principal Investigator (PI), [site]

	[Site address]

_____	_____
Date	[name] Designee, [site]

Signature Page

By signing the Revised Study Protocol Version # 6:

A multicenter, open-label, controlled phase II study to evaluate the safety and immunogenicity of MVA-BN® (IMVAMUNE®) smallpox vaccine in 18-40 year old subjects with diagnosed atopic dermatitis, Revised Protocol #6, dated 03-Feb-2010, DMID 05-0133

the undersigned parties agree that the Protocol was written according to international ethical and scientific quality standards (ICH GCP), in compliance with the current version of the Declaration of Helsinki, the U.S. Code of Federal Regulations applicable to clinical studies and local legal and regulatory requirements.

03-Feb-2010

Date

D. v. Bredow

Dorothea von Bredow, Ph.D.
Clinical Project Leader
Bavarian Nordic GmbH

03-Feb-2010

Date

A. v. Krempelhuber
Alfred von Krempelhuber, Ph.D.
Director Clinical Operations,
Bavarian Nordic GmbH03-FEB-2010

Date

Nathaly Arndtz-Wiedemann
Nathaly Arndtz-Wiedemann, MD
Medical Monitor
Bavarian Nordic GmbH03-Feb-2010

Date

Philip Young
Philip Young, PhD
Biostatistician and Data Manager
Bavarian Nordic GmbH03-FEB-2010

Date

Thomas Meyer
Thomas Meyer, PhD
Manager Clinical Analysis
Bavarian Nordic GmbH03-Feb-2010

Date

Robert Semich
Robert Semich, PhD
GCP Manager, Quality Assurance Development
Bavarian Nordic GmbH

Signature Page (cont.)


By signing the Revised Study Protocol Version # 6:

A multicenter, open-label, controlled phase II study to evaluate the safety and immunogenicity of MVA-BN[®] (IMVAMUNE[®]) smallpox vaccine in 18-40 year old subjects with diagnosed atopic dermatitis, Revised Protocol #6, dated 03-Feb-2010, DMID 05-0133

the undersigned parties agree that the Protocol was written according to international ethical and scientific quality standards (ICH GCP), in compliance with the current version of the Declaration of Helsinki, the U.S. Code of Federal Regulations applicable to clinical studies and local legal and regulatory requirements.

03 - Feb - 2010

Date


Prof. Dr. Richard N. Greenberg, M.D.
Coordinating Investigator
University of Kentucky

II. Protocol Amendment #6

**POX-MVA-008
DMID 05-0133**

Amendment #6 to revised study protocol #5, dated 24-SEP-2008

A multicenter, open-label, controlled phase II study to evaluate safety and immunogenicity of MVA-BN[®] (IMVAMUNE[®]) smallpox vaccine in 18-40 year old subjects with diagnosed atopic dermatitis

Date of Amendment #6: 03-Feb-2010

Rationale

This Amendment implements the following changes to Bavarian Nordic Clinical Study Protocol POX-MVA-008:

The safety report for a potential Emergency Use Authorization (EUA) application described in Revised Protocol #5 will be integrated into the final clinical study report instead of being provided as a separate report.

In the original POX-MVA-008 study protocol, a cut-off value of 6 for the plaque reduction neutralization test (PRNT; secondary endpoint) was specified to define the term seroconversion. Since the PRNT has recently been redeveloped, a new cut-off value of 15 will be applied as specified in the revision of SOP/CA/017 ("Plaque Reduction Neutralization Test Using Vaccinia Virus Western Reserve"). Due to the redevelopment and subsequent revalidation of the assay which causes a delay in the planned analysis, the data for the secondary endpoint concerned will be presented in an addendum to the final study report.

The definitions for Safety Set (SAS) and Full Analysis Set (FAS) were found to be incomplete and therefore have been clarified:

Safety Set (SAS)

The analysis of safety will be performed on the safety analysis set. It consists of all subjects

- o who had received at least one dose of study vaccine and
- o for whom **any** safety data are available

Full-analysis set (FAS):

This is the subset of subjects

- o who had received at least one dose of study vaccine and
- o **for whom any data are available**

For the analysis of the enzyme-linked immunospot (ELISPOT) data, an ELISPOT analysis set (EAS) was defined. This was included to add an alternative to the per-protocol set, which is not dependent on the availability of serum samples, and hence more relevant to the analysis of the ELISPOT data.

The EAS consists of all subjects

- o with a complete ELISPOT data set (Visits 1, 2 and 4 available)
- o the administration of both study vaccinations
- o without any relevant major protocol violations

In section 9.4.3 (Analysis of safety and reactogenicity), the two sentences regarding the listing of adverse events of special interest and of cardiac symptoms have been summarized and reduced to one sentence, since cardiac symptoms belong to the group of adverse events of special interest as defined in section 8.4.

Revised Protocol #5 did not specify in sufficient detail which information to collect during the telephone follow-up. Therefore these details have been added to Revised Protocol # 6. They include information on new serious adverse events (SAEs), adverse events (AEs) that were still ongoing at Visit 5 and adverse events of special interest. An interview on the atopic dermatitis (AD) status is not required in the telephone follow-up.

Administrative changes within the study team:

Kendle's local Medical Monitor, Luis Armando Bojorquez, MD, was replaced by Leonard Wassermann, MD, with immediate effect.

Bavarian Nordic's Medical Monitor, Garth Virgin, MD, was replaced by Nathaly Arndtz-Wiedemann, MD, with immediate effect.

Covance' laboratory Project Manager for both countries US and Mexico is now Scott Wooten (previously: Kellie Estes and Eric Steele).

"PPS", "SAS", "SIAS" and "EAS" had been added to and explained in the "list of abbreviations".

These changes to the study protocol are considered not to have any negative influence on the study procedures in general, on the safety of the study participants or on the validity of the main study results.

Changes

Changes/ added terms are highlighted in **bold** letters in the text, removed terms are ~~striketrough~~.

Major changes may be made as follows:

Final Protocol # 5, dated 24-Sep-2008	Amendment 6, Revised Protocol dated 03-Feb-2010
Previously written	Changed to:
Page 12, Responsibilities Medical Monitor: ~~Garth Virgin, MD~~ ~~Director Drug Safety~~ Bavarian Nordic GmbH Fraunhoferstr. 13 82152 Martinsried, Germany ~~Phone: +49-89-85651319~~ ~~Fax: +49-89-85651419~~ ~~e-mail: garth.virgin@bavarian-nordic.com~~	Page 13, Responsibilities Medical Monitor: Nathaly Arndtz, MD Vice President Medical Affairs Bavarian Nordic GmbH Fraunhoferstr. 13 82152 Martinsried, Germany Phone: +49-89-85651308 ~~Fax: +49-89-85651419~~ e-mail: nathaly.arndtz@bavarian-nordic.com
Pages 13/ 14, Responsibilities Covance CLS ~~US Contact: Kellie Estes~~ Project Manager 8211 SciCor Drive	Page 14, Responsibilities Covance CLS US and Mexico Contact: Scott Wooten Project Manager 8211 SciCor Drive

Indianapolis, IN 46221 USA Phone: +1 317 273 7612 Fax: +1 317 616 2360 E-mail: kellie.estes@covance.com _____ Mexico Contact: Eric Steele 8211 SciCor Drive Indianapolis, IN 46221 USA Phone: +1 317 271 1200 x7101 Fax: +1 317 616 2366 E-mail: eric.steele@covance.com	Indianapolis, IN 46221 USA Phone: +1-317-273-7628 Fax: +1-317-616-2360 E-mail: scott.wooten@covance.com
---	--

Page 15, Responsibilities	Page 16, Responsibilities
Luis Armando Bojorquez Guerrero, MD Medical Officer Latin America Kendle International Via Gustavo Baz 2160 Caseta 3 Tlalnepantla, Estado de Mexico CP 54060, Mexico Phone: (52 55) 2160 0302 Fax: (52 55) 5361 4411 Mobile: (151) 3387 9024 E-mail: bojorquez.luis@kendle.com LOCAL MEDICAL MONITOR (MEXICO) BACKUP: Isaias Gaona, MD Medical Officer Kendle International Periferico Sur 4194, 3er piso Col. Jardines del Pedregal Del. Alvaro Obregón C.P. 01900, Mexico D.F. Phone: (52 55) 5481 5944 Fax: (52 55) 5135 4768 Mobile: (52 55) 2690 7223 E-mail: gaona.isaias@kendle.com	Leonard Wassermann, MD Medical Officer Latin America Kendle International Av. Córdoba 1351 piso 12 Ciudad de Buenos Aires C1055AAD- Argentina Phone: +54 114136 8000 x197 Fax: +54 114136 8016 Mobile: +54 11 4136 8097 E-mail: wasserman.leonardo@kendle.com

Pages 18 and 19 (Abbreviations)	Pages 20 - 22 (Abbreviations)
	EAS ELISPOT Analysis Set PPS Per Protocol Set SAS Safety Analysis Set SIAE Adverse event of special interest / special interest adverse event
Page 22 (IV. Protocol Synopsis)	Page 24 (IV. Protocol Synopsis)
Seroconversion is defined as Appearance of	Seroconversion is defined as Appearance of

antibody titers $\geq$ 4:6 in a vaccinia specific plaque reduction neutralisation assay	antibody titers $\geq$ 15 in a vaccinia specific plaque reduction neutralisation assay
---	---

Page 60 (7.2.1 Humoral Immunogenicity) PRNT Seroconversion is defined as Appearance of antibody titers $\geq$ 4:6 in a vaccinia specific plaque reduction neutralisation assay...	Page 66 (7.2.1 Humoral Immunogenicity) PRNT Seroconversion is defined as Appearance of antibody titers $\geq$ 15 in a vaccinia specific plaque reduction neutralisation assay...
---	---

Page 66 (9.2.1 Immunogenicity endpoints) PRNT Seroconversion is defined as Appearance of antibody titers $\geq$ 4:6 in a vaccinia specific plaque reduction neutralisation assay...	Page 71 (9.2.1 Immunogenicity endpoints) PRNT Seroconversion is defined as Appearance of antibody titers $\geq$ 15 in a vaccinia specific plaque reduction neutralisation assay...
---	---

Pages 66, 67 (9.3 Cohorts to be evaluated) Safety set: This is the subset of subjects who received at least one dose of study vaccine and for whom safety data are available. The final safety analysis will be performed on this population. Full-analysis (FA) set: This is the subset of subjects who had received at least one dose of study vaccine.	Pages 71, 72 (9.3 Cohorts to be evaluated) Safety set (SAS): This is the subset of subjects who received at least one dose of study vaccine and for whom any safety data are available. The final safety analysis will be performed on this population. Full-analysis Set (FAS): This is the subset of subjects who had received at least one dose of study vaccine and for whom any data are available.
---	--

Per Protocol (PP) set: This is the subset of subjects who adhere to all protocol conditions, however, not relevant protocol violators can be included into this dataset. The decision whether a protocol deviation is relevant or not for the classification of subjects to subsets should be made case-by case in a blind review meeting. The primary population dataset will be the PP set. All confirmatory testing is based on this subgroup. For further descriptive purposes, the same statistical procedures will be applied to the FA dataset.	Per Protocol (PPS) Set: This is the subset of subjects who adhere to all protocol conditions, however, not relevant protocol violators can be included into this dataset. The decision whether a protocol deviation is relevant or not for the classification of subjects to subsets should be made case-by case in a blind review meeting. The primary population dataset for humoral immunogenicity analysis (ELISA and PRNT) will be the PPS. All confirmatory testing is based on this population. For further descriptive purposes, the same statistical procedures will be applied to the FAS. ELISPOT Analysis Set (EAS): This set is defined as the alternative PPS for the ELISPOT data analysis. It consists of all subjects with • a complete ELISPOT data set (Visits 1, 2 and 4 available) • the administration of both study vaccinations • without any relevant major protocol violations for this data set. ELISPOT data analysis will be descriptive and performed on both the EAS and the FAS.
---	--

Page 67 (9.4 Statistical Analysis) ~~As soon as the last subject has completed Visit 5 and after any necessary settlement of queries etc. in the CRFs, data from those patients and visits will be locked. For submission of safety data as part of the Emergency Use Authorization (EUA) data package, a preliminary safety analysis will then be performed on the population described in section 9.3 ('Study cohorts/data sets to be evaluated'). These safety data will be reported in an interim safety report. Once all subjects have completed the half-year follow up (Visit F-U), a full analysis of the data available will be performed and a final clinical study report prepared.~~	Page 72/ 73 (9.4 Statistical Analysis) Once all subjects have completed the half-year follow-up (Visit F-U) and after any necessary settlement of queries etc. in the CRFs, data from all patients and visits will be locked. A full analysis of the data available will be performed and a final clinical study report prepared. Results of the PRNT assay will be presented in an addendum to the clinical study report. For preparation of safety data as part of a potential Emergency Use Authorization (EUA) data package, a safety analysis will be performed on the population (MFAS) described in section 9.3 ('Study cohorts/data sets to be evaluated').
---	--

Page 68 (9.4.2. Analysis of Immunogenicity)	Page 73 (9.4.2. Analysis of Immunogenicity)
Descriptive statistics for Enzyme-Linked Immunospot (ELISPOT) will be provided. Summary tables will be provided for the FAS and the ~~PP~~ set.	Descriptive statistics for Enzyme-Linked Immunospot (ELISPOT) will be provided. T cell samples will be analyzed if samples are available for the subject from Visit 1 and at least one of Visit 2 or Visit 4. Summary tables will be provided for the EAS and the FAS.

Page 69 (9.4.3. Analysis of safety and reactogenicity)	Page 74 (9.4.3. Analysis of safety and reactogenicity)
<i>Adverse events of special interest</i> will be separately listed and tabulated. The incidence of such AEs will be compared between treatment groups by means of the exact test of Fisher (or its normal approximation, the chi-squared test). <i>Serious adverse events</i> will be listed separately. Each SAE will be described individually in detail. The number of subjects with at least one SAE will be compared between treatment groups by means of the exact test of Fisher (or its normal approximation, the chi-squared test). ~~The occurrence, relationship and intensity of any other cardiac symptom at any time during the study will be listed. The number of subjects with at least one cardiac symptom will be compared between treatment groups by means of the exact test of Fisher (or its normal approximation, the chi-squared test).~~	The occurrence, relationship and intensity of adverse events of special interest at any time during the study will be separately listed and tabulated. The incidence of such AEs will be compared between treatment groups by means of the exact test of Fisher (or its normal approximation, the chi-squared test). <i>Serious adverse events</i> will be listed separately. Each SAE will be described individually in detail. The number of subjects with at least one SAE will be compared between treatment groups by means of the exact test of Fisher (or its normal approximation, the chi-squared test).

Page 81 (16.4.2 Extension Protocol Flow Chart)			Page 87 (16.4.2 Extension Protocol Flow Chart)		
Visit	Visit 5	Telephone F-U	Visit	Visit 5	Telephone F-U
Day (d)	Visit 3 +28-35 d	Visit 3 +182-210 d	Day (d)	Visit 3 +28-35 d	Visit 3 +182-210 d
Brief interview on AD status ⁷		*	Brief interview on AD status ⁷		

Telephone Follow-up for serious adverse events		X		Telephone Follow-up for SAEs, SIAEs and AEs that were still ongoing at visit 5		X	
--	--	---	--	---	--	---	--

III. Responsibilities

STUDY NUMBER: POX-MVA-008

STUDY TITLE: A multicenter, open-label, controlled phase II study to evaluate safety and immunogenicity of MVA-BN[®] (IMVAMUNE[®]) smallpox vaccine in 18-40 year old subjects with diagnosed atopic dermatitis

COORDINATING INVESTIGATOR: Prof. Dr. Richard N. Greenberg, M.D.
Professor of Medicine
The Belinda Mason Carden and Paul Mason Professor of HIV/AIDS Research and Education
University of Kentucky School of Medicine
Department of Medicine, Room MN672
800 Rose Street
Lexington, KY 40536-0084, USA

Phone: +1-859-323-6327
Fax: +1-859-323-1631
Pager: +1-859-276-7352
E-mail: rngree01@email.uky.edu

SPONSOR and PRODUCT SUPPLY Bavarian Nordic A/S
Hejreskovvej 10A
DK-3490 Kvistgård, Denmark

Phone: +45-33-268383
Fax: +45-33-268380

MEDICAL MONITOR: Nathaly Arndtz-Wiedemann MD
VP Medical Affairs
Bavarian Nordic GmbH
Fraunhoferstrasse 13
82152 Martinsried, Germany

Phone: +49-89-85651308
Fax: +49-89-85651419
E-mail: nathaly.arndtz@bavarian-nordic.com

CLINICAL PROJECT LEADER: Dorothea von Bredow, PhD
Bavarian Nordic GmbH
Fraunhoferstrasse 13
82152 Martinsried, Germany

Phone: +49-89-85651318
Fax: +49-89-85651333
E-mail: dorothea.bredow@bavarian-nordic.com

CLINICAL DEVELOPMENT

MANAGER: Alfred von Krempelhuber, PhD
Bavarian Nordic GmbH
Fraunhoferstrasse 13
82152 Martinsried, Germany
Phone: +49-89-85651369
Fax: +49-89-85651333
E-mail: alfred.krempelhuber@bavarian-nordic.com

STUDY STATISTICIAN(S): Philip Young, PhD
Bavarian Nordic GmbH
Fraunhoferstrasse 13
82152 Martinsried, Germany
Phone: +49-89-85651462
Fax: +49-89-85651333
E-mail: philip.young@bavarian-nordic.com

CRO/PROJECT MANAGER: Emily Graham, MA
Project Leader
Global Clinical Development - North America Kendle
315 E. Eisenhower Pkwy, Suite 214
Ann Arbor, MI 48108
Phone: +1 734 274 8511
Fax: +1 866 552 9983
Email: graham.emilyr@kendle.com

**CRO/LEAD MONITOR:
(MEXICO)** Margarita Candela
Kendle Mexico
Periférico Sur # 4194-2 piso
Col. Jardines del Pedregal,
C.P. 01900. México, D.F.
Phone: +52-55-5481-5900 ext 137
Fax: +52-55-5135-4571
E-mail: candela.margarita@kendle.com

**CRO/LEAD MONITOR
(US):** Leslie Pies, MEd
Kendle International
1880 Pacific Place
Lawrenceburg, IN 47025
Phone: +1 812-637-5164
Fax: +1 866-612-5397 / 812-637-0739
E-mail: pies.leslie@kendle.com

**LABORATORY:
(SAFETY)** Covance CLS
US and Mexico Contact:
Scott Wooten
Project Manager
8211 SciCor Drive
Indianapolis, IN 46221
USA
Phone: +1-317-273-7628

RESTRICTED BUSINESS PROPRIETY

Fax: +1-317-616-2360
E-mail: scott.wooten@covance.com

**LABORATORY
(IMMUNOLOGY)**

Thomas Meyer, PhD
Bavarian Nordic GmbH
Fraunhoferstrasse 13
82152 Martinsried, Germany
Phone: +49-89-85651405
Fax: +49-89-85651333
E-mail: thomas.meyer@bavarian-nordic.com

Focus Diagnostics, Inc.
Contact: Keith Gottlieb
Scientist
10703 Progress Way
Cypress,
California 90630
USA
Phone: +1-714-220-1900
Fax: +1-714-484-1296
E-mail: kgottlieb@focusdx.com

**CENTRALIZED ECG
ASSESSMENT:**

Kendle UK Ltd.
Contact: Mary Hyman
38, Wellington Business Park
Crowthorne
Berkshire RG45 6LS
United Kingdom
Phone: +44-1344-753046
Fax: +44-1344-760995
E-mail: hyman.mary@kendle.com

CENTRAL CARDIOLOGIST: Lamin King, MD
28A Cambridge Avenue
Kilburn
London NW6 5BA
England
Phone: +44-7931-584974
E-mail: laminking@yahoo.com

**LOCAL MEDICAL
MONITOR (MEXICO):**

Leonard Wassermann, MD
Medical Officer Latin America
Av. Córdoba 1351 piso 12
Ciudad de Buenos Aires
C1055AAD– Argentina
+54 114136 8000 x197
+54 114136 8016
+54 11 4136 8097
wasserman.leonardo@kendle.com

Phone:

Fax:

Mobile:

E-mail:

Table of contents

I.	GENERAL INFORMATION	2
II.	PROTOCOL AMENDMENT #6	5
III.	RESPONSIBILITIES.....	13
IV.	PROTOCOL SYNOPSIS	23
V.	FLOW CHART	29
VI.	SCIENTIFIC SECTION	31
1.	INTRODUCTION.....	31
1.1	Background information.....	31
1.2	Origin and characteristics of MVA.....	32
1.3	Summary of Preclinical Data.....	33
1.4	Summary of Clinical Data.....	34
1.4.1	Clinical Experience with the MVA precursor vaccine.....	34
1.4.2	Clinical Experience with MVA-BN® (IMVAMUNE®).....	35
1.5	Rationale	40
1.6	Dose, route of administration, vaccination schedule	41
1.7	Benefit/risk assessment	41
2.	OBJECTIVES	42
3.	STUDY DESIGN	44
3.1	Experimental design	44
3.2	Description of study procedures	44
3.2.1	Screening phase	44
3.2.2	Active study phase	45
3.2.3	Follow-up phase	48
3.2.4	Protocol Extension	48
3.3	Study duration.....	48
4.	SELECTION OF SUBJECTS	49
4.1	Recruitment procedure.....	49
4.2	Inclusion criteria	50
4.3	Exclusion criteria	51
5.	STUDY HALTING/TERMINATION AND WITHDRAWAL OF SUBJECTS.....	53

5.1	Study halting and termination rule	53
5.2	Reporting of events fulfilling the study halting criteria.....	53
5.3	Data Safety Monitoring Board (DSMB).....	53
5.4	Individual withdrawal criteria during the study.....	53
5.5	Subject withdrawal procedure	54
5.6	Contraindications and precautions for further study vaccinations	54
6.	STUDY TREATMENT.....	55
6.1	Investigational product.....	55
6.2	Packaging and labelling	55
6.3	Vaccine storage, handling and dispensing	56
6.4	Dose, vaccination schedule and route of administration.....	56
6.5	Accountability and disposal.....	56
6.6	Concomitant medication	57
7.	CLINICAL AND LABORATORY ASSESSMENTS	58
7.1	Assessment of safety and reactogenicity.....	58
7.1.1	Medical history	58
7.1.2	Physical examination and vital signs.....	58
7.1.3	Laboratory measurements	58
7.1.4	ECG assessments.....	60
7.1.5	Assessment of solicited adverse events (Diary)	61
7.1.6	Assessment of unsolicited adverse events	62
7.1.7	Assessment of intensity for adverse events.....	63
7.1.8	Assessment of causality for adverse events.....	64
7.1.9	Algorithm for assessment of cardiac events	65
7.2	Assessment of immunogenicity	66
7.2.1	Humoral immunogenicity.....	66
7.2.2	Cellular immunogenicity	66
8.	ADVERSE EVENT DEFINITIONS AND REPORTING.....	67
8.1	Definition of adverse event	67
8.2	Definition of solicited adverse events.....	67
8.3	Definition of unsolicited adverse events	67
8.4	Definition of “adverse event of special interest”	67
8.5	Definition of serious adverse events (SAEs).....	68
8.6	Reporting of SAEs and adverse events of special interest.....	68
9.	STATISTICAL CONSIDERATIONS	70

9.1	Sample size calculation	70
9.2	Endpoints.....	70
9.2.1	Immunogenicity endpoints	70
9.2.2	Safety and reactogenicity endpoints	71
9.3	Study cohorts/data sets to be evaluated	71
9.4	Statistical analysis	72
9.4.1	Analysis of demographics and baseline characteristics.....	73
9.4.2	Analysis of Immunogenicity.....	73
9.4.3	Analysis of safety and reactogenicity.....	73
9.4.4	Data handling	75
10.	ETHICAL ASPECTS.....	76
10.1	Ethical and legal regulations.....	76
10.2	Approval of an Independent Ethics Committee (IEC) / Institutional Review Board (IRB) 76	76
10.3	Confidentiality and data protection	76
11.	INFORMED CONSENT	77
12.	CASE REPORT FORMS AND RETENTION OF RECORDS.....	77
12.1	Case report forms	77
12.2	Retention of records	77
13.	MONITORING OF THE STUDY	78
14.	RESPONSIBILITIES OF THE INVESTIGATOR.....	78
15.	REFERENCES	80
16.	APPENDICES.....	82
16.1	Appendix I: Toxicity Scale for laboratory values	82
16.2	Appendix II: Case Definitions Acute Myocarditis / Pericarditis	84
16.3	Appendix III: SCORAD Evaluation Form	85
16.4	Appendix IV: Proposed Extension Phase of the POX-MVA-008 trial.....	86
16.4.1	General Information and Rationale for an Extension Phase of the POX-MVA-008 trial.....	86
16.4.2	Extension Protocol Flow Chart.....	87
16.4.3	Inclusion & Exclusion Criteria.....	88
16.4.4	Statistical Considerations.....	88
16.5	Appendix V: Exchange of IMVAMUNE® vaccine lot 0170505 by IMVAMUNE® vaccine lot 0040707	89

List of abbreviations


ACIP	Advisory Committee on Immunization Practices
AD	Atopic Dermatitis
ADR	Adverse Drug Reaction
AE	Adverse Event
AIDS	Acquired Immunodeficiency Syndrome
ALT	Alanine Aminotransferase
ANC	Absolute Neutrophil Count
AST	Aspartate Aminotransferase
ATP	According to Protocol
CBC	Complete Blood Count
CD	Cluster of Differentiation
CEF	Chicken Embryo Fibroblast
CI	Confidence Interval
CRF(s)	Case Report Form(s)
CRO	Contract Research Organization
CTL	Cytotoxic T-Lymphocyte
CVA	Chorioallantois Vaccinia Virus Ankara
DHHS	United States Department of Health and Human Services
DMID	Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases
DNA	Deoxyribonucleic acid
DSMB	Data Safety Monitoring Board
EAS	ELISPOT Analysis Set
ECG	Electrocardiogram
ELISA	Enzyme-linked Immunosorbent Assay
ELISPOT	Enzyme-Linked Immunospot
EUA	Emergency Use Authorization
FAS	Full Analysis Set
F-U	Follow-up
GCP	Good Clinical Practice
GMT	Geometric Mean Titer
HCG	Human Choriogonadotropin
HIV	Human Immunodeficiency Virus

ICH	International Conference of Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use
ICS	Intracellular Cytokine Staining
i.d.	Intra-dermal
IEC	Independent Ethical Committee
IFN	Interferon
IgG	Immunoglobulin G
i.m.	Intra-muscular
i.n.	Intra-nasal
i.p.	Intra-peritoneal
IRB	Institutional Review Board
i.t.	Intra-tracheal
LL	Lower Limit
LLN	Lower Limit of Normal
MedDRA	Medical Dictionary for Regulatory Activities
MFAS	Modified Full Analysis Set
MVA	Modified Vaccinia Ankara Strain
MVA-BN [®]	Modified Vaccinia Ankara – Bavarian Nordic
n/N	Number
NCI	National Cancer Institute
NYCBOH	New York City Board of Health
PBMC	Peripheral Blood Mononuclear Cells
p.o.	Per-oral
PP	Per Protocol
PPS	Per Protocol Set
PRNT	Plaque Reduction Neutralization Test
PVC	Premature Ventricular Contractions
RBC	Red Blood Cells
SAE	Serious Adverse Event
SAS	Safety Analysis Set
s.c.	Subcutaneous
SCORAD	Scoring Atopic Dermatitis
SCR	Screening
SFU	Spot Forming Unit
SGOT	Serum Glutamic Oxaloacetic Transaminase

SGPT	Serum Glutamic Pyruvic Transaminase
SIAE	Adverse event of special interest / special interest adverse event
ST	ST Segment in Electrocardiogram
TCID ₅₀	Tissue Culture Infectious Dose 50
UL	Upper Limit
ULN	Upper Limit of Normal
V	Visit
VV	Vaccinia Virus
WBC	White Blood Cell Count
WHO	World Health Organization

IV. Protocol Synopsis

Title	A multicenter, open-label, controlled phase II study to evaluate immunogenicity and safety of MVA-BN [®] (IMVAMUNE [®]) smallpox vaccine in 18-40 year old subjects with diagnosed atopic dermatitis
Clinical phase	Phase II
Sponsor	Bavarian Nordic A/S Hejreskovvej 10A DK-3490 Kvistgård, Denmark
Coordinating Investigator	Prof. Dr. Richard N. Greenberg University of Kentucky, Lexington, KY, USA
Vaccination dose and schedule	One 0.5 ml dose MVA-BN [®] (IMVAMUNE [®]) liquid-frozen contains 1 x 10 ⁸ TCID ₅₀ Modified Vaccinia virus Ankara. Two vaccinations of 0.5 ml MVA-BN [®] (IMVAMUNE [®]) vaccine will be given according to schedule 0 – 4 weeks.
Route of administration	Each immunization consists of one subcutaneous (s.c.) injection in the non-dominant upper arm.
Study duration	Up to 39 weeks for each subject
Sample size	The total sample size will be 260 (130 per group). In an extension phase, 100 additional healthy subjects and 200 additional subjects with diagnosed atopic dermatitis (Group 2) will be enrolled.
Study design	Open-label, controlled, 2 study groups: Group 1: Healthy, vaccinia naïve subjects without atopic disease (n = 130) Group 2: Vaccinia naïve subjects with diagnosed atopic dermatitis (n = 130)



Visit Days						
-28- -1	0	7 - 10	28 - 35	V3 + 10-14	V3 + 28-35	V3 + 182-210
Scr	V1	V2	V3	V4	V5	F-U

1.1.1.1 After enrollment of 130 subjects each in Group 1 and Group

RESTRICTED BUSINESS PROPRIETY

2, the enrollment into the two study groups will be extended by another 100 vaccinia naïve healthy subjects and 200 vaccinia naïve subjects with 1.1.1.2 diagnosed atopic dermatitis. Please refer to Appendix IV for details of the protocol extension.

Primary objectives	To assess the humoral immune response (measured in ELISA) induced to MVA-BN [®] (IMVAMUNE [®]) in subjects with diagnosed atopic dermatitis compared to healthy subjects.
Secondary objectives	- To assess safety of MVA-BN[®] (IMVAMUNE[®]) in subjects with atopic dermatitis compared to healthy subjects. - To assess reactogenicity of MVA-BN[®] (IMVAMUNE[®]) in subjects with atopic dermatitis compared to healthy subjects. - To assess the immune responses measured with the plaque reduction neutralization test (PRNT) and Enzyme-Linked Immunospot (ELISPOT) induced to MVA-BN[®] (IMVAMUNE[®]) in subjects with diagnosed atopic dermatitis compared to healthy subjects. ELISPOT: Subgroup of 50 subjects from Group 1 (healthy) and 110 subjects from Group 2 (AD) with samples taken at each of the Visits 1, 2 and 4 collected at US sites. The first subjects enrolled into the study will be included in the subgroup until the numbers specified above are reached.
Primary endpoint	ELISA specific seroconversion rate at visit 4 <i>Seroconversion is defined as the appearance of antibody titers $\geq 1:50$ in a vaccinia specific IgG ELISA for initially seronegative subjects or twofold increase of the antibody titer compared to the pre-existing baseline titer for subjects with a pre-existing antibody titer in the ELISA.</i>
Secondary endpoints	- ELISA specific seroconversion rate at visits 2, 3 and 5 and F-U. - Geometric mean titers (at all blood sampling time points). <i>The geometric mean titer (GMT) is calculated by taking the antilogarithm of the mean of the log10 titer transformations. Antibody titers below the cut-off of the assay will be given an arbitrary value of one for the purpose of calculation.</i> - Neutralization assay specific seroconversion rates and geometric mean titers (at all blood sampling time points). <i>Seroconversion is defined as Appearance of antibody titers ≥ 15 in a vaccinia specific plaque reduction neutralisation assay for initially seronegative subjects or twofold increase of the antibody titer compared to the pre-existing baseline titer for subjects with a pre-existing antibody titer in the PRNT.</i> <i>The GMT is calculated by taking the antilogarithm of the mean of the log10 titer transformations. Antibody titers below the cut-off of the assay will be given an arbitrary value of one for the purpose of calculation.</i> - Subgroup of 50 subjects from Group 1 (healthy) and 110 subjects from Group 2 (AD) collected at US sites: IFN gamma producing T-cells collected at Visits 1, 2 and 4 in response to stimulation with MVA-BN[®] (IMVAMUNE[®]) detected by Enzyme-Linked Immunospot (ELISPOT). The percentage of IFN gamma positive cells in T-cell populations compared to non-stimulated cells will be reported.

- Occurrence of any grade 3 adverse event probably, possibly or definitely related to the study vaccine within 28 days after vaccination.
- Occurrence, relationship and intensity of any serious adverse event at any time during the study.
- Occurrence of solicited local adverse events (erythema, swelling and pain) within 1 week after each vaccination (Days 0-7): Intensity and duration of local adverse events.
- Occurrence of solicited systemic adverse events (pyrexia, headache, myalgia, nausea, fatigue and chills) within 1 week after each vaccination (Days 0-7): Intensity and duration of systemic adverse events.
- Occurrence of unsolicited non-serious adverse events within 4 weeks after each vaccination (Days 0-28): Intensity, duration and relationship to vaccination.

Inclusion criteria **Group 1:**

1. Subjects without present or history of any kind of atopy. Subjects with seasonal allergies can only be enrolled if an association with other atopic disorders such as allergic rhinitis and asthma can be excluded.

Group 2:

2. Subjects with diagnosed atopic dermatitis. "Diagnosed" atopic dermatitis includes subjects with either documented history of or subjects with currently active (defined as SCORAD $\leq$ 30, Kunz et al., 1997) atopic dermatitis. Currently active atopic dermatitis includes relapsing forms of atopic dermatitis, also when subjects are enrolled during inflammation-free intervals.

All study subjects:

3. Male and female subjects between 18 and 40 years of age without history of smallpox vaccination.
4. Women must have a negative serum pregnancy test at screening and a negative urine pregnancy test within 24 hours prior to vaccination.
5. Women of childbearing potential must have used an acceptable method of contraception for 30 days prior to the first vaccination, must agree to use an acceptable method of contraception during the study, and must not become pregnant for at least 28 days after the last vaccination. A woman is considered of childbearing potential unless post-menopausal or surgically sterilized. (Acceptable contraception methods are restricted to abstinence, barrier contraceptives, intrauterine contraceptive devices or licensed hormonal products.)
6. Read, signed and dated informed consent document after being advised of the risks and benefits of the study in a language understood by the subject signed, and prior to performance of any study specific procedure.
7. Troponin I < 2 fold ULN.

8. White blood cells $\geq 2500/\text{mm}^3$ and $< 11,000/\text{mm}^3$.
9. Absolute neutrophil count (ANC) within normal limits
10. Negative urine glucose by dipstick or urinalysis.
11. Hemoglobin within normal limits.
12. Platelets within normal limits.
13. Adequate renal function defined as:
 - a. Serum creatinine without clinically significant findings
 - b. Urine protein $< 30 \text{ mg/dL}$ or none or trace proteinuria (by urinalysis or dip stick).
14. Adequate hepatic function defined as:
 - a. Total bilirubin $\leq 1.5 \times \text{ULN}$ in the absence of other evidence of significant liver disease
 - b. AST (SGOT), ALT (SGPT) and alkaline phosphatase without clinically significant findings
15. Electrocardiogram (ECG) without clinically significant findings (e.g. any kind of atrioventricular or intraventricular conditions or blocks such as complete left or right bundle branch block, AV-node block, QTc or PR prolongation, premature atrial contractions or other atrial arrhythmia, sustained ventricular arrhythmia, 2 premature ventricular contractions (PVC) in a row, ST elevation consistent with ischemia).
16. Availability for follow-up for the planned duration of the study (26 weeks after last vaccination).

Exclusion
criteria

1. Pregnant or breast-feeding women.
2. Uncontrolled serious infection i.e. not responding to antimicrobial therapy.
3. History of any serious medical condition, which in the opinion of the Investigator would compromise the safety of the subject.
4. History of or active autoimmune disease. Persons with vitiligo or thyroid disease taking thyroid replacement are not excluded.
5. Known or suspected impairment of immunologic function including, but not limited to, clinically significant liver disease; diabetes mellitus; moderate to severe kidney impairment.
6. History of malignancy, other than squamous cell or basal cell skin cancer, unless there has been surgical excision that is considered to have achieved cure. Subjects with history of skin cancer at the vaccination site are excluded.
7. History or clinical manifestation of clinically significant and severe hematological, renal, hepatic, pulmonary, central nervous, cardiovascular or gastrointestinal disorders.
8. Clinically significant mental disorder not adequately controlled by medical treatment.
9. Any condition which might interfere with study objectives or would limit the subject's ability to complete the study or to be compliant in the opinion of the Investigator.
10. History of coronary heart disease, myocardial infarction, angina, congestive heart failure, cardiomyopathy, stroke or transient ischemic attack, uncontrolled high blood pressure.
11. History of an immediate family member (father, mother, brother, or sister) who has had onset of ischemic heart disease before age 50

- years.
12. Ten percent or greater risk of developing a myocardial infarction or coronary death within the next 10 years using the National Cholesterol Education Program's risk assessment tool:
(<http://hp2010.nhlbi.nih.net/atpiii/calculator.asp?usertype=prof>)
NOTE: This criterion applies only to volunteers 20 years of age and older.
 13. History of intravenous drug abuse.
 14. History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.
 15. Known allergy to egg or aminoglycoside (gentamicin).
 16. History of anaphylaxis or severe allergic reaction.
 17. Acute disease (illness with or without a fever) at the time of enrollment.
 18. Temperature $\geq 100.4^{\circ}\text{F}$ ($\geq 38.0^{\circ}\text{C}$) at the time of enrollment.
 19. Subjects undergoing treatment for tuberculosis infection or disease.
 20. Having received any vaccinations or planned vaccinations with a live vaccine within 30 days prior or after study vaccination.
 21. Having received any vaccinations or planned vaccinations with a killed vaccine within 14 days prior or after study vaccination.
 22. Chronic administration (defined as more than 14 days) of systemic immuno-suppressants during a period starting from six months prior to administration of the vaccine and ending at study conclusion. Subjects receiving chronic treatment (defined as more than 14 days) with topical calcineurine inhibitors (e.g. tacrolimus, pimecrolimus) on the body or $> 25\%$ of the facial area are excluded. A wash-out period of ≥ 14 days for tacrolimus and ≥ 28 days for pimecrolimus can be considered sufficient before enrollment into the study.
Subjects receiving chronic treatment (defined as more than 14 days) with high dose topical cortisone (> 30 grams/week of an intermediate potency [class IV] topical steroid [or equivalent], the treated area must not exceed 10% of the total body surface) are excluded.
 23. Post organ transplant subjects whether or not receiving chronic immunosuppressive therapy.
 24. Administration or planned administration of immunoglobulins and/or any blood products during a period starting from 3 months prior to administration of the vaccine and ending at study conclusion.
 25. Use of any investigational or non-registered drug or vaccine other than the study vaccine within 30 days preceding the first dose of the study vaccine, or planned administration of such a drug during the study period.
 26. Study personnel.

Statistical
Considerations

The sample size calculation is based on the primary immunogenicity endpoint '**MVA-specific seroconversion rate**'.

- o *Seroconversion is defined as the appearance of antibody titers $\geq 1:50$ in a vaccinia specific IgG ELISA for initially seronegative subjects or twofold increase of the antibody titer compared to the pre-existing baseline titer for*

subjects with a pre-existing antibody titer in the ELISA.

The primary hypothesis is to show that the humoral immune response of the group with diagnosed atopic dermatitis (Group 2) is not statistically inferior compared to the group with healthy subjects (Group 1). The study should demonstrate that the Group 2 seroconversion rate is not worse than the Group 1 seroconversion rate by more than a pre-specified amount. This amount is called the non-inferiority margin (Δ).

Suppose p_1 is the seroconversion rate in healthy subjects (group 1) and p_2 is the seroconversion rate in the subjects with atopic dermatitis (group 2).

The test on non-inferiority will be applied for the following hypothesis:

$$H_0: p_2 - p_1 \leq -\Delta \quad \text{versus} \quad H_1: p_2 - p_1 > -\Delta, \text{ where}$$

Δ is the non-inferiority margin and is chosen in this trial as 5%.

From the experience in the pilot trial POX-MVA-007 in subjects with atopic dermatitis subjects, it is anticipated that the seroconversion rate in both groups reaches at least 99%.

Assuming a significance level of 5%, a power of >80%, expected seroconversion rates of 99% in both groups, this yields to a sample size of 124 per group (248 in total). In order to account for about 5% drop out rate, a total of 130 subjects per group (260 in total) will be treated.

For the statistical consideration of the protocol extension, please refer to Appendix IV.

V. Flow Chart

VISIT ¹	SCREENING	VISIT 1	VISIT 2	VISIT 3	VISIT 4	VISIT 5	VISIT F-U
Day (D)	-28- -1 D	0	7-10 D	28-35 D	VISIT 3 +10-14 D	VISIT 3 +28-35 D	VISIT 3 +182-210 D
Vaccination		I		II			
Informed consent ²	X						
Screening examinations	X						
Check incl. / excl. criteria, esp. cardiac risk	X	X		X			
Medical History (incl. history of AD)	X						
Interview on history of AD ³	X						
Examination of AD including SCORAD ³ (active AD only)	X						
Brief interview on AD status ³ (including SCORAD for active AD only)						X	
Brief interview on AD status ³							X
Complete Physical examination incl. evaluation of vital signs, esp. listening to heart and lung	X						
Targeted physical exam.		X	X	X	X	X	X
ECG	X		X		X	(X) ⁴	(X) ⁴
Pregnancy test ³	X	X		X		X	
Safety Lab	X		X		X	(X) ⁴	(X) ⁴
Urine analysis	X						
Antibody analysis		X	X	X	X	X	X
T-Cell analysis (subgroup of 50 Gr.1 and 110 Gr. 2 subjects, US sites only)		X	X		X		
Handout of diary card ⁵		X		X			
Collection of diary card			X		X		
Exam of vaccination site			X		X		
AE-reporting		X	X	X	X	X	X ⁶
Review baseline signs and symptoms	X	X					
Blood sampling in ml ⁷	14	16	30	16	30	16 (+14) ⁴	16 (+14) ⁴
Approx. blood sampling in ml ⁷ including T cell analysis (subgroup)	14	80	94	16	94	16 (+14) ⁴	16 (+14) ⁴

¹ If clinically indicated additional visits may be necessary between scheduled visits and possibly additional blood draws may occur. Visits occurring between indicated scheduled visits will be identified with letters to indicate sequence of the visit until the next scheduled visit occurs (e.g. 1A, 1B etc. will indicate extra visits between visit 1 and 2).

² Consent process must be completed and form signed before any study-related procedures are conducted.

³ Serum or urine pregnancy test, women of childbearing potential only. At screening visit, a serum test must be performed.

⁴ Only required if clinically indicated.

⁵ The Diary Card should be completed daily for 7 days. If symptoms persist at day 7, temperature/symptom measurements should be recorded each day until resolved.

⁶ Serious adverse events only.

RESTRICTED BUSINESS PROPRIETY

⁷ Approx amount of blood needed for analysis: Safety lab: app.14 ml, Antibody analysis: app. 16 ml, T-Cell analysis (subgroup): app. 64 ml. Amount of blood taken during the study: app. 166 ml (subgroup up to 358 ml)

⁸ Group 2 (AD) only

VI. Scientific Section

1. Introduction

1.1 Background information

In Germany during the period from 1960 to 1974, Professor Anton Mayr succeeded in attenuating the dermal vaccinia strain Ankara (CVA) by over 500 continuous passages in primary chicken embryo fibroblast cultures (CEF). The rationale was to attenuate the smallpox vaccine so that the complications associated with vaccination could be reduced or completely eliminated and make safer parenteral vaccination possible. This highly attenuated virus of CVA was named MVA (modified vaccinia Ankara). It was demonstrated that it had retained its original immunogenicity and its protective effect against variola and general Orthopox infections and offers a greatly diminished virulence for humans and animals combined with the loss of contagiousness. It was shown that vaccination-induced disease does not occur in newborn animals (mice, rabbits, and chickens) and immunosuppressed vaccinated animals (by radiation, iatrogenic immune suppression). Local (cutaneous, oral, and intranasal) and parenteral (subcutaneous, intramuscular) administration of MVA are both possible, safe and retain immunizing efficacy (Mayr & Munz 1964; Stickl *et al.* 1974; Stickl, Hochstein-Mintzel, Mayr, Huber, Schafer, & Holzner 1974; Mayr *et al.* 1975).

In Germany, the MVA strain was officially authorized for two-stage parenteral smallpox vaccination in children in 1976. It was used in approximately 120,000 Caucasian individuals with no reported side effects, even though many of the subjects were among the population with high risk of developing complications (Mayr *et al.* 1978).

In May 1980, the World Health Organization (WHO) declared the global eradication of smallpox. Since 1982, smallpox vaccination has not been required for international travelers' vaccination and International Certificates of Vaccination no longer include smallpox. As smallpox vaccination was deleted from the vaccination schedules, production of the vaccine was no longer required.

Despite the fact that the WHO officially declared smallpox eradicated in 1980, a new threat exists from the use of variola in biological warfare and/or bio-terrorism. Indeed, as mass vaccination programs halted more than 20 years ago, most people have no existing immunity to smallpox, and as such the release of this highly contagious virus would have devastating effects. As a consequence, there is an urgent need by many Governments for a safe efficacious vaccine to protect the public against smallpox.

The original smallpox vaccines were based on a number of different vaccinia strains e.g. Lister-Elstree strain recommended by the World Health Organization (WHO) and used in Germany or the New York City Board of Health (NYCBOH) strain used in the United States. While these proved to be highly effective immunizing agents they also showed considerable side effects. Besides from local reactions with scab development and scarring, general symptoms observed frequently after smallpox vaccination have been fever, weakness, muscular pain, headache, swelling and soreness of local lymph nodes and rashes. Fever occurred in the majority of vaccinees, especially in small children: up to 70% got temperatures of 38°C, 15-20% showed even higher rates. Apart from less dramatic and transient side effects like erythematous or urticarial rashes, severe and potentially fatal cutaneous complications of vaccinia vaccination

include eczema vaccinatum and progressive vaccinia. Most feared are complications of the central nervous system, especially post-vaccinal encephalitis, followed in 15-25% by death and in 25% by neurologic sequelae (Goldstein *et al.* 1975; Lane *et al.* 1969; Lane *et al.* 1970). In Germany, the occurrence of neurological complications in primary vaccinees was reported in 1:20,000 to 30,000 vaccinees and while other countries such as the United States excluded high-risk individuals from vaccination, an average of seven persons a year still died from complications due to smallpox vaccination (McElwain 1972). Another consideration for the discontinued use of the classical smallpox vaccine is the world prevalence of HIV and AIDS. The classical replication competent smallpox vaccine could be lethal if given to immune compromised individuals. A study published in 1991 (Guillaume *et al.* 1991) reported the case of two HIV infected individuals that received an experimental immunotherapy in the form of paraformaldehyde fixed autologous T cells previously infected with recombinant vaccinia viruses. Both these patients were immune compromised and experienced necrotic skin lesions due to generalised vaccinia infections that led to death. However, complications can also occur in HIV infected individuals that have a good T cell count and appear healthy following vaccinations with vaccinia (Redfield *et al.* 1987) demonstrating the severe implications of a wide spread use of vaccinia based vaccines.

Bavarian Nordic's (BN's) proprietary Modified Vaccinia Ankara vector (MVA-BN[®]) is a live attenuated pox virus derived from Anton Mayr's seed virus used to vaccinate more than 120,000 people in Germany during the smallpox vaccination program in the late seventies. This vaccine possesses a number of characteristics that makes it highly suitable for prophylactic and therapeutic vaccination. The vaccine has a superior safety record in comparison to other viruses. The vaccine's immunogenic potential has been demonstrated in animal studies and is known from data in humans vaccinated during the two-step vaccination program in Germany (Mayr *et al.* 1978).

BN has established a state of the art current Good Manufacturing Practice (cGMP) rated production process for MVA-BN[®] (IMVAMUNE[®]) as well as for MVA-BN[®] derived recombinant viruses.

1.2 Origin and characteristics of MVA

Vaccinia virus (VV) is considered the best known member of the poxvirus family and the prototype live viral vaccine. VV replicates in the cytoplasm of the host cell, its DNA does not integrate into the host cell genome and it is non-oncogenic.

MVA was derived from the VV strain Ankara by 574 serial passages in CEF. From passage 530 the virus is named MVA and has a stabilized immunogenicity, extremely reduced transmission and no induction of a carrier status. During passaging, MVA has suffered a multitude of mutations within its genome and six major deletions resulting in the loss of 15% (30kbp) of original genetic information (Antoine *et al.* 1998). The deletions affect a number of virulence and host range genes as well as the gene for the Type A inclusion bodies (Antoine, Scheiflinger, Dorner, & Falkner 1998; Rosel *et al.* 1986; Meyer *et al.* 1991). As a consequence, MVA exhibits a severely restricted host range, and replicates only very poorly, if at all, in most mammalian cell types, including primary human cells and most transformed human cell lines (Sutter & Moss 1992; Carroll & Moss 1997; Blanchard *et al.* 1998; Drexler *et al.* 1998).

Although MVA exhibits a strongly attenuated replication in these cell types its genes are efficiently transcribed, with the block in viral replication being at the level of virus assembly and

egress (Sutter & Moss 1992; Carroll & Moss 1997). Genetic reconstitution of one of the deletions in the MVA genome affecting, besides other genes, the VV host range gene K1L restored MVA replication in some mammalian cell lines, but failed to restore the growth capacity of MVA in human cells (Meyer et al. 1991; Carroll & Moss 1997).

Taken together with the loss of 15% of its genome, MVA is therefore unlikely to be able to spontaneously regain its replication competency following injection into humans. Despite its high attenuation and reduced virulence, MVA has retained its stable immunogenic properties and variola-protective effect.

MVA is a potent inducer of type I interferon (IFN) in human cells and it expresses a soluble interleukin-1 receptor (Blanchard et al. 1998), which has been implicated as an anti-virulence factor for certain poxviruses (Alcami & Smith 1992; Alcamí & Smith 1996). In contrast to VV, MVA does not express soluble receptors for IFN γ , IFN α/β , tumor necrosis factor and CC chemokines (Antoine et al. 1998; Blanchard et al. 1998). MVA is known to have protective immunogenic potential against any kind of orthopox virus.

Taken together with its restricted host range these factors may explain the avirulent phenotype observed for MVA *in vivo* in a wide variety of mammalian species including humans (see below). As a consequence, MVA was used in more than 120,000 human subjects as part of a two-step vaccination protocol, combined with conventional vaccinia virus, against smallpox in Germany (Mayr et al. 1978).

MVA-BN[®] (IMVAMUNE[®]) is a highly attenuated, purified live vaccine produced under serum-free conditions in CEF cells. Extensive in-house studies have demonstrated that MVA-BN[®] (IMVAMUNE[®]) has superior characteristics compared to other MVA strains, which include:

- MVA-BN[®] (IMVAMUNE[®]) has a superior attenuation compared to other MVA strains that replicate in various human cells.
- MVA-BN[®] (IMVAMUNE[®]) vaccinations are safe in severely immune compromised animals, whereas other MVA strains replicate resulting in pathology and death.
- MVA-BN[®] (IMVAMUNE[®]) has a stable genotype, whereas other MVA strains rapidly lose their attenuation when cultured on mammalian cells.

Therefore, it can be concluded that MVA-BN[®] (IMVAMUNE[®]) is a promising safe human smallpox vaccine candidate.

1.3 Summary of Preclinical Data

Bavarian Nordic has performed an extensive preclinical development program for MVA-BN[®] (IMVAMUNE[®]) that has demonstrated the safety, efficacy and bio-equivalence of MVA-BN[®] (IMVAMUNE[®]) compared to other traditional smallpox vaccines (e.g. Dryvax[®] and MVA-571). Bavarian Nordic has also developed challenge models including an intratracheal (i.t.) monkeypox challenge model and two murine orthopox challenge models. Some key features include:

- MVA-BN[®] (IMVAMUNE[®]) has a superior attenuation compared to other MVA strains that replicate in various human cells.
- MVA-BN[®] (IMVAMUNE[®]) vaccinations are safe in rabbits with minimal and (in case of subcutaneous administration: “potentially”) reversible effects.

RESTRICTED BUSINESS PROPRIETY

- Administration of MVA-BN[®] (IMVAMUNE[®]) resulted in the detection of vaccine transcripts in distinct tissues with clearance of those transcripts within 7 days (with only the injection site skin and muscle being positive to a low frequency)
- MVA-BN[®] (IMVAMUNE[®]) vaccinations are safe in severely immune compromised animals, whereas other MVA strains replicate resulting in pathology and death.
- MVA-BN[®] (IMVAMUNE[®]) demonstrated a superior efficacy in a lethal vaccinia virus challenge model in mice compared to other MVA strains.
- MVA-BN[®] (IMVAMUNE[®]) vaccinations induce the same efficacy as traditional smallpox vaccine (e.g. DryVax[®]) against a lethal orthopox challenge given via various routes (intraperitoneal [i.p.] and intranasal [i.n.]).
- A single vaccination with MVA-BN[®] (IMVAMUNE[®]) induces equivalent protection in mice following intranasal challenge with high lethal doses of Ectromelia virus compared to a traditional smallpox vaccine (Dryvax[®])
- MVA-BN[®] (IMVAMUNE[®]) vaccinated mice are protected from a lethal vaccinia virus challenge applied within 4 days, whereas Dryvax[®] vaccinated mice are not protected.
- MVA-BN[®] (IMVAMUNE[®]) is a potent inducer of both antibody and T cells responses and induces equivalent levels of immunity as traditional smallpox vaccines (Dryvax[®] and Elstree) in both murine and non-human primates.
- BN has developed the first i.t. monkeypox challenge model that more closely mimics the natural route of a smallpox infection and results in a smallpox-like disease
- Non-human primates vaccinated with MVA-BN[®] (IMVAMUNE[®]) are protected from a lethal i.t. monkeypox challenge demonstrating an equivalent protection to traditional smallpox vaccines (Dryvax[®]).
- BN is in the process of validating the monkeypox and selected murine orthopox virus challenge models according to FDA approved protocols.

For more detailed information on preclinical data please refer to the respective section of the Investigator Brochure.

1.4 Summary of Clinical Data

1.4.1 Clinical Experience with the MVA precursor vaccine

Non-recombinant MVA has been extensively used in humans, forming part of a two-step smallpox vaccination program in combination with wild-type vaccinia virus in Germany in 1978. More than 120,000 human subjects received i.d. and s.c. injections with MVA as part of this program, with the majority of subjects being children and adults at risk for adverse reaction from the wild-type vaccine without prior immunization with an avirulent MVA (Mahnel & Mayr 1994; Mayr, Stickl, Muller, Danner, & Singer 1978; Stickl, Hochstein-Mintzel, Mayr, Huber, Schafer, & Holzner 1974; Stickl & Hochstein-Mintzel 1971). Mild local reactions including local reddening of the skin and infiltration were observed at the site of injection in ~75% of individuals vaccinated by the intradermal route (Mayr et al. 1978). Side effects on the injection site after MVA vaccination seen in 5308 vaccinia-naïve individuals (0.2 ml intradermally in the forearm) are shown in table I.

Table I: Local reactogenicity 24-48 hours and 5-7 days after vaccination with MVA

LOCAL REACTION	24-48 HOURS	5-7 DAYS
No reaction	7.25%	9.17%
Reddening up to 10 mm in diameter	54.9%	75,45%

RESTRICTED BUSINESS PROPRIETY

Reddening 10-20 mm in diameter	31.45%	14,05%
Reddening more than 20 mm in diameter	6.40%	1.53 %

No blistering, pustula or ulceration were observed at virus doses that produce such reactions in approximately 50% of naive individuals after application of conventional vaccinia. This indicated that the virulence of MVA for skin is very low. No encephalitic reaction was observed (Stickl et al. 1974).

Approximately 2-4% of the subjects (n = 7098) had slight fever and felt unwell (fever > 38°C in 2.28%, non-specific systemic symptoms in 4.11%), but the symptoms were much less than those observed with the normal smallpox vaccine. No serious adverse events were reported. In addition, vaccination with MVA before administering the normal smallpox vaccine (replication competent wild-type vaccinia virus) resulted in a reduced number of side effects from this administration and the development of smaller wild-type vaccinia-derived pocks.

Single dose vaccination with MVA elicited only weak hemagglutination inhibiting or virus neutralizing antibody response. However, after vaccination with wild-type vaccinia virus vaccinees presented with a strong booster effect, indicating the priming by MVA with specific humoral and cellular immune response (Mayr et al. 1978). In vaccinees having received a second dose of MVA, an increased level of antibody response was observed as well. It could be shown in animal experiments that protection against variola was provided even in the absence of an antibody response (Stickl et al. 1974).

1.4.2 Clinical Experience with MVA-BN® (IMVAMUNE®)

To date, 10 clinical studies using IMVAMUNE® have been initiated and more than 1800 subjects were vaccinated. The populations vaccinated include > 1200 healthy subjects as well as risk groups for which conventional smallpox vaccines are contraindicated such as > 500 HIV infected patients and > 100 patients with atopic dermatitis.

Vaccination of healthy population with MVA-BN® (IMVAMUNE®)

Study POX-MVA-001: 86 healthy volunteers were vaccinated in this clinical phase I trial conducted in Europe. The subjects were healthy males, stratified based on the presence or absence of a prior history of smallpox vaccination. Primary objective was to assess safety and tolerability of MVA-BN® (IMVAMUNE®) with secondary objectives comparing various routes of administration (subcutaneous [s.c.] versus intramuscular [i.m.]) with three different doses of vaccine being tested. There were five cohorts, with three cohorts receiving the vaccine s.c. at a dose of 10^6 , 10^7 , and 10^8 tissue culture infectious dose 50 (TCID₅₀), respectively. A fourth cohort received the vaccine i.m. at a dose of 10^8 TCID₅₀. All four cohorts were naïve to smallpox vaccination and received vaccine at baseline and week 4. A fifth cohort of subjects, who had been previously vaccinated against smallpox, received a single dose of 1×10^8 TCID₅₀ of MVA-BN® (IMVAMUNE®) s.c. In this study the vaccine induced a strong and dose dependent immune response and was safe and well tolerated even at high doses (Vollmar et al. 2005)

Study POX-MVA-004: This double-blind randomized, phase II, dose finding trial in 165 healthy, vaccinia naïve male and female volunteers aged 18–32 years evaluated the immunogenicity and safety of MVA-BN® (IMVAMUNE®) at doses of 2×10^7 , 5×10^7 or 1×10^8 TCID₅₀. Subjects were

randomly assigned to one of three treatment groups and were immunized twice at a 4 week interval using MVA-BN[®] (IMVAMUNE[®]) (s.c.). Results of PRNT and ELISA, detecting neutralizing antibodies and total IgG against vaccinia respectively are shown in Table II.

This study revealed that all three dose levels induced a 100% seroconversion after the second vaccination. The strongest immune response with earliest onset of seroconversion was achieved with the highest dose tested. In this group, 94% of the subjects already seroconverted after only 1 vaccination. The data obtained with neutralizing antibodies closely correlated to the ELISA results (Figure I). A significance test of the correlation shows a highly significant result: $p = 1.5^{-18}$ and confirms that both assays are highly correlated. T cell response data: Cellular immune responses were analyzed in this trial with intracellular cytokine staining (ICS) detecting vaccinia-specific IFN- γ producing CD4+ / CD8+ cells. Cellular immune response resulted in a dose-dependent CD8+ response (Figure II).

Table II: POX-MVA-004 Humoral immune response (per protocol population)

Group	Visit Day	N	ELISA			PRNT		
			n (%)	GMT	95% CI (LL / UL)	n (%)	GMT	95% CI (LL / UL)
Group 1 (N=54) 2x10 ⁷ TCID ₅₀	0	54	0 (0%)	1.00	- / -	0 (0%)	1.00	- / -
	28	54	32 (59.3%)	14.37	7.71 / 26.8	4 (7.4%)	1.31	1.01 / 1.70
	42	54	54 (100%)	377.22	288.33 / 493.53	23 (42.6%)	5.51	3.17 / 9.59
	84	54	51 (94.4%)	134.33	91.05 / 198.19	10 (18.5%)	1.94	1.31 / 2.85
Group 2 (N=49) 5x10 ⁷ TCID ₅₀	0	49	0 (0%)	1.00	- / -	0 (0%)	1.00	- / -
	28	49	40 (81.6%)	53.21	29.86 / 94.87	6 (12.2%)	1.55	1.10 / 2.19
	42	49	49 (100%)	583.62	461.58 / 737.94	29 (59.2%)	10.31	5.78 / 18.40
	84	49	49 (100%)	227.76	176.40 / 294.07	11 (22.4%)	2.32	1.47 / 3.66
Group 3 (N=52) 1x10 ⁸ TCID ₅₀	0	52	0 (0%)	1.00	- / -	0 (0%)	1.00	- / -
	28	52	49 (94.2%)	98.52	67.57 / 143.65	5 (9.6%)	1.39	1.05 / 1.85
	42	52	52 (100%)	813.77	628.74 / 1053.26	37 (71.2%)	19.43	11.05 / 34.16
	84	52	52 (100%)	323.63	246.84 / 424.30	15 (28.8%)	2.94	1.81 / 4.76


N = number of subjects with samples for antibody response, n (%) = number of seropositive subjects / percentage of seropositive subjects based on N, GMT = Geometric Mean Titer, n (%) = number/percentage of seropositive subjects, CI = Confidence Interval, LL: Lower Limit, UL: Upper Limit

Seropositivity rate was defined as the percentage of subjects with antibody titers $\geq$ the assay cut-off value.

ELISA: The assay cut-off value is 1:50.


PRNT: The assay cut-off value is 1:20.

Figure I: POX-MVA-004 ELISA/PRNT Correlation analysis



The ELISA titer versus the PRNT titer for all 162 available day 42 samples. The correlation calculation is based only on the samples where both titer values are positive – 94 positive pairs in all. 75% of the negative PRNT values had (log10 of) ELISA titers below 2.73, whereas all the samples with a positive PRNT titer had (log10 of) ELISA titers above 2.34.

Figure II: POX-MVA-004 Intracellular cytokine staining / vaccinia specific immunity



Group 1: 2×10^7 TCID₅₀, subcutaneous in subjects not vaccinated against smallpox

Group 2: 5×10^7 TCID₅₀, subcutaneous in subjects not vaccinated against smallpox

Group 3: 1×10^8 TCID₅₀, subcutaneous in subjects not vaccinated against smallpox

Analysis was performed on the per protocol population

Study POX-MVA-002: In addition MVA-BN[®] (IMVAMUNE[®]) is currently being tested in the US in a Phase I study (POX-MVA-002) in healthy subjects in combination with the licensed smallpox vaccine Dryvax[®].

A total of 90 subjects were enrolled 75 of which have received MVA-BN[®] (IMVAMUNE[®]) in different doses. Currently, the study is still blinded and it is expected that final results of the study will become available during 2006. However no serious and unexpected adverse events related to MVA-BN[®] (IMVAMUNE[®]) have been reported. One subject reported shortness of breath 2 weeks after vaccination with Dryvax[®] and this cardiac adverse event was assessed by the Investigator as definitely being related to Dryvax[®].

MVA-BN[®]-based vaccination of populations for which Dryvax[®] is contraindicated

Patients belonging to risk populations such as immune compromised (e.g. HIV infected patients) or otherwise immunologically impaired (e.g. patients with atopic disorders) are normally excluded from vaccination with traditional smallpox vaccines (e.g. Dryvax[®]). To show that MVA-BN[®] (IMVAMUNE[®]) is a safe and immunogenic even in these patients, Bavarian Nordic up to date initiated three clinical trials in HIV infected subjects and/or subjects with atopic dermatitis with MVA-BN[®] (IMVAMUNE[®]) or MVA-BN[®] based vaccines. Initial trials in HIV-1 infected subjects using the recombinant MVA-BN[®] based Nef vaccine are completed and study reports available.

Studies HIV-NEF-001 and HIV-NEF-002: Both phase I vaccination studies conducted in Germany had the objective to evaluate safety and tolerability of a recombinant MVA vaccine expressing the HIV-1 nef-gene (MVA-nef) in HIV-1 infected patients on HAART. In study HIV-NEF-002 the subjects underwent a structured therapy interruption after the third vaccination. 24 patients with CD4 counts $\geq 400/\mu\text{l}$ were enrolled and immunized with 5×10^8 TCID₅₀ of the MVA-nef vaccine, administered subcutaneously. In both studies it was demonstrated that 5×10^8 TCID₅₀ MVA-nef was safe and well tolerated in HIV-1 infected patients with CD4 counts $\geq 400/\mu\text{l}$. The most frequent adverse reactions were mild injection site reactions such as induration or pain.

Study POX-MVA-007: To evaluate safety and immunogenicity of MVA-BN[®] (IMVAMUNE[®]) smallpox vaccine in subjects with atopic disorders, this open-label, controlled phase I pilot study was started in Germany in May 2004.

Primary objective of the trial is to expand the available data on the safety of MVA-BN[®] (IMVAMUNE[®]) in a population with atopic disorders. Vaccinia-naïve volunteers between 18 and 40 years were assigned to the following study groups depending on their medical history and current health status:

- Healthy subjects (n=15)
- Subjects with history of atopic dermatitis (n=16)
- Subjects with mild active atopic dermatitis (n=15)
- Subjects with mild allergic rhinitis (n=14)

All subjects are immunized twice at a 4 week interval using MVA-BN[®] (IMVAMUNE[®]) subcutaneously in a dose of 1×10^8 TCID₅₀. The study duration is up to 36 weeks for each subject. All subjects will be followed for at least 24 weeks after having received the last study vaccination

A full safety report of the first nineteen subjects in this study is available. This interim safety report demonstrates a low number of grade 3 adverse events (AEs) and confirms a favorable safety profile of MVA-BN[®] (IMVAMUNE[®]) even in a population in which conventional smallpox vaccines are contraindicated. Non-serious unsolicited and solicited AEs documented in this

RESTRICTED BUSINESS PROPRIETY

report were comparable to typical adverse reactions expected with other modern injectable vaccines (Table III).

Table III: Adverse reactions with an occurrence of > 10% in at least one subject group (29-day follow-up period after vaccination) - per subject (full analysis set, N = 60)

Symptom	Healthy (N* = 15)			History of atopic dermatitis (N* = 16)			Active atopic dermatitis (N* = 15)			Allergic rhinitis (N* = 14)		
	n	(%)	n*	n	(%)	n*	n	(%)	n*	n	(%)	n*
Injection site pain	14	(93.3)	27	14	(87.5)	25	15	(100.0)	30	14	(100.0)	27
Injection site induration	13	(86.7)	23	11	(68.8)	17	15	(100.0)	23	12	(85.7)	18
Injection site swelling	12	(80.0)	22	13	(81.3)	20	11	(73.3)	18	11	(78.6)	17
Injection site erythema	12	(80.0)	23	15	(93.8)	26	15	(100.0)	25	14	(100.0)	26
Injection site pruritus	3	(20.0)	5	4	(25.0)	5	5	(33.3)	7	1	(7.1)	1
Inj. site discolouration	2	(13.3)	3	0	(0.0)	0	1	(6.7)	1	1	(7.1)	1
Injection site warmth	0	(0.0)	0	2	(12.5)	2	1	(6.7)	1	0	(0.0)	0
Fatigue	5	(33.3)	6	10	(62.5)	13	7	(46.7)	9	9	(64.3)	13
Headache	6	(40.0)	7	7	(43.8)	12	5	(33.3)	6	6	(42.9)	6
Myalgia	0	(0.0)	0	6	(37.5)	9	2	(13.3)	4	4	(28.6)	4
Nausea	1	(6.7)	1	1	(6.3)	1	2	(13.3)	2	2	(14.3)	2
Pyrexia	1	(6.7)	1	2	(12.5)	2	3	(20.0)	3	0	(0.0)	0
Pruritus	0	(0.0)	0	0	(0.0)	0	2	(13.3)	3	0	(0.0)	0
Dermatitis atopic	0	(0.0)	0	0	(0.0)	0	2	(13.3)	2	0	(0.0)	0

% = Percentages based on N*, N = number of subjects, N* = number of subjects with documented vaccination periods, n = number of subjects with findings in specific category, n* = number of events

Study POX-MVA-010: In July 2005, BN initiated a multi-center, open-label phase I/II study with the objective to generate safety and immunogenicity data with MVA-BN[®] (IMVAMUNE[®]) in HIV infected subjects with CD4+ counts >350 / μ l compared to healthy subjects. 150 male and female vaccinia-naïve and pre-immune volunteers are assigned to the following study groups depending on their medical history and health status:

Group 1: HIV infected subjects without history of previous smallpox vaccination (n=30)

Group 2: HIV infected subjects with history of previous smallpox vaccination (n=60)

Group 3: Healthy subjects without history of previous smallpox vaccination (n=30)

Group 4: Healthy subjects with history of previous smallpox vaccination (n=30)

The subjects are immunized (s.c.) with a MVA-BN[®] (IMVAMUNE[®]) dose of 1×10^8 TCID₅₀. Group 1 and 3 will receive two vaccine administrations 4 weeks apart; group 2 and 4 a single administration.

The study is being performed at 5 study centers in the US and enrollment of volunteers has been completed.

Solicited systemic adverse reactions $\geq$ grade 3 observed to date are shown in Table IV.

Table IV: POX-MVA-010 (un-cleaned data) -- Solicited systemic adverse reactions $\geq$ grade 3

Symptom	HIV vacc. naïve (N=30)	HIV pre-immune (N=61)	Healthy vacc. naïve (N=30)	Healthy pre-immune (N=30)
	n (%)	n (%)	n (%)	n (%)
Injection site pain	0 (0%)	2 (3.3%)	2 (6.7%)	1 (3.3%)
Injection site erythema	0 (0%)	1 (1.6%)	0 (0%)	1 (3.3%)
Injection site swelling	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Injection site induration	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Fever	0 (0%)	1 (1.6%)	0 (0%)	1 (3.3%)
Headache	1 (3.3%)	0 (0%)	2 (6.7%)	1 (3.3%)
Myalgia	0 (0%)	1 (1.6%)	1 (3.3%)	1 (3.3%)
Chills	1 (3.3%)	1 (1.6%)	2 (6.7%)	1 (3.3%)
Nausea	0 (0%)	1 (1.6%)	0 (0%)	2 (6.7%)
Fatigue	1 (3.3%)	3 (4.9%)	2 (6.7%)	0 (0%)

N=Number of subjects, n=Number of subjects fulfilling criteria, %=n/N

Study HIV-NEF-004: This phase II study is currently being conducted in Germany to evaluate immunogenicity and safety of two doses of a recombinant MVA vaccine expressing the HIV-1 nef-gene (1×10^8 and 5×10^8 MVA-nef) and one dose of 1×10^8 TCID₅₀ MVA-BN[®]. To date, a total of 77 HIV-1 infected subjects with CD4 counts $> 250/\mu\text{l}$ have been enrolled and have received all 3 vaccinations.. To date, MVA-nef and MVA-BN[®] (IMVAMUNE[®]) are well tolerated. Most frequent adverse reactions are mild injection site reactions like induration and pain.

1.5 Rationale

The fact that conventional smallpox vaccines have an unfavourable safety profile with vaccine-associated adverse events such as death, permanent disability and scarring, has lead to a considerable reluctance to vaccinate major parts of the population even on a voluntary basis. Current guidelines from the Advisory Committee on Immunization Practices (ACIP) for administering the smallpox vaccine state that subjects with eczema of any degree and those with a past history of eczema should not be vaccinated under routine circumstances because of the higher risk of developing eczema vaccinatum. Given that the lifetime prevalence of atopic dermatitis is ~10% to 15%, that probably even more people have a “history of eczema” and that about twice this many people have a contact with the above, it is conceivable that up to half of the population currently would not be eligible to routinely receive smallpox vaccination.

Although it is known that people with atopic dermatitis are at increased risk to develop eczema vaccinatum there are not many studies published. One publication documented the incidence of eczema vaccinatum in England and Wales during a mass vaccination campaign in 1962. Of the 6.5 million people vaccinated (with approximately 50% primary vaccinees), 185 developed

eczema vaccinatum and 11 of these 185 patients (6%) died. Rash anamnesis (active or past) indicated that 80% of those with eczema vaccinatum suffered from atopic dermatitis. Two thirds of the patients with atopic dermatitis did not have active disease at the time of exposure (Copeman and Wallace, 1964). Smallpox vaccine complication rates documented in the United States show an occurrence of eczema vaccinatum in 123 per million primary vaccinees, with case fatality rates of approx. 1% (Lane et al., 1971).

Relatively few recent research is available on potential causes of eczema vaccinatum, though specific immune defects in patients with atopic dermatitis are presumed to be causative (Leung et al., 1983; Lever et al, 1985; Kimura et al., 1998; Campbell et al., 1999; Higashi et al., 2001). Patients with atopic dermatitis have also been shown to have reduced cytotoxic T-cell generation and decreased IFN γ production. Both components of the immune response have been found to be critical for protection against vaccinia infection (Engler et al., 2002).

Due to the fact that MVA-BN[®] (IMVAMUNE[®]) is based on a non-replicating virus it is presumed to be safe in patients with atopic dermatitis, although very rare but potentially severe side effects cannot be excluded in a clinical trial setting. However, due to the fact that proposed causes of eczema vaccinatum after vaccination with conventional vaccinia vaccines include specific immune defects, it will be important to evaluate whether patients with atopic dermatitis will generate an adequate immune response after vaccination with highly attenuated vaccinia strains such as MVA-BN[®] (IMVAMUNE[®]).

1.6 Dose, route of administration, vaccination schedule

MVA-BN[®] (IMVAMUNE[®]) will be given subcutaneously. The rationale for the selected dose and the route of administration comes from historical use as well as preclinical and clinical data (study V-POX-00.1 (POX-MVA-001)) that showed satisfactory immune responses after a 1×10^8 TCID₅₀ dose and a good safety profile of MVA-BN[®] (IMVAMUNE[®]) if administered via the subcutaneous route.

All subjects will receive two vaccinations each with a dose of 0.5 ml MVA-BN[®] (IMVAMUNE[™]) containing 1×10^8 TCID₅₀ vaccine administered subcutaneously according to a 0 – 4 weeks schedule (Day 0 / Day 28-35).

1.7 Benefit/risk assessment

Preclinical data with MVA-BN[®] (IMVAMUNE[®]) reveal no special hazard for humans based on conventional studies of safety. Over 1000 healthy and over 100 subjects with HIV or Melanoma have been vaccinated in clinical trials with vaccines using MVA-BN[®] (IMVAMUNE[®]) alone (to develop an improved smallpox vaccine) or with MVA-BN[®] as vector (with HIV specific inserts or inserts to be used as melanoma vaccine).

The good safety profile of MVA-BN[®] as a viral vector vaccine is supported by the historical experience with the MVA-BN[®] (IMVAMUNE[®]) precursor vaccine, which was used in Germany during the smallpox vaccination for two-stage parenteral vaccination in children in 1976. MVA was used in over 120,000 Caucasian individuals with no reported major side effects, even though many of the subjects were among the population with high risk of developing complications (Mayr et al., 1978).

It could be concluded that from the previous experience with MVA based vaccines adverse reactions to MVA-BN[®] (IMVAMUNE[®]) are expected to be comparable to typical adverse reactions seen with other modern vaccines.

The severe and life-threatening adverse reactions such as progressive vaccinia, eczema vaccinatum, generalized vaccinia and inadvertent inoculation that are observed after the administration of conventional smallpox vaccines are due to the replication of the vaccinia strains. Since MVA-BN[®] (IMVAMUNE[®]) is replication incompetent in human cells it has a better safety and tolerability profile and can consequently not induce the severe side effects such as progressive vaccinia which is associated with replication competent vaccinia viruses. Apart from the better safety profile with regard to severe reactions the available clinical experience with MVA-BN[®] (IMVAMUNE[®]) shows that it is generally better tolerated (e.g. local reactions) than conventional smallpox vaccines.

Based on the available data with MVA-BN[®] (IMVAMUNE[®]) the risk for the study participants is not expected to be higher than the risk observed with other modern vaccines. The main risk is the development of local reactions at the vaccination site (e.g. erythema, pain, swelling and induration).

In addition, the study participants can contribute significantly to the development of a safe smallpox vaccine. They might acquire a potential protection against smallpox. However, it cannot be concluded that the vaccine is efficacious against this disease, as MVA based vaccines are currently in an early phase of development. In view of the expected side effects of MVA-BN[®] (IMVAMUNE[®]) the potential risks associated for the study participants in this study seems to be limited and justify the potential benefit for society.

2. Objectives

The primary objective of the trial is:

- To assess the humoral immune responses (measured by ELISA) induced to MVA-BN[®] (IMVAMUNE[®]) in subjects with diagnosed atopic dermatitis compared to healthy subjects.

The secondary objectives of the trial are:

- To assess safety of MVA-BN[®] (IMVAMUNE[®]) in subjects with atopic dermatitis compared to healthy subjects
- To assess reactogenicity of MVA-BN[®] (IMVAMUNE[®]) in subjects with atopic dermatitis compared to healthy subjects
- To assess the immune responses measured with the plaque reduction neutralization test (PRNT) and the Enzyme-Linked Immunospot (ELISPOT) assay induced to MVA-BN[®] (IMVAMUNE[®]) in subjects with diagnosed atopic dermatitis compared to healthy subjects. ELISPOT: Subgroup of 50 subjects from Group 1 (healthy) and 110 subjects from Group 2 (AD) with samples taken at each of the Visits 1, 2 and 4 collected at US sites. The first subjects enrolled into the study will be included in the subgroup until the numbers specified above are reached.

3. Study design


3.1 Experimental design

This study is an open-label, controlled, phase II clinical trial to evaluate immunogenicity and safety of MVA-BN[®] (IMVAMUNE[®]) smallpox vaccine in 18-40 year old subjects with diagnosed atopic dermatitis.

The following two subject groups are compared:

Group 1: Healthy, vaccinia naïve subjects without atopic disease

Group 2: Vaccinia naïve subjects with diagnosed atopic dermatitis. “Diagnosed” atopic dermatitis includes subjects with either history of or subjects with currently active (defined as SCORAD ≤ 30, Kunz et al., 1997) atopic dermatitis.



3.2 Description of study procedures

The study will be conducted according to the Study Flow Chart (section III).

Visits should be scheduled within the given intervals.

3.2.1 Screening phase

Screening Visit (SCR, day -28 to -1 / week -4 to -1)

The informed consent must be reviewed with and signed and dated by the subject (volunteer) prior to the initiation of any evaluations or procedures required by the protocol. All subjects must be thoroughly informed of all aspects of the study (e.g. study visit schedule, required evaluations and procedures) as described in the informed consent document.

After informed consent has been collected, subjects will enter a screening period of up to four weeks before the first vaccination.

An extensive screening assessment will be performed during the screening period (visit SCR).

VISIT SCR (DAYS -28 TO -1)

- Informed Consent
- Check inclusion/exclusion criteria
- Screening examinations
- Check cardiac risk factors (including Total, HDL and LDL cholesterol)
- Check medical history
- Complete physical examination including evaluation of vital signs, especially listening to heart and lung
- Interview on history of AD (Group 2 only)
- Examination of AD including SCORAD (Group 2, active AD only)
- Baseline ECG
- Serum pregnancy test (if applicable)
- Urine analysis
- Safety laboratory
- Recording and documentation of Baseline Signs and Symptoms

The assessment of the atopic dermatitis group will be done by interviewing the subjects concerning their history of AD and/or doing a SCORAD evaluation in subjects with currently active AD. A photograph of the most prominent active AD area(s) could be taken.

All conditions leading to the decision to enroll a subject either into Group 1 or Group 2 have to be thoroughly documented in the source data!

If a subject was screened and could not be enrolled because of a certain transient condition (e.g. abnormal lab value due to an acute condition or a missing lab evaluation due to mishandling of the sample), then the subject could be re-screened and the respective tests should be repeated as a "partial" re-screening rather than a full re-screening. The re-screening visit must be within the 28 days window started by the first screening visit and the window -28 to -1 before 1st vaccination must not be exceeded. A "partial" re-screening visit is indicated by filling only the respective re-screening CRF pages.

If a subject could not be enrolled due to other circumstances (e.g. intermediate closure of the study group because of an interim safety analysis) and the 28 day period is over, a complete re-screening assessment including physical examination, lab examination, ECG must be performed. The clock then re-starts at the re-screening visit with day -28 before 1st vaccination. A "complete" re-screening visit is indicated by filling all re-screening CRF pages.

3.2.2 Active study phase

After successful screening period the subject will enter the active study phase starting with Visit 1.

The procedures performed at Visit 1 and all following visits are listed below. Blood draws and all other examinations listed above the vaccination events must always be performed **prior** to vaccination!

Investigators will be informed, if blood for T cell analysis will be drawn from their study subjects.

Subjects of both study groups will receive two s.c. vaccinations with 0.5 ml MVA-BN[®] (IMVAMUNE[®]) vaccine containing 1×10^8 TCID₅₀, four weeks apart (Visit 1 / Day 0 and Visit 3 / Visit 1 + 28-35 days) in the non-dominant upper arm (deltoid region).

Following vaccination subjects will be kept under close observation for at least 30 minutes, with appropriate medical treatment readily available in case of a rare anaphylactic reaction following the administration of vaccines.

Any adverse events (AE) that occur during or after vaccination will be recorded. A diary card will be provided to each subject for the recording of solicited AEs occurring on the vaccination day and the seven days following vaccination.

At Visit 5, the subjects of study group 2 will be interviewed about the status of their AD. In case of significant changes (improvement / worsening), a photograph of the most prominent active AD area(s) could be taken.

VISIT 1 (DAY 0)

- Re-check inclusion/exclusion criteria
- Check cardiac risk factors
- Targeted physical examination with focus on evaluation of vital signs, especially listening to the heart and lungs
- Recording and documentation of baseline signs and symptoms
- Urine pregnancy test (if applicable)
- Blood draw for antibody analysis
- Blood draw for T cell analysis (subgroup)

Blood draws and all other tasks mentioned above must always be performed prior to vaccination!

- 1st vaccination
- Handout of diary card for 1st vaccination
- Recording and documentation of AEs

VISIT 2 (VISIT 1 + 7-10 DAYS)

- Examination of the vaccination site
- Targeted physical examination with focus on evaluation of vital signs, especially listening to the heart and lungs
- ECG
- Safety Lab
- Blood draw for antibody analysis
- Blood draw for T cell analysis (subgroup)
- Collection of the diary card for 1st vaccination, review together with subject and transfer to the Case Report Form (CRF)
- Recording and documentation of AEs

VISIT 3 (VISIT 1 + 28-35 DAYS)

- Re-check inclusion/exclusion criteria
- Check cardiac risk factors
- Targeted physical examination with focus on evaluation of vital signs, especially listening to the heart and lungs
- Urine pregnancy test (if applicable)
- Blood draw for antibody analysis

Blood draws and all other tasks mentioned above must always be performed prior to vaccination!

- 2nd vaccination
- Handout of diary card for 2nd vaccination
- Recording and documentation of AEs

VISIT 4 (VISIT 3 + 10-14 DAYS)

- Examination of the vaccination site
- Targeted physical examination with focus on evaluation of vital signs, especially listening to the heart and lungs
- ECG
- Safety Lab
- Blood draw for antibody analysis
- Blood draw for T cell analysis (subgroup)
- Collection of the diary card for 2nd vaccination, review together with subject and transfer to the Case Report Form (CRF)
- Recording and documentation of AEs

VISIT 5 (VISIT 3 + 28-35 DAYS)

- Targeted physical examination including evaluation of vital signs, especially listening to the heart and lungs
- Brief interview concerning AD status- including SCORAD (Group 2, active AD only)
- ECG (only if clinically indicated)
- Urine pregnancy test (if applicable)
- Safety Lab (only if clinically indicated)
- Blood draw for antibody analysis
- Recording and documentation of AEs

3.2.3 Follow-up phase

To secure long-term safety, the subject has to come in for an examination in a follow-up phase 26 (+4) weeks after the last vaccination.

VISIT F-U (VISIT 3 + 182 – 210 DAYS)

- Targeted physical examination including evaluation of vital signs, especially listening to the heart and lungs
- Brief interview concerning AD status
- ECG (only if clinically indicated)
- Safety laboratory (only if clinically indicated)
- Blood draw for antibody analysis
- Recording and documentation of Serious Adverse Events (SAEs)

3.2.4 Protocol Extension

After enrollment of 130 subjects each in Group 1 and Group 2, the enrollment into the two study groups will be extended by another 100 vaccinia naïve healthy subjects and 200 vaccinia naïve subjects with diagnosed atopic dermatitis. Please refer to Appendices IV and V for details of the protocol extension.

3.3 Study duration

The total duration of the study for each subject including the screening period and follow-up visit will be up to 39 weeks. The duration of the study as a whole is dependent on the recruitment period. It is intended to perform recruitment within a reasonable time frame to limit the total study duration.

All subjects will be followed for at least 26 weeks after having received the last study vaccination. Please refer to Appendix IV for details of the protocol extension.

4. Selection of subjects

4.1 Recruitment procedure

Volunteers will be recruited actively. Methods of recruitment mainly include Investigator databases and referrals from dermatological clinics and general practitioners specialized on dermatology. Recruitment strategies including paid advertisements, announcements and distribution of flyers will be evaluated.

In total, 560 individuals (260 subjects in the main study and then a further 100 healthy and 200 AD subjects in the extension phase) as defined in Section 4.2 will be enrolled. After signing the Informed Consent, subjects undergo screening procedures to check eligibility due to the following inclusion/exclusion criteria. In the event of a screen failure secondary to mild or limited acute illness or abnormal laboratory values the patient may be re-screened after resolution of the event. Re-screening may require only an additional blood draw or a complete re-screening evaluation, depending on the circumstances of and the time interval from the initial screening failure.

The Investigator will keep a log of subjects screened for the study, and provide the reason in case of exclusion.

Information about every patient entering the study will be provided to the contracted CRO.

Enrollment will be tracked to ensure that at least 50% of the subjects enrolled into Group 2 of the trial have active Atopic Dermatitis rather than history of Atopic Dermatitis. If it becomes apparent that less than 50% of group 2 have active AD then further enrollment of subjects with history of AD will be temporarily halted until the balance is once again achieved.

4.2 Inclusion criteria

Group 1:

1. Subjects without present or history of any kind of atopy. Subjects with seasonal allergies can only be enrolled if an association with other atopic disorders such as allergic rhinitis and asthma can be excluded.

Group 2:

2. Subjects with diagnosed atopic dermatitis. "Diagnosed" atopic dermatitis includes subjects with either documented history of or subjects with currently active (defined as SCORAD $\leq$ 30, Kunz et al., 1997) atopic dermatitis. Currently active atopic dermatitis includes relapsing forms of atopic dermatitis, also when subjects are enrolled during inflammation-free intervals.

All study subjects:

3. Male and female subjects between 18 and 40 years of age without history of smallpox vaccination.
4. Women must have a negative serum pregnancy test at screening and a negative urine pregnancy test within 24 hours prior to vaccination.
5. Women of childbearing potential must have used an acceptable method of contraception for 30 days prior to the first vaccination, must agree to use an acceptable method of contraception during the study, and must not become pregnant for at least 28 days after the last vaccination. A woman is considered of childbearing potential unless post-menopausal or surgically sterilized. (Acceptable contraception methods are restricted to abstinence, barrier contraceptives, intrauterine contraceptive devices or licensed hormonal products.)
6. Read, signed and dated informed consent document after being advised of the risks and benefits of the study in a language understood by the subject signed, and prior to performance of any study specific procedure.
7. Troponin I < 2 fold ULN.
8. White blood cells $\geq 2500/\text{mm}^3$ and $< 11,000/\text{mm}^3$.
9. Absolute neutrophil count (ANC) within normal limits.
10. Negative urine glucose by dipstick or urinalysis.
11. Hemoglobin within normal limits.
12. Platelets within normal limits.
13. Adequate renal function defined as:
 - a. Serum creatinine without clinically significant findings
 - b. Urine protein < 30 mg/dL or none or trace proteinuria (by urinalysis or dip stick)
14. Adequate hepatic function defined as:
 - a. Total bilirubin $\leq 1.5 \times$ ULN in the absence of other evidence of significant liver disease
 - b. AST (SGOT), ALT (SGPT) and alkaline phosphatase without clinically significant findings
15. Electrocardiogram (ECG) without clinically significant findings (e.g. any kind of atrioventricular or intraventricular conditions or blocks such as complete left or right bundle branch block, AV-node block, QTc or PR prolongation, premature atrial contractions or other atrial arrhythmia, sustained ventricular arrhythmia, 2 premature ventricular contractions (PVC) in a row, ST elevation consistent with ischemia).
16. Availability for follow-up for the planned duration of the study (26 weeks after last vaccination).

4.3 Exclusion criteria

1. Pregnant or breast-feeding women.
2. Uncontrolled serious infection i.e. not responding to antimicrobial therapy.
3. History of any serious medical condition, which in the opinion of the Investigator would compromise the safety of the subject.
4. History of or active autoimmune disease. Persons with vitiligo or thyroid disease taking thyroid replacement are not excluded.
5. Known or suspected impairment of immunologic function including, but not limited to, clinically significant liver disease; diabetes mellitus; moderate to severe kidney impairment.
6. History of malignancy, other than squamous cell or basal cell skin cancer, unless there has been surgical excision that is considered to have achieved cure. Subjects with history of skin cancer at the vaccination site are excluded.
7. History or clinical manifestation of clinically significant and severe hematological, renal, hepatic, pulmonary, central nervous, cardiovascular or gastrointestinal disorders.
8. Clinically significant mental disorder not adequately controlled by medical treatment.
9. Any condition which might interfere with study objectives or would limit the subject's ability to complete the study or to be compliant in the opinion of the Investigator.
10. History of coronary heart disease, myocardial infarction, angina, congestive heart failure, cardiomyopathy, stroke or transient ischemic attack, uncontrolled high blood pressure.
11. History of an immediate family member (father, mother, brother, or sister) who has had onset of ischemic heart disease before age 50 years.
12. Ten percent or greater risk of developing a myocardial infarction or coronary death within the next 10 years using the National Cholesterol Education Program's risk assessment tool. (<http://hp2010.nhlbi.nih.net/atpiii/calculator.asp?usertype=prof>) NOTE: This criterion applies only to volunteers 20 years of age and older.
13. History of intravenous drug abuse.
14. History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.
15. Known allergy to egg or aminoglycoside (gentamicin).
16. History of anaphylaxis or severe allergic reaction.
17. Acute disease (illness with or without a fever) at the time of enrollment.
18. Temperature $\geq 100.4^{\circ}\text{F}$ ($\geq 38.0^{\circ}\text{C}$) at the time of enrollment.
19. Subjects undergoing treatment for tuberculosis infection or disease.
20. Having received any vaccinations or planned vaccinations with a live vaccine within 30 days prior or after study vaccination.
21. Having received any vaccinations or planned vaccinations with a killed vaccine within 14 days prior or after study vaccination.
22. Chronic administration (defined as more than 14 days) of systemic immuno-suppressants during a period starting from six months prior to administration of the vaccine and ending at study conclusion. Subjects receiving chronic treatment (defined as more than 14 days) with topical calcineurine inhibitors (eg tacrolimus, pimecrolimus) on the body or $> 25\%$ of the facial area are excluded. A wash-out period of ≥ 14 days for tacrolimus and ≥ 28 days for pimecrolimus can be considered sufficient before enrollment into the study. Subjects receiving chronic treatment (defined as more than 14 days) with high dose topical cortisone (> 30 grams/week of an intermediate potency [class IV] topical steroid [or equivalent], the treated area must not exceed 10% of the total body surface) are excluded.

23. Post organ transplant subjects whether or not receiving chronic immunosuppressive therapy.
24. Administration or planned administration of immunoglobulins and/or any blood products during a period starting from 3 months prior to administration of the vaccine and ending at study conclusion.
25. Use of any investigational or non-registered drug or vaccine other than the study vaccine within 30 days preceding the first dose of the study vaccine, or planned administration of such a drug during the study period.
26. Study personnel.

5. Study halting/termination and withdrawal of subjects

5.1 Study halting and termination rule

A temporary halting or termination for single study subjects or for the study as a whole can be decided in case of an occurrence of

- a serious adverse event (SAE)
- an unexpected grade 3 or higher systemic reaction or lab toxicity

with an at least reasonable possibility of a causal relationship to the administration of MVA-BN[®] (IMVAMUNE[®]), i.e. the relationship cannot be ruled out.

These parameters are not all-inclusive. Other adverse events could occur that would trigger a Data Safety Monitoring Board (DSMB) review. Any member of the DSMB, the Principal Investigator, BN Safety Officer, or DMID Medical Officer could request a Safety Monitoring Committee review based on any observation.

5.2 Reporting of events fulfilling the study halting criteria

If an event fulfilling the study halting criteria reaches the Investigator's attention, the Investigator has the liability to alert Kendle's Safety Department immediately (within 24 hours) and provide a comprehensive documentation of the event.

5.3 Data Safety Monitoring Board (DSMB)

The DSMB is an independent board that oversees the safety of volunteers participating in the study. The members of the DSMB are selected by BN and the DMID in accordance with the DMID guidelines. The primary responsibilities of the DSMB are to periodically review and evaluate the accumulated study data for participant safety, study conduct and progress, and make recommendations to BN, the DMID and the Principal Investigator(s) concerning the continuation, modification, or termination of the trial program. The DSMB considers study specific data as well as relevant background knowledge about the disease, test agent, and patient population under study. A separate charter describes in detail relevant operational procedures, communication pathways, roles and responsibilities of the DSMB.

In case an event occurs which fulfills the study halting criteria the DSMB will review the event in a timely manner and give a recommendation to BN, the DMID and the Principal Investigator(s) to halt, resume or terminate the study participation of the affected subject and/or the study as a whole.

5.4 Individual withdrawal criteria during the study

Subjects may withdraw or be removed from the study for any of the reasons cited below:

- An adverse event occurs that, in the opinion of the Investigator, makes it unsafe for the subject to continue the study. In this case, the appropriate measures will be taken.
- Subject's request to withdraw.

- Subject unwilling or unable to comply with study requirements.
- Clinical need for concomitant or ancillary therapy not permitted in the study.
- Unrelated intercurrent illness that, in the judgment of the Principal Investigator, will affect assessment of clinical status to a significant degree.

The following criteria should be checked at any visit after enrollment into the study. If any become applicable during the study, the subject may be withdrawn:

Use of any investigational or non-registered drug or vaccine other than the study vaccine(s).
Administration of a licensed vaccine not foreseen by the study protocol during the study period.
Start of chronic administration (defined as more than 14 days) of systemic immuno-suppressants during the study period.
Administration of immunoglobulins and/or any blood products during the study period.

5.5 Subject withdrawal procedure

If a subject discontinues prior to completion of the study, the date and reason for the discontinuation will be obtained. The date of the last dose of study medication will also be obtained.

Once a subject receives MVA-BN[®] (IMVAMUNE[®]), he/she must be followed for safety as stated in the protocol. From the time of discontinuation, all diagnostic procedures and evaluations scheduled for the last main study visit (Visit 5) should be performed (see III. FLOW CHART).

As a general rule, subjects who discontinued the trial after having received at least one vaccination will not be replaced.

Subjects included in the study but already discontinued the trial prior to the first vaccination should be replaced.

5.6 Contraindications and precautions for further study vaccinations

Absolute contra-indications:

The following events constitute absolute contra-indications to further administration of the study vaccine; if any of these occur during the study, the subject must not receive additional doses of vaccine, but may continue other study procedures at the discretion of the Investigator. The subject must be followed until resolution of the event, as with any adverse event:

- Anaphylactic reaction following the administration of vaccine(s).
- Pregnancy.

Subjects who become pregnant during the study period (up to and including one month [minimum 28 days] after receiving the last vaccine dose) must not receive additional doses of vaccine but may continue other study procedures at the discretion of the Investigator.

Subjects should be instructed to notify the Investigator if it is determined after completion of the study that they became pregnant either during the study or within one month (minimum 28 days) after receiving the last vaccine dose. Pregnancy must be reported to BN on a Pregnancy Form within 24 hours of the Investigator's becoming aware of the event.

A pregnancy should be followed to term, any premature terminations reported, and the health status of the mother and child including date of delivery and the child's gender and weight should be reported to Bavarian Nordic after delivery.

Temporary deferral of vaccination:

The following adverse event constitutes a contra-indication to administration of the study vaccine at that point in time; if this adverse event occurs at the time scheduled for vaccination, the subject may be vaccinated at a later date or withdrawn at the discretion of the Investigator. The subject must be followed until resolution of the event, as with any adverse event:

- Acute disease at the time of vaccination. (Acute disease is defined as the presence of a moderate or severe illness with or without fever. The vaccine can be administered to persons with a minor illness such as diarrhea, mild upper respiratory infection with or without low-grade febrile illness, i.e., oral temperature $\leq 100.4^{\circ}\text{F}$ ($\leq 38.0^{\circ}\text{C}$).

6. Study treatment

6.1 Investigational product

MVA-BN[®] (IMVAMUNE[®]) is a highly attenuated live vaccinia virus. MVA-BN[®] (IMVAMUNE[®]) will be provided in liquid-frozen aliquots. One dose of 0.5 ml liquid-frozen vaccine contains 1×10^8 TCID₅₀ Modified Vaccinia virus Ankara. MVA-BN[®] (IMVAMUNE[®]) is provided by BN. For details see current version of Investigator's Brochure.

Bavarian Nordic decided to exchange the IMVAMUNE[®] vaccine lot 170505 by IMVAMUNE[®] lot 0040707 during the study. For details, please refer to Appendix V.

6.2 Packaging and labelling

MVA-BN[®] (IMVAMUNE[®]) lot 0040707 is produced at Bavarian Nordic A/S and filled and labeled at the contract manufacturer IDT Biologika GmbH.

Address:

IDT Biologika GmbH
Dr. Margrit Gehrt
Am Pharmapark
06861 Dessau-Rosslau, Germany
Phone: +49-34901-885 0

The packages and vials will be labeled according to the national law of the respective study site.

6.3 Vaccine storage, handling and dispensing

The liquid frozen MVA-BN[®] (IMVAMUNE[®]) vaccine has to be stored at $-20^{\circ}\text{C} \pm 5^{\circ}\text{C}$ / $-4^{\circ}\text{F} \pm 9^{\circ}\text{F}$. Do not re-freeze a vial once it has been thawed.

For administration, the vaccine vial will be thawed at room temperature. To ensure homogeneity, upon thawing the vial will be swirled gently (not shaken!) for at least 30 seconds. After thawing, the drug product should appear as a pale milky colored suspension. The liquid vaccine should be visually inspected for any foreign particulate matter prior to administration. In case foreign particulate matter is visible, the vaccine must not be used anymore.

The injection volume of 0.5 ml per dose will be withdrawn with a syringe using an injection needle long enough to reach the bottom of the vial. After withdrawal of the vaccine, the injection needle should be changed and the vaccine administered to the subject immediately.

If the vaccine cannot be administered immediately, it is recommended to administer the product within 12 hours after thawing. During this time the thawed vaccine vial has to be stored at $+2^{\circ}\text{C}$ to $+8^{\circ}\text{C}$ / 35.6°F to 46.4°F in the dark.

Details on vaccine handling can be found in Bavarian Nordic's SOP, SOP/CLIN/16, entitled "Storage, Handling and Preparation of Liquid Frozen MVA-BN for Vaccination".

6.4 Dose, vaccination schedule and route of administration

Subjects of both study groups will receive two s.c. vaccinations with 0.5 ml MVA-BN[®] (IMVAMUNE[®]) vaccine containing 1×10^8 TCID₅₀, four weeks apart (Visit 1 / Day 0 and Visit 3 / Visit 1 + 28-35 days) in the non-dominant upper arm (deltoid region). Details on vaccine administration can be found in Bavarian Nordic's SOP, SOP/CLIN/16, entitled "Storage, Handling and Preparation of Liquid Frozen MVA-BN for Vaccination".

6.5 Accountability and disposal

Used and unused vials should be stored in a safe place and remain the property of BN. The Principal Investigator of the respective site or his designee is responsible for ensuring adequate accountability of all used and unused study drug. This includes acknowledgement of receipt of each shipment of study drug (quantity and condition) and drug accountability using a drug inventory log. The drug inventory log will document quantity of study drug received from BN, quantity of study drug used for vaccination (including lot number, date dispensed, subject identification number and initials of the person dispensing the study medication) and quantity of study drug returned to BN or destroyed.

Additionally, the quantity of study drug returned to Bavarian Nordic or destroyed has to be documented on a study drug return form. In case destruction is agreed, material should be autoclaved or incinerated and discarded at site according to local regulations.

Additionally, used-syringes should be autoclaved or incinerated and discarded at site according to local regulations.

6.6 Concomitant medication

All concomitant medication must be recorded in the CRF with the reason for administration, the dosage regimen, and the onset and end of treatment.

For subjects with active AD, the use of calcineurin inhibitors during the study defined as ≤ 10 grams/week of tacrolimus (0.1% ointment) or pimecrolimus (1% cream) only on small areas of the face (defined as $\leq 25\%$ of facial surface area) is allowed. The use of calcineurin inhibitors on body areas other than the face is not allowed.

Low dose topical cortisone therapy defined as ≤ 30 grams/week of an intermediate potency (class IV) topical steroid (or equivalent) is allowed, but the treated area must not exceed 10% of total body surface.

7. Clinical and laboratory assessments

7.1 Assessment of safety and reactogenicity

Taking into account the medical history of the subject, safety will be monitored by performing physical examinations including vital signs, routine laboratory measurements and ECGs as well as by evaluating local and systemic solicited adverse events and unsolicited adverse events.

Details regarding definitions and reporting of adverse events are described in chapter 8 of this protocol.

7.1.1 Medical history

The baseline assessment for safety parameters will be performed during screening visit. Medical history will be documented during the screening period (visit SCR). History will focus particularly on any important diseases and in case of infections or tumors, the pathogen involved or the pathological diagnosis, respectively, if available. A special attention should be given to history of prior allergic reactions, especially to vaccines.

7.1.2 Physical examination and vital signs

A physical examination and a check of vital signs will be performed during the screening period (visit SCR) for baseline assessment and on every following visit (Visits 1 – 5 and F-U).

PHYSICAL EXAMINATION:

The complete physical examination will be performed at the screening visit. The examination includes a review of major organ systems and weight. The examination should be directed at finding evidence of any infections, tumors and lymphadenopathy.

In addition, listening to the heart and lungs specifically for heart failure, presence of rubs, gallops, murmurs, crackles, and rales will be performed.

TARGETED PHYSICAL EXAMINATION:

A targeted physical examination, guided by any signs or symptoms previously identified or any new symptoms that the subject has experienced since the last visit, is required at all visits of the treatment period (Visits 1 – 5) and at the F-U Visit. Blood pressure, pulse rate, temperature will be taken. In addition, listening to the heart and lungs specifically for heart failure, presence of rubs, gallops, murmurs, crackles and rales will be performed.

VITAL SIGNS:

Blood pressure and pulse rate will be taken after the subject was seated for two minutes. Temperature will be measured orally.

7.1.3 Laboratory measurements

The intensity of laboratory / systemic quantitatively measured toxicities will be graded according to the toxicity scale in Appendix I. These grading scales include the laboratory values determined with the routine safety parameters. In case of other laboratory values not included in the routine safety laboratory and not listed in Appendix I, the National Cancer Institute (NCI) Common Toxicity Criteria table, Version 2.0, published April 30, 1999 will be used for grading of laboratory toxicities.

SAFETY LABORATORY:

Safety laboratory is determined at the screening visit (Visit SCR) and 7 – 14 days after each vaccination (for Visit 2: 7-10 days and Visit 4: V3+10-14 days). At Visit 5 and at follow-up visit (Visit F-U) safety laboratory is only done if clinically indicated. The safety laboratory measurements are performed at the central laboratory. Laboratory normal ranges are provided by the central laboratory and filed in the Investigator file. Safety laboratory parameters to be evaluated are:

Hematology:

Red blood cell count, hemoglobin, total and differential WBC, platelet count..

Serum chemistry:

Total bilirubin, alkaline phosphatase, AST, ALT, serum creatinine, sodium, potassium, calcium, troponin I.

PREGNANCY TEST:

β-HCG pregnancy test will be conducted for all women with reproductive potential at screening (Visit SCR), within 24 hours prior to each vaccination (Visits 1 and 3) and at Visit 5. At screening, a serum β-HCG pregnancy test will be conducted, all other pregnancy test will be conducted as urine β-HCG test.

The following parameters will only be evaluated during the screening period (Visit SCR) for check of inclusion / exclusion criteria:

CHOLESTEROL:

Total, HDL and LDL.

URINE ANALYSIS (E.G. WITH COMBUR-10 STICK):

Protein, glucose, occult blood, nitrites, leucocytes, pH, bilirubin, ketones, urobilinogen, specific gravity.

7.1.4 ECG assessments

A standard 12-lead ECG will be taken on all subjects at screening (Visit SCR) and 7 - 14 days after each vaccination (for Visit 2: 7-10 days and Visit 4: V3+10-14 days). For Visit 5 and the follow-up visit, an ECG is only done if clinically indicated.

ECGs will be evaluated by a centralized procedure. Unclear ECG abnormalities will additionally be evaluated by a central Cardiologist. The workflow / communication flow will be provided in a separate manual.

If clinically indicated, or in case of any kind of cardiac symptoms such as but not limited to chest pain, dyspnoea, arrhythmia, or edema subjects will be referred for a cardiac evaluation by a Cardiologist and further diagnostic tests will be done as recommended by this Cardiologist (e.g. (treadmill) ECG, cardiac enzymes, echocardiogram). Subjects will then be followed up for at least one year in a frequency determined by the Cardiologist.

Such adverse events fulfill the definition of an “adverse event of special interest” and are to be handled respectively reported as described under section 8.4.

Using replication-competent vaccinia-based smallpox vaccines during smallpox vaccination programs in the US during the last years, cases of acute myocarditis and pericarditis were observed (Grabenstein and Winkenwerder, 2003).

Case definitions as published by the US Center of Disease Control (CDC) ("Update: Cardiac-Related Events During the Civilian Smallpox Vaccination Program --- United States, MMWR May 30, 2003, Vol. 52, No. 21, p. 494") are provided in Appendix II in order to:

- help Investigators to recognize possible events of acute myocarditis and/or pericarditis and
- distinguish from unspecific and isolated ECG changes without or with unclear clinical meaning

Subjects who develop any kind of cardiac symptoms during the study such as but not limited to chest pain, dyspnea, arrhythmia, or edema are referred to a Cardiologist for cardiac evaluation including (treadmill) ECG, cardiac enzymes and echocardiogram. Depending on the results of this evaluation further diagnostic tests will be done as recommended by the Cardiologist and patients will be followed up for at least one year in a frequency determined by the Cardiologist. Furthermore unclear ECG abnormalities observed during the study will be examined upon recommendation of the cardiologist.

The observation of an adverse event as defined in section 8 will be rated by the investigator as "adverse event of special interest" and then be reported as described under section 8.7.

7.1.5 Assessment of solicited adverse events (Diary)

After each vaccination each subject receives a diary to record solicited local and systemic adverse events most likely to occur on the day of vaccination or the following 7 days. All solicited symptoms observed after vaccination with details concerning the intensity and the course of the reaction should be documented there. The Investigator will collect this information during the next scheduled visit and transfer it to the CRF.

In case of severe and unexpected local and systemic reactions, the study physician should be contacted outside from scheduled study visits.

Ongoing local and systemic reactions will be followed up and documented until resolved.

SOLICITED LOCAL ADVERSE EVENTS

The solicited local symptoms erythema, swelling and pain at the injection site have to be documented in the diary by the subject and intensity is assessed in the following way:

Injection site

Erythema:	size measured in diameter
Swelling:	size measured in diameter

The maximum intensity will be scored as follows:

0 =	0
1 =	< 30 mm
2 =	≥ 30 – <100 mm
3 =	≥ 100 mm

Injection site

Pain: 0 = Absent
 1 = Painful on touch
 2 = Painful when limb is moved
 3 = Spontaneously painful / prevents normal activity

SOLICITED SYSTEMIC ADVERSE EVENTS

Subjects are asked to document the solicited systemic adverse events as described in the table below on the day of vaccination and the following 7 days on their diary card. If symptoms persist at day 7, temperature/symptom measurements should be recorded each day until resolved.

In the subject's diary, the grading of maximum symptom intensity is described in basic, easily understood language based on the following descriptions:

MedDRA coded Preferred Term Systemic Adverse Events	Grade	Maximum Intensity
Body temperature*	0	< 99.5°F (< 37.5°C)
	1	≥ 99.5 - <100.4°F (≥ 37.5° - < 38.0°C)
	2	≥ 100.4 - 102.2°F (≥ 38.0 - < 39.0°C)
	3	≥ 102.2 - 104°F (≥ 39.0 - < 40.0°C)
	4	≥ 104°F (40.0°C)
Headache, Chills, Myalgia, Nausea and Fatigue	0	None
	1	Mild: Easily tolerated, minimal discomfort and no interference with daily activity
	2	Moderate: Some interference with daily activity
	3	Severe: Prevents daily activity
	4	Life-threatening or disabling

*Pyrexia is defined as oral temperature ≥ 100.4°F (≥38.0°C).

7.1.6 Assessment of unsolicited adverse events

During every study visit following screening, the Investigator has to report any unsolicited adverse event experienced by the subject.

Unsolicited adverse events following the vaccination will generally be recorded by the subjects in a special section of the diary card and transferred by the Investigator to the adverse event section of the CRF. In addition, all intercurrent diseases not recorded on the diary card but reported when the Investigator actively inquires of the subject will be documented in the respective section of the case report form.

Adverse Events will be assessed and documented at all visits of the active study phase and if ongoing followed until resolution or F-U visit at the latest. Serious Adverse Events will be assessed and documented at all study visits, including the F-U-Visit. Ongoing SAEs will be followed up until resolution or achievement of stable clinical conditions.

7.1.7 Assessment of intensity for adverse events

The scale for grading the maximum intensity of all adverse events will be based on the following descriptions:


- 1 = An adverse event which is easily tolerated by the subject, causing minimal discomfort and not interfering with daily activities.
- 2 = An adverse event which is sufficiently discomforting to interfere with daily activities.
- 3 = An adverse event which prevents daily activities. (Such an adverse event would, for example, prevent attendance at work and would necessitate the administration of corrective therapy.)
- 4 = Life threatening or disabling

7.1.8 Assessment of causality for adverse events

The relationship between the occurrence of an adverse event and the study drug will be assessed using the following categories:

None	The time interval between the administration of the study drug and the occurrence or worsening of the AE rules out a relationship
	<i>and/or</i>
Unlikely	another cause is established and there is no evidence of a (concomitant) causal connection with or worsening caused by the study medication.
	The time interval between administration of the study drug and the occurrence or worsening of the AE makes a causal relationship unlikely
	<i>and/or</i>
	the known effects of the study medication or substance class provide no indication of a (concomitant) causal connection with or worsening caused by the study medication and there is another cause which serves as an adequate explanation
	<i>and/or</i>
Possible	although the known effects of the study medication or substance class make it possible to derive a plausible causal chain with regard to a (concomitant) causal connection or worsening, however, another cause is considerably more likely
	<i>and/or</i>
	another cause of the AE has been identified and a (concomitant) causal connection with or worsening caused by the study medication is unlikely.
	A plausible causal chain with regard to a (concomitant) causal connection with / worsening of the AE can be derived from the pharmacological properties of the study medication or substance class. However, other approximately equally likely causes are known
	<i>or</i>
Probable	although the pharmacological properties of the study medication or substance class provide no indication of a (concomitant) causal connection with / worsening of the AE, there is no other known cause which provides an adequate explanation.
	The pharmacological properties of the study medication or substance class
	<i>and/or</i>
	the course of the AE after discontinuation of the study drug and possible subsequent re-exposure
	<i>and/or</i>
Definite	specific findings (e.g. positive allergy test or antibodies against the trial drug / metabolites) suggest a (concomitant) causal connection with / worsening of the AE resulting from the study medication, however another cause cannot completely be ruled out.
	The pharmacological properties of the study medication or substance class
	<i>and/or</i>
	the course of the AE after discontinuation of the study drug and possible subsequent re-exposure
	<i>and/or</i>
	specific findings (e.g. positive allergy test or antibodies against the trial drug / metabolites) definitely indicate that there is a (concomitant) causal connection with / worsening of the AE resulting from the study medication and there are no indications of other causes.

7.1.9 Algorithm for assessment of cardiac events



*At any protocol-scheduled ECG and/or Troponin abnormality the algorithm will begin at this point.

7.2 Assessment of immunogenicity

Immune response analysis is planned at any study visit except the screening visit. The baseline assessment for immunogenicity parameters will be performed during Visit 1 (before vaccination).

The methods of collection, storage and handling of lab specimen for the immune analysis are specified in the Covance (Central Laboratory) Laboratory Manual which will be provided to the investigators before enrollment. Additionally, training will be provided on the procedures during the investigator meeting and/or at the initiation visit.

7.2.1 Humoral immunogenicity

Antibody responses against MVA-BN[®] (IMVAMUNE[®]) will be measured using a direct ELISA and a plaque reduction neutralization test (PRNT), both validated assays. Tests will be performed at Bavarian Nordic GmbH in 82152 Martinsried, Germany. Focus Diagnostics Inc., Cypress, CA 90630, USA, acts as a back-up laboratory.

ELISA

Seroconversion is defined as:

appearance of antibody titers $\geq 1:50$ in a vaccinia specific IgG ELISA for initially seronegative subjects or

twofold increase of the antibody titer compared to the pre-existing baseline titer for subjects with a pre-existing antibody titer in the ELISA.

The geometric mean titer (GMT) is calculated by taking the antilogarithm of the mean of the log₁₀ titer transformations. Antibody titers below the cut-off of the assay will be given an arbitrary value of one for the purpose of calculation.

PRNT

Seroconversion is defined as Appearance of antibody titers ≥ 15 in a vaccinia specific plaque reduction neutralisation assay for initially seronegative subjects or twofold increase of the antibody titer compared to the pre-existing baseline titer for subjects with a pre-existing antibody titer in the PRNT.

The GMT is calculated by taking the antilogarithm of the mean of the log₁₀ titer transformations. Antibody titers below the cut-off of the assay will be given an arbitrary value of one for the purpose of calculation.

7.2.2 Cellular immunogenicity

MVA-specific T-cell responses will be monitored in a subgroup of 50 subjects from Group 1 (healthy) and 110 subjects from Group 2 (AD) with samples taken at each of the Visits 1, 2 and 4 collected at US sites by measurement of IFN- γ production after stimulation with MVA-BN using an IFN- γ ELISPOT assay. A MVA-specific response is defined by a frequency of at least 50 SFU (spot forming units) / 10^6 cells after correction for background (SFU / 10^6 non-stimulated cells).

The immune cell analyses will be performed at BN's laboratory at Bavarian Nordic GmbH, 82152 Martinsried, Germany.

8. Adverse event definitions and reporting

Any change in health observed before first vaccination will be recorded in the “baseline signs and symptoms” section of the CRF and will not be considered an adverse event.

8.1 Definition of adverse event

Adverse events are defined as any untoward (undesirable) medical occurrence in a clinical trial subject administered a medicinal product and which does not necessarily have a causal relationship with this medication. All adverse events (e.g. feeling of ill-health, subjective symptoms and objective signs, intercurrent diseases, accidents, etc.) observed by the Investigator and/or reported by the subject must be recorded in the CRF regardless of the assessment of causality in relationship with the study drug.

Abnormal laboratory values that were assessed as clinically significant by the Investigator are to be documented as AEs. In addition, abnormal laboratory values fulfilling the Grade 3 criterion according to the toxicity scale (Appendix I) are to be documented as AEs, regardless of whether they are considered clinically relevant or not.

8.2 Definition of solicited adverse events

Within this study protocol solicited adverse events are defined as all events recorded by the subjects in the diary provided to them following every vaccination. For each of the 7 days post-vaccination the subjects are requested to monitor and record local symptoms, i.e. erythema, swelling and pain at the site of injection as well as systemic symptoms, i.e. body temperature, headache, chills, myalgia, nausea and fatigue.

8.3 Definition of unsolicited adverse events

At every study visit the Investigator should ask the subject if they have experienced any adverse events since their last visit. All intercurrent diseases reported by the subject, regardless of whether recorded in the subject diary or not, need to be recorded by the Investigator in the appropriate page of the case report form.

The intensity and causality of the events will be graded according to the procedures described under 7.1.7 and 7.1.8 respectively.

8.4 Definition of “adverse event of special interest”

An “adverse event of special interest” is defined in this study as an adverse event fulfilling any of the following features:

- Any cardiac symptom
- ECG changes, which are determined to be clinically significant
- Cardiac enzymes elevated above ULN

Adverse events of special interest are to be reported according to the procedures and timelines applicable for serious adverse events.

8.5 Definition of serious adverse events (SAEs)

A serious adverse event (experience) or reaction is any untoward medical occurrence or effect that at any dose:

1. Results in death,
2. Is life-threatening*,
3. Requires inpatient hospitalization or prolongation of existing hospitalization,
4. Results in persistent or significant disability or incapacity,
5. Is a congenital anomaly or birth defect,
6. or is an otherwise important medical event.

**The term "life-threatening" in the definition of "serious" refers to an event in which the patient was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe.*

Medical and scientific judgment should be exercised in deciding whether expedited reporting is appropriate in other situations, such as important medical events that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the patient or may require intervention to prevent one of the other outcomes listed in the definition above. These should also usually be considered serious.


Examples of such events are intensive treatment in an emergency room or at home for allergic bronchospasm; blood dyscrasias or convulsions that do not result in hospitalization; or development of drug dependency or drug abuse.

8.6 Reporting of SAEs and adverse events of special interest

All serious adverse events (SAEs) or adverse events of special interest (see definition 8.4) occurring throughout the entire course of the study have to be reported to Kendle Safety Department. The study site has to send by e-mail or fax the completed serious adverse event form to Kendle Safety Department within 24 hours of becoming aware of the adverse event.

Kendle Safety forwards all serious adverse events and adverse events of special interest within 24 hours to Bavarian Nordic Drug Safety. Bavarian Nordic is responsible for expedited reporting to the US regulatory authorities (FDA) in compliance with regulations and to the responsible NIH-DMID representatives. For Mexico, all expedited cases will be forwarded by Bavarian Nordic Drug Safety to Kendle Mexico for submission to the Mexican Ministry of Health with an accompanying cover letter in Spanish.

The flowchart below outlines the reporting process and timelines:



* if at least possibly causally related

Please fax SAE reports to the following number depending upon the country of origin:

Kendle Safety US:

fax: +1-866-395-9505
(Tel: +1- 866-395-8568)

Kendle Safety Mexico:

From sites outside Mexico City,

fax: 01-800-714-8106
(Tel: 01-800-714-9244)

From sites inside Mexico City,

fax: 51 35 47 68
(Tel: 54 81 59 44)

The Investigator should not delay reporting because of missing information. Nonetheless, the report should be as complete as possible. This initial notification should include, as a minimum, sufficient information to permit identification of the following:

the reporter
adverse event(s)
involved study medication

the subject
date of onset

9. Statistical Considerations

The primary objective of this trial is to compare the two vaccination groups with regard to total antibodies.

9.1 Sample size calculation

The sample size calculation is based on the primary immunogenicity endpoint '**MVA-specific seroconversion rate**'.

The primary hypothesis is to show that the humoral immune response of the group with diagnosed atopic dermatitis (Group 2) is not statistically inferior compared to the group with healthy subjects (Group 1) at 10-14 days after the second vaccination (Visit 4). The study should demonstrate that the Group 2 seroconversion rate is not worse than the Group 1 seroconversion rate by more than a pre-specified amount. This amount is called the non-inferiority margin (Δ).

Suppose p_1 is the seroconversion rate in healthy subjects (group 1) and p_2 is the seroconversion rate in the subjects with atopic dermatitis (group 2).

The test on non-inferiority will be applied for the following hypothesis:

$$H_0: p_2 - p_1 \leq -\Delta \quad \text{versus} \quad H_1: p_2 - p_1 > -\Delta, \text{ where}$$

Δ is the non-inferiority margin and is chosen in this trial as 5%.

From the experience in the pilot trial POX-MVA-007 in subjects with atopic dermatitis subjects, it is anticipated that the seroconversion rate in both groups reaches at least 99%.

The above hypothesis will be tested based on an exact, unconditional test for binomial differences. In addition an exact one-sided 97.5% unconditional confidence interval for the difference of proportions will be calculated. If the lower limit of this confidence interval is greater than $\tilde{\alpha}$ 5% (or equivalent the p-value of the non-inferiority test is less than 5%) then the null hypothesis will be rejected (StatXact®, Chan 1998, Agresti and Min 2001).

Assuming a significance level of 5%, a power of > 80%, expected seroconversion rates of 99% in both groups, this yields to a sample size of 124 per group (248 in total). In order to account for drop outs, a total of 130 subjects per group (260 in total) will be treated.

For the statistical consideration of the protocol extension, please refer to Appendix IV.

9.2 Endpoints

9.2.1 Immunogenicity endpoints

Primary endpoint

- ELISA specific seroconversion rate at visit 4
 - *Seroconversion is defined as the appearance of antibody titers $\geq 1:50$ in a vaccinia specific IgG ELISA for initially seronegative subjects or twofold increase of the antibody titer compared to the pre-existing baseline titer for subjects with a pre-existing antibody titer in the ELISA.*

Secondary endpoints

- ELISA specific seroconversion rate at visits 2, 3, 5 and F-U.
- Geometric mean titers (at all blood sampling time points).
 - *The geometric mean titer (GMT) is calculated by taking the antilogarithm of the mean of the log₁₀ titer transformations. Antibody titers below the cut-off of the assay will be given an arbitrary value of one for the purpose of calculation.*
- Neutralization assay specific seroconversion rates and geometric mean titers (at all blood sampling time points).
 - *Seroconversion is defined as Appearance of antibody titers ≥ 15 in a vaccinia specific plaque reduction neutralisation assay for initially seronegative subjects or twofold increase of the antibody titer compared to the pre-existing baseline titer for subjects with a pre-existing antibody titer in the PRNT.*
 - *The GMT is calculated by taking the antilogarithm of the mean of the log₁₀ titer transformations. Antibody titers below the cut-off of the assay will be given an arbitrary value of one for the purpose of calculation.*
- Subgroup of 50 subject samples from Group 1 (healthy) and 110 subject samples from Group 2 (AD) collected at US sites: IFN gamma producing T-cells collected at Visits 1, 2 and 4 in response to stimulation with MVA-BN[®] (IMVAMUNE[®]) detected by Enzyme-Linked Immunospot (ELISPOT). The percentage of IFN gamma positive cells in T-cell populations compared to non-stimulated cells will be reported.

The primary time point for data analysis will be 10 – 14 days after the last vaccination (Visit 4) . Other time points at Visit 2, 3, 5 and F-U are used as secondary analysis time points.

9.2.2 Safety and reactogenicity endpoints

Secondary endpoints

- Occurrence of any grade 3 adverse event probably, possibly or definitely related to the study vaccine within 28 days after vaccination.
- Occurrence, relationship and intensity of any serious adverse event at any time during the study.
- Occurrence of solicited local adverse events (redness, swelling and pain) within 1 week after each vaccination (Days 0-7): Intensity, duration, and relationship to vaccination.
- Occurrence of solicited systemic adverse events (redness, swelling and pain) within 1 week after each vaccination (Days 0-7): Intensity, duration, and relationship to vaccination.
- Occurrence of unsolicited non-serious adverse events within 4 weeks after each vaccination (Days 0-28): Intensity, duration and relationship to vaccination.

9.3 Study cohorts/data sets to be evaluated

For the statistical analysis the included subjects will be divided up into the following datasets:

Safety set (SAS): This is the subset of subjects who received at least one dose of study vaccine and for whom any safety data are available.

The final safety analysis will be performed on this population.

Full-analysis set (FAS): This is the subset of subjects who had received at least one dose of study vaccine and for whom any data are available.

Modified Full Analysis Set (MFAS):

This set is defined to consist of all enrolled vaccinia-naïve healthy (Group 1) and at least 300 atopic dermatitis (Group 2) subjects.

- who have been enrolled as vaccinia-naïve based on the verbal confirmation of the volunteer not to have had a smallpox vaccination in the past and on examination of both arms for absence of a typical smallpox vaccination scar.
- who had received both doses of study vaccine and completed all study visits including Visit 4 and
- for whom safety data are available.

Per Protocol (PP) set: This is the subset of subjects who adhere to all protocol conditions, however, not relevant protocol violators can be included into this dataset.

The decision whether a protocol deviation is relevant or not for the classification of subjects to subsets should be made case-by case in a blind review meeting.

The primary population dataset for humoral immunogenicity analysis (ELISA and PRNT) will be the PP set. All confirmatory testing is based on this population. For further descriptive purposes, the same statistical procedures will be applied to the FA dataset.

ELISPOT Analysis Set (EAS):

This set is defined as the alternative PPS for the ELISPOT data analysis. It consists of all subjects with

- a complete ELISPOT data set (Visits 1, 2 and 4 available)
- the administration of both study vaccinations
- without any relevant major protocol violations for this data set.

ELISPOT data analysis will be descriptive and performed on both the EAS and the FAS.

Since two different vaccine lots will be used during the conduct of the study, a stratified subgroup analysis comparing subjects vaccinated either with vaccine lot 0170505 or vaccine lot 0040707 will be performed.

Any subject not included in the Full Analysis Set (FAS) will be considered a drop-out.

9.4 Statistical analysis

Once all subjects have completed the half-year follow-up (Visit F-U) and after any necessary settlement of queries etc. in the CRFs, data from all patients and visits will be locked. A full

analysis of the data available will be performed and a final clinical study report prepared. Results of the PRNT assay will be presented in an addendum to the clinical study report. For preparation of safety data as part of a potential Emergency Use Authorization (EUA) data package, a safety analysis will be performed on the population (MFAS) described in section 9.3 ('Study cohorts/data sets to be evaluated').

9.4.1 Analysis of demographics and baseline characteristics

The results will be compared descriptively (shown in a table). If large differences become apparent then a test will be done to check the significance.

9.4.2 Analysis of Immunogenicity

Antibody titers and resulting seroconversion rates will be assessed by direct ELISA and PRNT method as described in section 7.2.

The primary immunogenicity endpoint is the MVA-specific seroconversion rate derived from the ELISA specific antibody titers.

The primary hypothesis is to show that the humoral immune response of the study group with atopic dermatitis (Group 2) is not statistically inferior compared to the study group of healthy subjects (Group 1).

The above hypothesis will be tested based on an exact, unconditional test for binomial differences. In addition an exact one-sided 97.5% unconditional confidence interval for the difference of proportions will be calculated. If the lower limit of this confidence interval is greater than 5% (or equivalent the p-value of the non-inferiority test is less than 5%) then the null hypothesis will be rejected (StatXact®, Chan (1998), Agresti and Min (2001)).

In a first step, the primary null hypothesis as stated in section 9.1 will be tested 2 weeks after the last vaccination.

Secondary analysis will be done with the timepoints of Visit 2, Visit 3, Visit 5 and F-U and with the neutralization assay specific seroconversion rates (from PRNT) as above.

Descriptive statistics for Enzyme-Linked Immunospot (ELISPOT) will be provided.

T-cell samples will be analyzed if samples are available for the subject from Visit 1 and at least one of Visit 2 or Visit 4.

Summary tables will be provided for the FAS and the EAS.

All statistical tests for secondary time points and comparisons are regarded descriptive. No adjustment for multiple testing will therefore be done.

Seroconversion rates for each group at all visits will be tabulated and presented graphically by means of bar charts.

Tables showing geometric mean titer (GMT) with 95% confidence limits for each group at all blood sampling time points will be prepared. Additionally, the distribution of antibody titers will be displayed graphically by means of reverse cumulative curves.

9.4.3 Analysis of safety and reactogenicity

Solicited local adverse events

The occurrence of solicited local adverse events within 1 week after each vaccination will be summarized on a per patient and per vaccination basis.

The maximum intensity over the 7-day period after vaccination will be used and categorized as follows:

Pain: Grade > 0

Grade ≥ 2

Grade ≥ 3

For measurements of diameter size: Diameter > 0 mm

Diameter ≥ 30 mm

Diameter ≥ 100 mm

These categories will be compared between treatment groups by means of the exact test of Fisher (or its normal approximation, the chi-squared test).

Solicited systemic adverse events

Occurrence of solicited systemic adverse events within 1 week after each vaccination will be summarized per patient and vaccination.

The maximum intensity over the 7-day period after vaccination will be used and categorized as follows:

Grade > 0

Grade ≥ 2

Grade ≥ 3

These categories will be compared between treatment groups by means of the exact test of Fisher (or its normal approximation, the chi-squared test).

Unsolicited adverse events:

Unsolicited adverse events will be coded with the MedDRA coding terminology. The intensity of adverse events will be graded according to section 7.1.7.

The number of adverse events and number of patients with at least one adverse event for each preferred term will be descriptively compared between treatment groups.

The occurrence of any grade 3 or higher adverse reaction probably, possibly or definitely related to the study vaccine within 28 days after vaccination will be compared between treatment groups.

The occurrence, relationship and intensity of *adverse events of special interest* at any time during the study will be separately listed and tabulated. The incidence of such AEs will be compared between treatment groups by means of the exact test of Fisher (or its normal approximation, the chi-squared test).

Serious adverse events will be listed separately. Each SAE will be described individually in detail. The number of subjects with at least one SAE will be compared between treatment groups by means of the exact test of Fisher (or its normal approximation, the chi-squared test).

Safety laboratory and urine analysis:

Clinical laboratory test results will be marked whether the result is below, within or above the respective reference range. The number of values outside of the reference range will be counted.

RESTRICTED BUSINESS PROPRIETY

ECG

The ECG will be evaluated by a centralized procedure. The transmitted standard ECG results like PQ, QRS, QT and QTc duration and heart rate will be summarized per visit and treatment group.

The number of subjects with normal/abnormal ECGs and clinically significant ECGs (resulting in AEs) will be compared between treatment groups by means of the exact test of Fisher (or its normal approximation, the chi-squared test).

Detailed descriptive analysis of the reasons (category) of abnormality will be done.

9.4.4 Data handling

All data obtained in this study and documented in the case report forms (CRFs) will be listed. For parameters of interest, summary tables with descriptive group statistics (mean, standard deviation, minimum, maximum, number of valid cases) for metrical variables will be prepared. For ordinal/dichotomous variables summary tables showing the absolute and relative count in each category will be prepared.

Further statistical analysis may be performed as appropriate.

Kendle Inc. and GmbH will be responsible for data management and statistical evaluation. Data will be analysed using SAS[®] PC. The procedure for accounting for missing, unused and spurious data will be given in the Statistical Analysis Plan.

10. Ethical aspects

10.1 Ethical and legal regulations

The Principal Investigators make sure that this clinical trial is conducted in complete accordance with the provisions of the Declaration of Helsinki (and its amendments of Tokyo, Venice, Hong Kong, Somerset West and Edinburgh), the national laws and other guidelines for the conduct of clinical studies like the ICH Harmonised Tripartite Guideline for Good Clinical Practice to guarantee the greatest possible subject protection.

10.2 Approval of an Independent Ethics Committee (IEC) / Institutional Review Board (IRB)

The protocol must be reviewed by the competent IEC / IRB according to the national law of the respective site before the first subject is included in this study.

If one of the Investigators is a member of one of these committees, he may not vote on any aspect of the review of this protocol.

The Sponsor will assure that the IEC / IRB is informed of any amendment to the protocol and any unanticipated problems involving risks to human subjects included in the study. Such information will be provided to the committee at intervals appropriate to the degree of subject risk involved, but not less than once a year. Copies of all correspondence between the Investigator and the committee must be forwarded immediately to the sponsor. In case of withdrawal of IEC / IRB approval of the study, the sponsor has to be contacted immediately by facsimile or telephone.

10.3 Confidentiality and data protection

The Principal Investigator of the respective site is obliged to ensure anonymity of the subject. He/she has to make sure that all documents including CRFs provided (e.g. in the course of a marketing authorization procedure) to third parties (in this case: to the manufacturer of MVA-BN® (IMVAMUNE®) or to an authority) contain no subject names.

Only a subject and center number, not by their name or clinic and subject's file number, may identify subjects respectively. The Principal Investigators keep separate confidential subject logs for study enrollment, which allows subject numbers to be matched with names and addresses of subjects at any time. Documents not meant to be passed on to third parties have to be stored confidentially by the Principal Investigator.

Any information collected in the course of the study may be made available only to persons directly involved in this study (Principal Investigator and his staff members, monitor, statistician) or to authorized persons by the sponsor or the Principal Investigator or authorities.

11. Informed consent

No subject can participate in this study without having given informed consent in writing after the Investigator or his delegate has informed the subject clearly and completely, verbally and in writing, over the purpose, procedures, potential benefits and risks of the current study and prior to study drug administration.

One signed original of the informed consent must be given to each subject and one signed original must remain in the study documentation file and be available for verification by the monitor or competent regulatory authorities at any time.

Subjects must be informed unequivocally that they may refuse participation in the study and that they may withdraw from the study at any time and for whatever reason and that withdrawal of consent will not affect their subsequent medical treatment or relationship with the treating physician.

Subjects also consent to authorize the monitor, quality assurance personnel and regulatory authorities to inspect source documents for quality assurance purposes. Such verifications will always be conducted on site and under the ethical supervision of the Investigator. All aspects of the confidentiality of the subject's data will be guaranteed.

The informed consent form will be prepared in accordance with ICH-GCP guidelines and must be approved by the appropriate IEC / IRB.

12. Case report forms and retention of records

12.1 Case report forms

All CRFs are to be filled out completely by the examining personnel, then reviewed and signed by the Principal Investigator to indicate their correctness.

It is the Principal Investigators responsibility to ensure that all subject discontinuations or changes in study or other medications entered on the subject's CRF are also made on the subjects medical records.

The CRFs for any subject leaving the study should be completed at the time of the final visit or shortly thereafter.

12.2 Retention of records

The Investigator shall maintain the records of disposition of drug receipts, drug accountability forms, his copies of the CRFs, subject files and regulatory documents (e.g. informed consents, IEC / IRB approval, FDA1572, Financial Disclosure Forms) according to applicable national law after the end of the study.

13. Monitoring of the study

The monitor is responsible for obtaining an overview of the course of the trial in co-operation with the Investigator, checking if the trial protocol is being observed, and helping the Investigators to solve any problems which may arise. All documents in the context with this clinical trial will be handled confidentially at any time.

The Investigator has agreed to give the monitor access to relevant hospital or clinical records to confirm their consistency with the CRF entries and to obtain an adequate overview of the course of the trial. The monitor checks entries on the CRF for completeness, accuracy and correctness. The entries on the CRF will be verified against source documents with respect to the following criteria and in the following frequencies:

Informed consent	100%
Demographic data	100%
In-/exclusion criteria	100%
Primary target parameters	100%
Administration of study vaccine	100%
Adverse events	100%
Time points of visits	100%
Laboratory parameters	100%
Vital signs	100%

This will be done under preservation of data protection.

The source data verification must be performed by direct insight. If a subject refuses to consent to this procedure he/she must not be enrolled in the study.

The Investigator (or a representative) has further agreed to support the monitor in solving any problems he/she discovers during his/her visits.

14. Responsibilities of the Investigator

The Investigator agrees to carry out the study in accordance with the guidelines and procedures outlined in this trial protocol. The Investigator especially consents to strictly adhere to the ethical principles (see section 10 of this protocol).

The Investigator knows that he/she must, according to professional regulations for physicians, obtain the approval of the competent IEC / IRB.

Any deviation from the trial protocol must, before its implementation, be agreed to by the sponsor in writing, and by the IEC / IRB initially consulted.

Changes to the protocol require written "Amendments to the protocol" and written approval by Principal Investigator. Changes are allowed only if study value is not reduced and if they are ethically justifiable. The statistician must agree to the amendment, if appropriate, his statement is to be submitted to the IEC / IRB. The amendment must be passed on to all participating Investigators with the obligation to adhere to its provisions. If warranted, the subject information has to be changed accordingly.

It is within the responsibility of the Investigator that a CRF is completed and signed after the subject has finished the trial for each subject participating in the study.

All entries on the CRFs must be made in black ball-point pen; corrections are made by placing a single horizontal line through the incorrect entry, so that it can still be seen, and placing the revised entry beside it. The revised entry must be filled in, initialled and dated by a member of the Investigator's research team authorized to make CRF entries. Correction fluid must not be used.

At the conclusion of the study, the Investigator will return all partly used, unused and empty drug containers to the sponsor.

The Investigator may ask to terminate the study due to administrative or other reasons. If this should be the case, appropriate measures which safeguard the interests of the participating subjects must be taken after verification and consultation with the Principal Investigator.

By signing this protocol, the Investigator confirms that he/she has read the entire trial protocol, agrees to its procedures, and will comply strictly with the formulated guidelines.

15. References

1. Agresti A, Min Y. (2001). On small-sample confidence intervals for parameters in discretedistributions. *Biometrics*. 2001 Sep;57(3):963-71
2. Alcami A & Smith GL (1992) A soluble receptor for interleukin-1 beta encoded by vaccinia virus: a novel mechanism of virus modulation of the host response to infection. *Cell* 71, 153-167.
3. Alcami A & Smith GL (1996) A mechanism for the inhibition of fever by a virus. *Proc. Natl. Acad. Sci. U.S.A* 93, 11029-11034.
4. Antoine G, Scheiflinger F, Dorner F, & Falkner FG (1998) The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. *Virology* 244, 365-396.
5. Blanchard TJ, Alcami A, Andrea P, & Smith GL (1998) Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine. *J. Gen. Virol.* 79 (Pt 5), 1159-1167.
6. Carroll MW & Moss B (1997) Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line. *Virology* 238, 198-211.
7. Chan I (1998). Exact tests of equivalence and efficacy with a non-zero lower bound for comparative studies. *Statistics in Medicine* 17, 1403-1413.
8. Drexler I, Heller K, Wahren B, Erfle V, & Sutter G (1998) Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells. *J. Gen. Virol.* 79 (Pt 2), 347-352.
9. Goldstein JA, Neff JM, Lane JM, & Koplan JP (1975) Smallpox vaccination reactions, prophylaxis, and therapy of complications. *Pediatrics* 55, 342-347.
10. Guillaume JC, Saiag P, Wechsler J, Lescs MC, & Roujeau JC (1991) Vaccinia from recombinant virus expressing HIV genes. *Lancet* 337, 1034-1035.
11. Grabenstein JD, Winkenwerder W. Jr. (2003) US Military Smallpox Vaccination Program Experience. *JAMA* 2003, Vol. 289, No. 24, 3278 - 3282
12. Kunz B, Oranje AP, Labreze L, Stadler JF, Ring J, Taieb A. Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis. *Dermatology* 1997, 195:10-19
13. Lane JM, Ruben FL, Neff JM, & Millar JD (1969) Complications of smallpox vaccination, 1968. *N. Engl. J. Med.* 281, 1201-1208.
14. Lane JM, Ruben FL, Neff JM, & Millar JD (1970) Complications of smallpox vaccination, 1968: Results of ten statewide surveys. *J. Infect. Dis.* 122, 303-309.

15. Mahnel H & Mayr A (1994) [Experiences with immunization against orthopox viruses of humans and animals using vaccine strain MVA]. *Berl Munch. Tierarztl. Wochenschr.* 107, 253-256.
16. Mayr A, Hochstein-Mintzel V, & Stickl H (1975) Passage History: Abstammung, Eigenschaften und Verwendung des attenuierten Vaccina-Stammes MVA. *Infection* 3, 6-14.
17. Mayr A & Munz E (1964) [Changes in the vaccinia virus through continuing passages in chick embryo fibroblast cultures]. *Zentralbl. Bakteriol. [Orig.]* 195, 24-35.
18. Mayr A, Stickl H, Muller HK, Danner K, & Singer H (1978) [The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism (author's transl)]. *Zentralbl. Bakteriol. [B]* 167, 375-390.
19. McElwain WP (1972) Complications of smallpox vaccination. *J. Ky. Med. Assoc.* 70, 165-166.
20. Meyer H, Sutter G, & Mayr A (1991) Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. *J. Gen. Virol.* 72 (Pt 5), 1031-1038.
21. Redfield RR, Wright DC, James WD *et al.* (1987) Disseminated vaccinia in a military recruit with human immunodeficiency virus (HIV) disease. *N. Engl. J. Med* 316, 673-676.
22. Rosel JL, Earl PL, Weir JP, & Moss B (1986) Conserved TAAATG sequence at the transcriptional and translational initiation sites of vaccinia virus late genes deduced by structural and functional analysis of the HindIII H genome fragment. *J. Virol.* 60, 436-449.
23. Stickl, H. A. (1974) Smallpox vaccination and its consequences: first experiences with the highly attenuated smallpox vaccine "MVA". *Prev. Med.* 3[1], 97-101.
24. Stickl H & Hochstein-Mintzel V (1971) [Intracutaneous smallpox vaccination with a weak pathogenic vaccinia virus ("MVA virus")]. *Munch. Med. Wochenschr.* 113, 1149-1153.
25. Stickl H, Hochstein-Mintzel V, Mayr A *et al.* (1974) [MVA vaccination against smallpox: clinical tests with an attenuated live vaccinia virus strain (MVA) (author's transl)]. *Dtsch. Med. Wochenschr.* 99, 2386-2392.
26. Sutter G & Moss B (1992) Nonreplicating vaccinia vector efficiently expresses recombinant genes. *Proc. Natl. Acad. Sci. U. S. A* 89, 10847-10851.
27. Vollmar, J *et al.* (2005) Safety and Immunogenicity of IMVAMUNE: A promising candidate as a third generation smallpox vaccine. *Vaccine, in press.*

16. Appendices

16.1 Appendix I: Toxicity Scale for laboratory values

SERUM CHEMISTRY				
Lab value	Mild (Grade 1)	Moderate (Grade 2)	Severe (Grade 3)	Potentially Life Threatening (Grade 4)
Sodium – Hyponatremia mmol/L	< LLN - ≥ 132	< 132 - ≥ 130	< 129 - ≥ 125	<125
Sodium – Hypernatremia mmol/L	$\geq$ ULN - < 150	≥ 150 - < 155	≥ 155 - < 160	≥ 160
Potassium – Hyperkalemia mmol/L	$\geq$ ULN - < 5.5	≥ 5.5 - < 6.0	≥ 6.0 - < 7.0	≥ 7.0
Potassium – Hypokalemia mmol/L	< LLN - ≥ 3.5	< 3.5 - ≥ 3.4	< 3.4 - ≥ 3.2	< 3.2
Calcium – Hypercalcaemia mmol/L	$\geq$ ULN - < 2.9	≥ 2.9 - < 3.1	≥ 3.1 - < 3.4	≥ 3.4
Calcium - Hypocalcaemia mmol/L	< LLN - ≥ 2.0	< 1.75 - ≥ 2.0	< 1.6 - ≥ 1.75	< 1.5
Serum creatinine - mg/dL	$\geq$ ULN - < 1.5 x ULN	≥ 1.5 - < 3 x ULN	$\geq 3 - 6$ x ULN	> 6 x ULN
Alkaline Phosphatase - increase by factor	> 1.25 - < 2.0 x ULN	≥ 2.0 - < 3.0 x ULN	≥ 3.0 x ULN	
Liver Function Tests - increase by factor	> 1.0 - < 2.5 x ULN	≥ 2.5 - < 4 x ULN	≥ 4 x ULN	
Total Bilirubin - increase by factor	> ULN – 1.5 x ULN	> 1.5 - 3.0 x ULN	> 3.0 - 10.0 x ULN	> 10.0 x ULN
Cardiac Troponin I	>ULN – <2.0 x ULN	≥ 2.0 - < 5.0 x ULN	≥ 5.0 x ULN	
Total Cholesterol mg/dL	> ULN - 300	> 300 - 400	> 400	

HEMATOLOGY				
Lab Value	Mild (Grade 1)	Moderate (Grade 2)	Severe (Grade 3)	Potentially Life Threatening (Grade 4)
Hemoglobin (Female) - g/dl	< LLN - $\geq$ 10.5	< 10.5 - $\geq$ 10.0	< 10.0	
Hemoglobin (Male) - g/dl	< LLN - $\geq$ 12.0	< 12.0 - $\geq$ 11.0	< 11.0	
WBC Increase - cell/mm ³	$\geq$ ULN - < 15,000	$\geq$ 15,000 - < 20,000	$\geq$ 20,000	
WBC Decrease - cell/mm ³	< LLN - $\geq$ 2,500	< 2,500 - $\geq$ 1,500	< 1,500	
Lymphocytes Decrease - cell/mm ³	< 1,000 - $\geq$ 750	< 750 - $\geq$ 500	< 500	
Neutrophils Decrease - cell/mm ³	< 2,000 - $\geq$ 1,500	< 1,500 - $\geq$ 1,000	< 1,000	
Platelets Decreased - cell/mm ³	< LLN - $\geq$ 100,000	< 100,000 - $\geq$ 75,000	< 75,000	
URINE				
Protein	Trace - $\leq$ 1+	> 1+ - $\leq$ 2+	> 2+ - $\leq$ 3+	> 3+ - nephritic syndrome
Glucose	Trace	1+	2+	>2+
Blood (microscopic) – red blood cells per high power field (rbc/hpf)	$\geq$ 0- $\leq$ 10	$\geq$ 10 - < 50	$\geq$ 50	Gross
Blood (measured by Combur urinsticks)	Trace - $\leq$ 1+	> 1+ - $\leq$ 2+	> 2+ - $\leq$ 3+	> 3+
SYSTEMIC QUANTITATIVE				
Tachycardia - beats per minute	101 - 115	116 – 130	$\geq$ 131	
Bradycardia - beats per minute	54 - 50	49 – 45	$\leq$ 44	
Hypertension (systolic) - mm Hg	141 - 155	156 – 165	$\geq$ 166	
Hypertension (diastolic) - mm Hg	91 - 95	96 – 100	$\geq$ 101	
Hypotension (systolic) - mm Hg	89 - 85	84 – 80	$\leq$ 79	

16.2 Appendix II: Case Definitions Acute Myocarditis / Pericarditis

Case Definition for Acute Myocarditis

A possible case of acute myocarditis is defined by the following criteria and the absence of evidence of any other likely cause of symptoms:

Presence of dyspnea, palpitations, or chest pain of probable cardiac origin in a patient with either one of the following:

- Electrocardiogram (ECG) abnormalities beyond normal variants, not documented previously, including
 - o ST-segment or T-wave abnormalities,
 - o Paroxysmal or sustained atrial or ventricular arrhythmias,
 - o AV nodal conduction delays or intraventricular conduction defects, or
 - o Continuous ambulatory electrocardiographic monitoring that detects frequent atrial or ventricular ectopy

Or

- Evidence of focal or diffuse depressed left-ventricular (LV) function of indeterminate age identified by an imaging study (e.g., echocardiography or radionuclide ventriculography).

A probable case of acute myocarditis, in addition to the above symptoms and in the absence of evidence of any other likely cause of symptoms, has one of the following:

- o Elevated cardiac enzymes, specifically, abnormal levels of cardiac troponin I, troponin T, or creatine kinase myocardial band (a troponin test is preferred);
- o Evidence of focal or diffuse depressed LV function identified by an imaging study (e.g., echocardiography or radionuclide ventriculography) that is documented to be of new onset or of increased degree of severity (in the absence of a previous study, findings of depressed LV function are considered of new onset if, on follow-up studies, these findings resolve, improve, or worsen); or
- o Abnormal result of cardiac radionuclide imaging (e.g., cardiac MRI with gadolinium or gallium-67 imaging) indicating myocardial inflammation.

A case of acute myocarditis is confirmed if histopathologic evidence of myocardial inflammation is found at endomyocardial biopsy or autopsy.

Case Definition for Acute Pericarditis

A possible case of acute pericarditis is defined by the presence of

- o Typical chest pain (i.e., pain made worse by lying down and relieved by sitting up and/or leaning forward) and no evidence of any other likely cause of such chest pain.



A probable case of acute pericarditis is a possible case of pericarditis, or a case in a person with pleuritic or other chest pain not characteristic of any other disease, that, in addition, has one or more of the following:

- o Pericardial rub, an auscultatory sign with one to three components per beat,
- o ECG with diffuse ST-segment elevations or PR depressions without reciprocal ST depressions that are not previously documented, or
- o Echocardiogram indicating the presence of an abnormal collection of pericardial fluid (e.g., anterior and posterior pericardial effusion or a large posterior pericardial effusion alone).

A case of acute pericarditis is confirmed if histopathologic evidence of pericardial inflammation is evident from pericardial tissue obtained at surgery or autopsy.

16.3 Appendix III: SCORAD Evaluation Form

POX-MVA-008		SCORAD Evaluation Form	
Visit No.		Visit date	
Subject Study No.			
Examiner (Name) _____			

Figures in parenthesis for children under two years

A: EXTENT. Please indicate the area involved _____

B: INTENSITY. (as rated below) _____

CRITERIA	INTENSITY
Erythema	
Edema/Papulation	
Oozing/crust	
Excoriation	
Lichenification	
Dryness	

Is evaluated on all involved areas

C: SUBJECTIVE SYMPTOMS
PRURITUS + SLEEP LOSS

SCORAD $A/5 + 7B/2 + C$

Visual analog scale
(average for the last
3 days or nights)

PRURITUS (0 to 10)

SLEEP LOSS (0 to 10)

0 1 2 3 4 5 6 7 8 9 10

0 1 2 3 4 5 6 7 8 9 10

0 1 2 3 4 5 6 7 8 9 10

0 1 2 3 4 5 6 7 8 9 10

16.4 Appendix IV: Proposed Extension Phase of the POX-MVA-008 trial

16.4.1 General Information and Rationale for an Extension Phase of the POX-MVA-008 trial

- The original protocol was designed to evaluate immunogenicity and safety of MVA-BN[®] (IMVAMUNE[®]) in vaccinia-naïve subjects with diagnosed atopic dermatitis compared to healthy subjects.

This extension phase implements the following major changes to Bavarian Nordic protocol POX-MVA-008:

- A protocol extension, which allows the recruitment of a further 100 healthy and 200 vaccinia-naïve subjects with diagnosed atopic dermatitis. A visit schedule describing examinations performed is detailed in section 16.4.2 “Extension Protocol Flowchart”.
- An additional interim analysis (proposed in Amendment #2) will no longer be conducted at the end of the main phase of the study (once 260 subjects have been enrolled in the main study and have completed their Visit 5). An analysis of the complete study population will be done once all 560 subjects have been enrolled and have completed their Visit 5, and will be performed as described under section 9.4. Once all 560 subjects have completed their Follow-Up assessment an addendum will be prepared including all follow-up data.
- The enrollment of a total of 300 subjects with diagnosed atopic dermatitis will allow the detection of 1 (one) unexpected adverse reaction in 100 (one hundred) subjects with 95% confidence, provided there is no background incidence of the respective adverse reaction.
- The sample size of 300 subjects with atopic dermatitis will meet the requirements suggested by CBER’s “Current Thinking” position paper regarding the data recommended in support of the use of MVA vaccines in a post-event setting under an EUA for individuals with contraindications to vaccinia vaccines.

The changes are not considered to have any negative influence on the study procedure in general, on the safety of the participants or on the validity of the main study results.

16.4.2 Extension Protocol Flow Chart

VISIT ¹	SCREENING	VISIT 1	VISIT 2	VISIT 3	VISIT 4	VISIT 5	TELEPHONE F-U
Day (D)	-28- -1 D	0	7-10 D	28-35	VISIT 3 +10-14 D	VISIT 3 +28-35 D	VISIT 3 +182-210 D
Vaccination		I		II			
Informed consent ²	X						
Screening examinations	X						
Check incl. / excl. criteria, esp. cardiac risk	X	X		X			
Medical History (incl. history of atopic dermatitis)	X						
Interview on history of AD ⁷	X						
Examination of AD including SCORAD ⁷ (active AD only)	X						
Brief interview on AD status ⁷ (including SCORAD for active AD only)						X	
Brief interview on AD status ⁷							
Complete Physical examination incl. evaluation of vital signs, esp. listening to heart and lung	X						
Targeted physical exam.		X	X	X	X	X	
ECG	X		X		X	(X) ⁴	(X) ⁴
Pregnancy test ³	X	X		X		X	
Safety Lab	X		X		X	(X) ⁴	(X) ⁴
Urine analysis	X						
Antibody analysis		X	X	X	X	X	
Handout of diary card ⁵		X		X			
Collection of diary card			X		X		
Exam of vaccination site			X		X		
AE-reporting		X	X	X	X	X	
Telephone Follow-up for SAEs, SIAEs and AEs that were still ongoing at visit 5							X
Review baseline signs and symptoms	X	X					
Approx. blood sampling in ml ⁶	14	16	30	16	30	16 (+14) ⁴	(14) ⁴

¹ If clinically indicated additional visits may be necessary between scheduled visits and possibly additional blood draws may occur. Visits occurring between indicated scheduled visits will be identified with letters to indicate sequence of the visit until the next scheduled visit occurs (e.g. 1A, 1B etc. will indicate extra visits between visit 1 and 2).

² Consent process must be completed and form signed before any study-related procedures are conducted.

³ Serum or urine pregnancy test, women of childbearing potential only. At screening visit, a serum test must be performed.

⁴ Only required if clinically indicated.

⁵ The Diary Card should be completed daily for 7 days. If symptoms persist at day 7, temperature/symptom measurements should be recorded each day until resolved.

⁶ Approximate amount of blood needed for analysis: Safety lab: app.14 ml, Antibody analysis: app. 16 ml.

Amount of blood taken during the extension phase: app. 150 ml

⁷ Group 2 (AD) only

For clarification:

Lot 170505: 1st enrolment period is from subject 1 to subject 177 (main phase)

Lot exchange: 2nd enrolment period is from subject 178 to subject 260 (main phase)

Lot exchange: 3rd enrolment period is from subject 261 to subject 530 (extension study)

RESTRICTED BUSINESS PROPRIETY

16.4.3 Inclusion & Exclusion Criteria

The same inclusion and exclusion criteria from the main protocol apply, please refer to section “II Protocol Synopsis” (pages 13-15) and “4.2 Inclusion Criteria” and “4.3 Exclusion Criteria” (pages 32-33). .

16.4.4 Statistical Considerations

The primary objective of this protocol extension is to estimate the frequency of common and uncommon reactions in 300 vaccinia-naïve subjects with diagnosed atopic dermatitis. This sample size will allow the detection of 1 (one) unexpected adverse reaction in 100 (one hundred) subjects with 95% confidence, provided there is no background incidence of the respective adverse reaction.

The below table provides information on different scenarios for this assumption. The following sample sizes are needed to detect 1, 2 or 3 ADR with 95% certainty¹:

<i>Expected incidence of ADR</i>	Number of subjects required to detect 1 ADR	Number of subjects required to detect 2 ADR	Number of subjects required to detect 3 ADR
1:10	28	46	61
1:50	148	235	313
1:100	298	473	627

¹ Calculated by solving the following equation for N : $B(p_a; N, N_A - 1) = \beta$, where B is the accumulated binomial distribution, N_A is the number of adverse events we wish to (be able to) detect and $\beta = 0.05$.

16.5 Appendix V: Exchange of IMVAMUNE® vaccine lot 0170505 by IMVAMUNE® vaccine lot 0040707

The FDA has agreed with BN that lot 0170505 can be used to generate clinical data to support an EUA and have further agreed with BN's strategy to demonstrate comparability between IMVAMUNE® lots manufactured at different sites. However, in recent discussions with the US Department of Health and Human Services (DHHS), the importance of using a vaccine lot from Good Manufacturing Practice (GMP) lot-consistent manufacturing runs was re-emphasized again to comply with their own definition of a "usable product". Therefore, even though BN's previous strategy of using lot 0170505 had been approved by FDA, to ease the decision-making at DHHS to accept IMVAMUNE® for the national stockpile, BN has decided to change to IMVAMUNE® lot 0040707 for all subsequently enrolled study subjects in Bavarian Nordic's clinical study protocols.

For the study POX-MVA-008 this means that the currently used IMVAMUNE® vaccine lot 0170505 will be exchanged by IMVAMUNE® vaccine lot 0040707 with effective date Februar 1st, 2008.

The difference between the two IMVAMUNE® vaccine lots mainly lays in a so-called "re-derivation step" reducing the anyway minimal risk of transmission of particles causing the disease "transmissible/bovine spongiform encephalopathy" (TSE/BSE). Summarizing the process of re-derivation, the original MVA-BN® virus seed stock was re-cloned through 5 rounds of plaque purification by limited dilution reducing the risk of TSE/BSE contamination further down to a factor of 3.33×10^{-36} . The re-derived Master Seed Virus (MSV) is now being used as the starting material for lot 0040707.

Materials from the currently used lot 0170505 and from the new virus seed stock used for the production of lot 0040707 were compared both genetically and phenotypically and were confirmed to be 100% identical. Additionally, a GLP animal comparability study in mice revealed that IMVAMUNE® vaccine from both the original and the re-derived MSV induces an identical humoral immune response in mice resulting in equal protection of the animals against an orthopox challenge.

In Protocol Amendment #2 dated 12 December 2006 it was stated and explained that the IMVAMUNE® vaccine lot 0170505 would be exchanged by lot 0031105. With regard to an optimized clinical comparability program Bavarian Nordic has since then decided that it would be most ideal in this situation to take advantage of replacing the original vaccine lot 0170505 with a vaccine lot from the **final production run** planned to be supplied to the US Government for use under the Emergency Use Authorization guideline. This final batch is currently in the final stages of production at Bavarian Nordic's vaccine manufacturing facility in Denmark and the currently expected re-start and extension phase of the POX-MVA-008 clinical study is now scheduled for February 2008.

The final production run of IMVAMUNE® vaccine, lot 0040707, also uses re-derived Master Seed Virus, hence reducing the anyway minimal risk of transmission of particles causing the disease "transmissible/bovine spongiform encephalopathy" (TSE/BSE) referred to in Protocol Amendment #2.

All vials of the previously used IMVAMUNE® vaccine lot 0170505 have been retrieved from sites and destroyed and all of the subjects already enrolled into the study have now completed their follow-up visits.

To secure an adequate exchange of the currently used vaccine lot 0170505 against lot 0040707, the following rules in on-going trials with respect to the treatment of study subjects should apply:

1. Subjects currently in screening can be vaccinated with the currently delivered vaccine lot 0170505 until December 22nd, 2006.
2. Subjects who have been in screening and could not be vaccinated by December 22nd, 2006 have to wait until vaccine lot 0040707 is available. Due to the extended time of availability of vaccine lot 0040707 at the investigational site, these subjects will have to be re-screened.
3. Subjects who received the first vaccination using vaccine lot 0170505 will get the second vaccination also with vaccine lot 0170505. Vaccination of a subject with two different vaccine lots is not permitted.
4. Vaccine lot 0040707 will be delivered to clinical sites once FDA and IRB approval has been obtained.
5. As soon as the vaccine lot 0040707 is available at the investigational site, subjects will be exclusively vaccinated with this vaccine lot.

For evaluation of possible influence of the lot exchange, a stratified subgroup analysis comparing subjects vaccinated either with vaccine lot 170505 or vaccine lot 0040707 will be performed during the statistical analysis of the study.

The following table outlines the current enrollment status and the plans to include 100 additional healthy subjects in the trial to guarantee a statistically valid analysis of the trials using two different vaccine lots:

	Initially Planned	Subjects vaccinated with lot 0170505 until December 22nd, 2006	Planned no. of subjects vaccinated with lot 0040707 starting as soon as the vaccine is available at sites	Total
Group1: Healthy	130	105	125	230
Group 2: Diagnosed AD	300	72	258	330
Total	430	177	383	560

The sample size of 230 in the group enrolling healthy subjects will ensure that 125 healthy subjects are vaccinated with IMVAMUNE[®] lot 0040707 and could subsequently be statistically evaluated according to the statistical considerations in Section 9 of the study protocol. The total sample size including 200 AD subjects enrolled in the extension phase (outlined in Clinical Protocol Amendment #1) and 100 additional healthy subjects (outlined in Clinical Protocol Amendment #2) will therefore increase to 560 subjects.

Supplemental Tables

Unsolicited Adverse Events: Relationship (FAS=632)

Relationship	Healthy (N=282) n (%)	Atopic Dermatitis (N=350) n (%)
None	144 (33.1)	171 (31.7)
Unlikely	117 (26.9)	86 (16.0)
Possible	76 (17.5)	111 (20.6)
Probable	60 (13.8)	92 (17.1)
Definite	38 (8.7)	79 (14.7)
Total	435 (100.0)	539 (100.0)


N: Number of subjects; n: Number of events; %: Percentage based on total number of events

Unsolicited Adverse Events: Intensity (FAS=632)

Intensity	Healthy (N=282) n (%)	Atopic Dermatitis (N=350) n (%)
Grade 1	298 (68.5)	432 (80.1)
Grade 2	108 (24.8)	86 (16.0)
Grade 3	29 (6.7)	21 (3.9)
Grade 4	0 (0.0)	0 (0.0)
Total	435 (100.0)	539 (100.0)

N: Number of subjects; n: Number of events; %: Percentage based on total number of events

Intensity: Grade 1 = AE tolerated by subject; Grade 2 = AE discomforting activities; Grade 3 = AE prevents activities; Grade 4 = Life threatening (SAE)



List of IECs / IRBs

Site No.	Principal Investigator	IEC / IRB – Site	IEC/IRB Address	Country
001	Galan Herrera, Juan F	Comité de Inv. para Estudios en Humanos	Puente de Piedra No.150, Col. Toriello Guerra, Tlalpan Mexico City, Mexico 14050	MEXICO
002	Barba Gomez, Jose F	Comité de Ética del Instituto Dermatológico de Jalisco	Avenida Federalismo Norte 3120 Col. Atemajac del Valle Zapopan, Jalisco, Mexico 45190	MEXICO
003	Hernandez Garcia, Araceli	Comité de Ética de la Unidad de Investigación en Salud de Chihuahua	Ortiz Mena 2200, Fracc. Las Palmas, Chihuahua, Chih. Chihuahua 31205	MEXICO
004	Gomez Vera, Javier	Comde Inv y Bioética del Hosp Adolfo López M	Av. Universidad No. 1321, Col. Florida Mexico City, Mexico City 01030	MEXICO
005	Gonzalez Diaz, Sandra N	Comité de Investigación y Ética de la Facultad de Medicina y Hospital Universitario "Dr. José Eleuterio González" Universidad Autónoma de Nuevo León	Av. Francisco I. Madero Pte s/n y Av.Gonzalitos s/n. Col. Mitras Centro Monterrey, Nuevo León 64460	MEXICO
013	Rojo Gutierrez, Maria I	Comité de Ética en Investigación del Hospital Juárez de México	Av. Instituto Politécnico Nacional #5160, Col. Magdalena de las Salinas, Mexico DF, CP 07760	MEXICO
015	Mata Lara, Maria G	Comité de Ética del Hospital "Doctor Ángel Leño"	Av. Dr. Ángel Leño #500 Esq. Av. Juan Gil, Col. Los Robles, Zapopan, Jalisco, CP 45200	MEXICO
008	Greenberg, Richard N	University of	315 Kinkead Hall,	USA

		Kentucky	University of Kentucky; Lexington, KY 40506	
009	Rich, Phoebe	IntegReview IRB	3001 S. Lamar Blvd., Suite 210 Austin, TX 78704	USA
011	Mraz, Serena M	IntegReview IRB	3001 S. Lamar Blvd., Suite 210 Austin, TX 78704	USA
012	Lundell, Stefanie	IntegReview IRB	3001 S. Lamar Blvd., Suite 210 Austin, TX 78704	USA
017	Davis, Steven A	IntegReview IRB	3001 S. Lamar Blvd., Suite 210 Austin, TX 78704	USA
018	Dinh, Dinh V	IntegReview IRB	3001 S. Lamar Blvd., Suite 210 Austin, TX 78704	USA
020	Hurley, Yadira	Saint Louis University IRB	3556 Caroline Street; Caroline Bldg C110; St. Louis, MO 63104	USA
021	Laumann, Anne	Northwestern University	Rubloff Hall, 7th Floor; 750 N. Lake Shore Dr., Chicago, IL 60611	USA
022	Tu, John H	IntegReview IRB	3001 S. Lamar Blvd., Suite 210 Austin, TX 78704	USA
023	Stough, IV, Dowling B	IntegReview IRB	3001 S. Lamar Blvd., Suite 210 Austin, TX 78704	USA
024	Tschen, Eduardo H	IntegReview IRB	3001 S. Lamar Blvd., Suite 210 Austin, TX 78704	USA
025	Wadsworth, L. (Larkin) Tyler T	IntegReview IRB	3001 S. Lamar Blvd., Suite 210 Austin, TX 78704	USA
026	Essink, Brandon J	IntegReview IRB	3001 S. Lamar Blvd., Suite 210 Austin, TX 78704	USA
027	Abramovits, William	IntegReview IRB	3001 S. Lamar Blvd., Suite 210 Austin, TX 78704	USA
028	Kaplan, David L	IntegReview IRB	3001 S. Lamar Blvd., Suite 210 Austin, TX 78704	USA

Unique Subject Identifier	Visit name	Results for ELISA MVA Titre	Results for PRNT MVA Titre	Stratified Study Group	Per Protocol Population	Number of vaccinations
POX-MVA-008-2001-002	VISIT 1	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2001-002	VISIT 3	100	15	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2001-002	VISIT 4	6369	183	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2001-002	VISIT 5	6308	280	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2001-010	VISIT 1	1	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	1
POX-MVA-008-2001-013	VISIT 1	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2001-013	VISIT 2	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2001-013	VISIT 3	100	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2001-013	VISIT 4	1719	15	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2001-013	VISIT 5	735	15	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2001-013	FOLLOW-UP VISIT	224	15	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2001-014	VISIT 1	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-	VISIT 2	1	1	HEALTHY, VACCINIA NAIVE	N	2

Unique Subject Identifier	Visit name	Results for ELISA MVA Titre	Results for PRNT MVA Titre	Stratified Study Group	Per Protocol Population	Number of vaccinations
2001-014				SUBJECTS WITHOUT ATOPIC DISEASE		
POX-MVA-008-2001-014	VISIT 3	50	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2001-014	VISIT 4	347	328	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2001-014	VISIT 5	200	98	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2001-014	FOLLOW-UP VISIT	50	15	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2001-016	VISIT 1	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2001-016	VISIT 2	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2001-016	VISIT 3	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2001-016	VISIT 4	538	185	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2001-016	VISIT 5	223	113	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2001-016	FOLLOW-UP VISIT	50	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2001-022	VISIT 1	1	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2001-022	VISIT 2	1	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-	VISIT 3	1	1	VACCINIA NAIVE SUBJECTS WITH	N	2

Unique Subject Identifier	Visit name	Results for ELISA MVA Titre	Results for PRNT MVA Titre	Stratified Study Group	Per Protocol Population	Number of vaccinations
2001-022				ACTIVE ATOPIC DERMATITIS		
POX-MVA-008-2001-022	VISIT 4	224	15	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2001-022	VISIT 5	100	15	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2001-022	FOLLOW-UP VISIT	1	15	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2001-036	VISIT 1	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2001-036	VISIT 2	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2001-036	VISIT 3	219	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2001-036	VISIT 4	1576	379	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2001-036	VISIT 5	1700	247	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2001-041	VISIT 1	1	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2001-041	VISIT 2	100	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2001-041	VISIT 3	100	15	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2001-041	VISIT 4	1459	584	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-	VISIT 5	612	113	VACCINIA NAIVE SUBJECTS WITH	N	2

Unique Subject Identifier	Visit name	Results for ELISA MVA Titre	Results for PRNT MVA Titre	Stratified Study Group	Per Protocol Population	Number of vaccinations
2001-041				ACTIVE ATOPIC DERMATITIS		
POX-MVA-008-2001-041	FOLLOW-UP VISIT	100	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2001-042	VISIT 1	1	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2001-042	VISIT 2	100	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2001-042	VISIT 3	50	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2001-042	VISIT 4	647	420	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2001-042	VISIT 5	656	144	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2001-042	FOLLOW-UP VISIT	50	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2001-044	VISIT 1	50	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2001-044	VISIT 2	258	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2001-044	VISIT 3	245	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2001-044	VISIT 4	998	15	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2001-044	VISIT 5	2080	15	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-	FOLLOW-	50	15	VACCINIA NAIVE SUBJECTS WITH	N	2

Unique Subject Identifier	Visit name	Results for ELISA MVA Titre	Results for PRNT MVA Titre	Stratified Study Group	Per Protocol Population	Number of vaccinations
2001-044	UP VISIT			ACTIVE ATOPIC DERMATITIS		
POX-MVA-008-2002-002	VISIT 1	50	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2002-002	VISIT 2	1	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2002-002	VISIT 3	1	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2002-002	VISIT 4	100	15	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2002-002	VISIT 5	50	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2002-002	FOLLOW-UP VISIT	1	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2002-004	VISIT 1	1	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2002-004	VISIT 2	1	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2002-004	VISIT 3	50	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2002-004	VISIT 4	282	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2002-004	VISIT 5	294	15	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2002-004	FOLLOW-UP VISIT	1	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-	VISIT 1	1	1	VACCINIA NAIVE SUBJECTS WITH	N	2

Unique Subject Identifier	Visit name	Results for ELISA MVA Titre	Results for PRNT MVA Titre	Stratified Study Group	Per Protocol Population	Number of vaccinations
2002-005				ACTIVE ATOPIC DERMATITIS		
POX-MVA-008-2002-005	VISIT 2	1	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2002-005	VISIT 3	1	.	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2002-005	VISIT 4	50	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2002-005	VISIT 5	100	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2002-005	FOLLOW-UP VISIT	50	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2002-006	VISIT 1	1	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2002-006	VISIT 2	1	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2002-006	VISIT 3	1	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2002-006	UNSCHED ULED VISIT 4A	100	15	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2002-006	VISIT 5	100	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2002-006	FOLLOW-UP VISIT	50	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2002-007	VISIT 1	1	1	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2

Unique Subject Identifier	Visit name	Results for ELISA MVA Titre	Results for PRNT MVA Titre	Stratified Study Group	Per Protocol Population	Number of vaccinations
POX-MVA-008-2002-007	VISIT 2	1	1	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2002-007	VISIT 3	1	1	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2002-007	VISIT 4	250	1	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2002-007	VISIT 5	260	1	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2002-007	FOLLOW-UP VISIT	1	1	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2002-008	VISIT 1	1	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2002-008	VISIT 2	1	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2002-008	VISIT 3	100	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2002-008	VISIT 4	236	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2002-008	VISIT 5	200	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2002-008	FOLLOW-UP VISIT	1	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2002-041	VISIT 1	1	1	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2002-041	VISIT 2	1	1	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2

Unique Subject Identifier	Visit name	Results for ELISA MVA Titre	Results for PRNT MVA Titre	Stratified Study Group	Per Protocol Population	Number of vaccinations
POX-MVA-008-2002-041	VISIT 3	50	1	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2002-041	VISIT 4	328	15	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2002-041	VISIT 5	421	105	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2002-041	FOLLOW-UP VISIT	100	15	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2002-054	VISIT 1	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2002-054	VISIT 2	50	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2002-054	VISIT 3	100	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2002-054	VISIT 4	1208	864	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2002-054	VISIT 5	1796	619	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2002-058	VISIT 1	1	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2002-058	VISIT 2	1	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2002-058	VISIT 3	50	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2002-058	VISIT 4	515	162	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2

Unique Subject Identifier	Visit name	Results for ELISA MVA Titre	Results for PRNT MVA Titre	Stratified Study Group	Per Protocol Population	Number of vaccinations
POX-MVA-008-2002-058	VISIT 5	213	101	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2002-063	VISIT 1	1	1	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2002-063	VISIT 2	1	1	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2002-063	VISIT 3	100	15	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2002-063	VISIT 4	689	90	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2002-063	VISIT 5	324	1	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2002-070	VISIT 1	1	1	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2002-070	VISIT 2	1	1	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2002-070	VISIT 3	100	1	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2002-070	VISIT 4	5752	248	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2002-070	VISIT 5	2798	114	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2002-071	VISIT 1	1	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2002-071	VISIT 2	1	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2

Unique Subject Identifier	Visit name	Results for ELISA MVA Titre	Results for PRNT MVA Titre	Stratified Study Group	Per Protocol Population	Number of vaccinations
POX-MVA-008-2002-071	VISIT 3	100	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2002-071	VISIT 4	579	15	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2002-071	VISIT 5	278	15	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2002-071	FOLLOW-UP VISIT	1	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2002-076	VISIT 1	1	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	1
POX-MVA-008-2002-076	VISIT 2	1	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	1
POX-MVA-008-2003-006	VISIT 1	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2003-006	VISIT 2	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2003-006	VISIT 3	200	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2003-006	VISIT 4	1619	15	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2003-006	VISIT 5	1588	15	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2003-006	FOLLOW-UP VISIT	100	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2003-010	VISIT 1	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2

Unique Subject Identifier	Visit name	Results for ELISA MVA Titre	Results for PRNT MVA Titre	Stratified Study Group	Per Protocol Population	Number of vaccinations
POX-MVA-008-2003-010	VISIT 2	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2003-010	VISIT 3	50	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2003-010	VISIT 5	100	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2003-010	FOLLOW-UP VISIT	100	1393	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2003-011	VISIT 1	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2003-011	VISIT 2	50	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2003-011	VISIT 3	100	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2003-011	VISIT 5	386	15	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2003-011	FOLLOW-UP VISIT	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2004-001	VISIT 1	1	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2004-001	VISIT 2	1	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2004-001	VISIT 3	1	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2004-001	VISIT 4	3705	293	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2

Unique Subject Identifier	Visit name	Results for ELISA MVA Titre	Results for PRNT MVA Titre	Stratified Study Group	Per Protocol Population	Number of vaccinations
POX-MVA-008-2004-001	VISIT 5	451	155	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2004-001	FOLLOW-UP VISIT	100	15	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2004-002	VISIT 1	1	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2004-002	VISIT 2	1	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2004-002	VISIT 3	50	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2004-002	VISIT 4	50	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2004-002	VISIT 5	294	15	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2004-002	FOLLOW-UP VISIT	1	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2004-004	VISIT 1	1	1	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2004-004	VISIT 2	388	15	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2004-004	VISIT 3	463	15	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2004-004	VISIT 4	937	94	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2004-004	VISIT 5	993	102	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2

Unique Subject Identifier	Visit name	Results for ELISA MVA Titre	Results for PRNT MVA Titre	Stratified Study Group	Per Protocol Population	Number of vaccinations
POX-MVA-008-2004-004	FOLLOW-UP VISIT	342	15	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2004-005	VISIT 1	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2004-005	VISIT 2	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2004-005	VISIT 3	50	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2004-005	VISIT 4	952	15	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2004-005	VISIT 5	721	15	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2004-005	FOLLOW-UP VISIT	100	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2004-006	VISIT 1	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2004-006	VISIT 2	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2004-006	VISIT 3	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2004-006	VISIT 4	381	15	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2004-006	VISIT 5	235	15	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2004-006	FOLLOW-UP VISIT	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2

Unique Subject Identifier	Visit name	Results for ELISA MVA Titre	Results for PRNT MVA Titre	Stratified Study Group	Per Protocol Population	Number of vaccinations
POX-MVA-008-2004-008	VISIT 1	1	1	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2004-008	VISIT 2	1	1	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2004-008	VISIT 3	1	1	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2004-008	VISIT 4	828	1	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2004-008	VISIT 5	355	15	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2004-008	FOLLOW-UP VISIT	1	1	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2004-009	VISIT 1	50	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2004-009	VISIT 2	444	104	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2004-009	VISIT 3	261	15	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2004-009	VISIT 4	333	79	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2004-009	VISIT 5	309	15	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2004-009	FOLLOW-UP VISIT	100	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2004-011	VISIT 1	100	15	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2

Unique Subject Identifier	Visit name	Results for ELISA MVA Titre	Results for PRNT MVA Titre	Stratified Study Group	Per Protocol Population	Number of vaccinations
POX-MVA-008-2004-011	VISIT 2	786	280	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2004-011	VISIT 3	292	80	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2004-011	VISIT 4	343	253	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2004-011	VISIT 5	273	129	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2004-011	FOLLOW-UP VISIT	209	76	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2004-012	VISIT 1	1	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2004-012	VISIT 2	1	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2004-012	VISIT 3	50	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2004-012	VISIT 4	206	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2004-012	VISIT 5	100	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2004-012	FOLLOW-UP VISIT	50	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2004-013	VISIT 1	1	1	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2004-013	VISIT 2	1	1	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2

Unique Subject Identifier	Visit name	Results for ELISA MVA Titre	Results for PRNT MVA Titre	Stratified Study Group	Per Protocol Population	Number of vaccinations
POX-MVA-008-2004-013	VISIT 3	100	1	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2004-013	VISIT 4	491	15	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2004-013	VISIT 5	379	15	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2004-013	FOLLOW-UP VISIT	50	1	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2004-014	VISIT 1	1	1	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2004-014	VISIT 2	1	1	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2004-014	VISIT 3	50	1	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2004-014	VISIT 4	1009	15	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2004-014	VISIT 5	293	1	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2004-014	FOLLOW-UP VISIT	100	1	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2004-015	VISIT 1	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2004-015	VISIT 2	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2004-015	VISIT 3	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2

Unique Subject Identifier	Visit name	Results for ELISA MVA Titre	Results for PRNT MVA Titre	Stratified Study Group	Per Protocol Population	Number of vaccinations
POX-MVA-008-2004-015	VISIT 4	224	15	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2004-015	VISIT 5	220	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2004-015	FOLLOW-UP VISIT	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2004-022	VISIT 1	1	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2004-022	VISIT 2	1	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2004-022	VISIT 3	50	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2004-022	VISIT 4	446	81	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2004-022	VISIT 5	213	180	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2004-022	FOLLOW-UP VISIT	50	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2004-023	VISIT 1	50	1	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	1
POX-MVA-008-2004-023	VISIT 2	50	1	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	1
POX-MVA-008-2004-049	VISIT 1	1	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2004-049	VISIT 2	228	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2

Unique Subject Identifier	Visit name	Results for ELISA MVA Titre	Results for PRNT MVA Titre	Stratified Study Group	Per Protocol Population	Number of vaccinations
POX-MVA-008-2004-049	VISIT 3	309	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2004-049	VISIT 4	450	92	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2004-049	VISIT 5	470	88	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2005-001	VISIT 1	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2005-001	VISIT 2	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2005-001	VISIT 3	50	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2005-001	VISIT 4	290	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2005-001	VISIT 5	210	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2005-002	VISIT 1	1	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2005-002	VISIT 2	50	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2005-002	VISIT 3	100	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2005-002	VISIT 4	449	15	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2005-002	VISIT 5	454	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2

Unique Subject Identifier	Visit name	Results for ELISA MVA Titre	Results for PRNT MVA Titre	Stratified Study Group	Per Protocol Population	Number of vaccinations
POX-MVA-008-2005-003	VISIT 1	50	15	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2005-003	VISIT 2	201	15	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2005-003	VISIT 3	293	80	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2005-003	VISIT 4	268	112	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2005-003	VISIT 5	223	93	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2005-004	VISIT 1	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2005-004	VISIT 2	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2005-004	VISIT 3	50	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2005-004	VISIT 4	463	87	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2005-004	VISIT 5	290	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2005-005	VISIT 1	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2005-005	VISIT 2	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2005-005	VISIT 3	50	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2

Unique Subject Identifier	Visit name	Results for ELISA MVA Titre	Results for PRNT MVA Titre	Stratified Study Group	Per Protocol Population	Number of vaccinations
POX-MVA-008-2005-005	VISIT 4	639	15	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2005-005	VISIT 5	348	15	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2005-006	VISIT 1	1	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2005-006	VISIT 2	1	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2005-006	VISIT 3	100	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2005-006	VISIT 4	780	15	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2005-006	VISIT 5	301	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2005-007	VISIT 1	1	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2005-007	VISIT 2	1	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2005-007	VISIT 3	50	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2005-007	VISIT 4	230	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2005-007	VISIT 5	100	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2005-009	VISIT 1	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2

Unique Subject Identifier	Visit name	Results for ELISA MVA Titre	Results for PRNT MVA Titre	Stratified Study Group	Per Protocol Population	Number of vaccinations
POX-MVA-008-2005-009	VISIT 2	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2005-009	VISIT 3	50	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2005-009	VISIT 4	221	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2005-009	VISIT 5	272	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2005-011	VISIT 1	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	1
POX-MVA-008-2005-011	VISIT 2	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	1
POX-MVA-008-2005-013	VISIT 1	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2005-013	VISIT 2	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2005-013	VISIT 3	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2005-013	VISIT 4	324	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2005-013	VISIT 5	100	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2005-014	VISIT 1	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2005-014	VISIT 2	100	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2

Unique Subject Identifier	Visit name	Results for ELISA MVA Titre	Results for PRNT MVA Titre	Stratified Study Group	Per Protocol Population	Number of vaccinations
POX-MVA-008-2005-014	VISIT 3	200	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2005-014	VISIT 4	438	15	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2005-014	VISIT 5	334	15	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2005-014	FOLLOW-UP VISIT	100	15	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2005-015	VISIT 1	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2005-015	VISIT 2	50	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2005-015	VISIT 3	50	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2005-015	VISIT 4	100	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2005-015	VISIT 5	100	15	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2005-015	FOLLOW-UP VISIT	50	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2005-021	VISIT 1	1	1	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2005-021	VISIT 2	100	1	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2005-021	VISIT 3	100	1	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2

Unique Subject Identifier	Visit name	Results for ELISA MVA Titre	Results for PRNT MVA Titre	Stratified Study Group	Per Protocol Population	Number of vaccinations
POX-MVA-008-2005-021	VISIT 4	1122	593	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2005-021	VISIT 5	494	222	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2009-003	VISIT 1	50	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2009-003	VISIT 2	1	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2009-003	VISIT 3	100	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2009-004	VISIT 1	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2009-004	VISIT 2	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2009-004	VISIT 3	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2009-004	VISIT 4	.	.	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2009-004	FOLLOW-UP VISIT	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2009-005	VISIT 1	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2009-005	VISIT 2	.	.	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2009-005	VISIT 3	100	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2

Unique Subject Identifier	Visit name	Results for ELISA MVA Titre	Results for PRNT MVA Titre	Stratified Study Group	Per Protocol Population	Number of vaccinations
POX-MVA-008-2009-005	VISIT 4	.	.	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2009-005	FOLLOW-UP VISIT	50	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2009-006	VISIT 1	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2009-006	VISIT 2	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2009-006	VISIT 3	50	15	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2009-006	FOLLOW-UP VISIT	50	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2009-007	VISIT 1	1	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2009-007	VISIT 2	1	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2009-007	VISIT 3	100	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2009-007	VISIT 4	.	.	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2009-007	VISIT 5	200	15	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2009-007	FOLLOW-UP VISIT	50	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2009-010	VISIT 1	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2

Unique Subject Identifier	Visit name	Results for ELISA MVA Titre	Results for PRNT MVA Titre	Stratified Study Group	Per Protocol Population	Number of vaccinations
POX-MVA-008-2009-010	VISIT 2	.	.	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2009-010	VISIT 3	50	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2009-010	VISIT 4	.	.	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2009-010	FOLLOW-UP VISIT	100	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2009-012	VISIT 1	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2009-012	VISIT 2	.	.	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2009-012	VISIT 4	.	.	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2009-012	FOLLOW-UP VISIT	50	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2009-014	VISIT 1	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2009-014	VISIT 2	.	.	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2009-014	VISIT 3	100	15	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2009-014	VISIT 4	.	.	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2009-020	VISIT 2	1	1	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	1

Unique Subject Identifier	Visit name	Results for ELISA MVA Titre	Results for PRNT MVA Titre	Stratified Study Group	Per Protocol Population	Number of vaccinations
POX-MVA-008-2009-026	VISIT 2	1	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2009-026	VISIT 3	100	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2009-026	VISIT 4	318	15	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2009-026	VISIT 5	261	15	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2011-009	VISIT 1	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	1
POX-MVA-008-2011-009	VISIT 2	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	1
POX-MVA-008-2011-009	VISIT 3	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	1
POX-MVA-008-2011-025	VISIT 1	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2011-025	VISIT 2	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2011-025	VISIT 3	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2011-025	VISIT 4	50	15	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2011-025	VISIT 5	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2011-025	FOLLOW-UP VISIT	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2

Unique Subject Identifier	Visit name	Results for ELISA MVA Titre	Results for PRNT MVA Titre	Stratified Study Group	Per Protocol Population	Number of vaccinations
POX-MVA-008-2011-032	VISIT 1	1	1	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2011-032	VISIT 2	1	1	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2011-032	VISIT 3	50	1	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2011-032	VISIT 4	100	1	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2011-032	VISIT 5	298	1	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2011-032	FOLLOW-UP VISIT	50	1	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2011-039	VISIT 1	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2011-039	VISIT 2	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2011-039	VISIT 3	50	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2011-039	UNSCHED ULED VISIT 4A	100	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2011-039	VISIT 5	100	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2011-039	FOLLOW-UP VISIT	50	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-	VISIT 1	1	1	HEALTHY, VACCINIA NAIVE	N	1

Unique Subject Identifier	Visit name	Results for ELISA MVA Titre	Results for PRNT MVA Titre	Stratified Study Group	Per Protocol Population	Number of vaccinations
2011-059				SUBJECTS WITHOUT ATOPIC DISEASE		
POX-MVA-008-2011-059	VISIT 2	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	1
POX-MVA-008-2011-059	VISIT 5	225	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	1
POX-MVA-008-2011-069	VISIT 1	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2011-069	VISIT 2	100	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2011-069	VISIT 3	100	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2011-069	VISIT 4	478	130	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2011-069	VISIT 5	424	148	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2011-077	VISIT 1	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2011-077	VISIT 2	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2011-077	VISIT 3	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2011-077	VISIT 4	505	15	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2011-077	VISIT 5	278	15	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-	VISIT 1	1	1	VACCINIA NAIVE SUBJECTS WITH	N	1

Unique Subject Identifier	Visit name	Results for ELISA MVA Titre	Results for PRNT MVA Titre	Stratified Study Group	Per Protocol Population	Number of vaccinations
2011-100				ACTIVE ATOPIC DERMATITIS		
POX-MVA-008-2011-100	VISIT 2	1	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	1
POX-MVA-008-2011-100	VISIT 5	50	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	1
POX-MVA-008-2012-001	VISIT 1	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	1
POX-MVA-008-2012-001	VISIT 2	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	1
POX-MVA-008-2012-001	VISIT 5	100	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	1
POX-MVA-008-2012-015	VISIT 1	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2012-015	VISIT 2	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2012-015	VISIT 3	333	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2013-003	VISIT 1	50	15	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2013-003	VISIT 2	199	109	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2013-003	VISIT 3	454	810	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2013-003	VISIT 4	1383	3529	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-	VISIT 5	985	2797	VACCINIA NAIVE SUBJECTS WITH	N	2

Unique Subject Identifier	Visit name	Results for ELISA MVA Titre	Results for PRNT MVA Titre	Stratified Study Group	Per Protocol Population	Number of vaccinations
2013-003				ACTIVE ATOPIC DERMATITIS		
POX-MVA-008-2013-005	VISIT 1	50	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2013-005	VISIT 2	50	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2013-005	VISIT 3	417	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2013-005	VISIT 4	1830	299	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2013-005	VISIT 5	1122	387	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2013-007	VISIT 1	1	1	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2013-007	VISIT 2	1	1	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2013-007	VISIT 3	1	1	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2013-007	VISIT 4	212	15	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2013-007	VISIT 5	284	15	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2015-006	VISIT 1	1	1	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2015-006	VISIT 2	1	1	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-	VISIT 3	50	1	VACCINIA NAIVE SUBJECTS WITH	N	2

Unique Subject Identifier	Visit name	Results for ELISA MVA Titre	Results for PRNT MVA Titre	Stratified Study Group	Per Protocol Population	Number of vaccinations
2015-006				HISTORY OF ATOPIC DERMATITIS		
POX-MVA-008-2015-006	VISIT 4	100	1	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2015-006	VISIT 5	50	1	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2015-009	VISIT 1	1	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2015-009	VISIT 2	1	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2015-009	VISIT 3	50	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2015-009	VISIT 4	200	15	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2015-009	VISIT 5	100	15	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2015-010	VISIT 1	1	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2015-010	VISIT 2	100	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2015-010	VISIT 3	100	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2015-010	VISIT 4	222	15	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2015-010	VISIT 5	217	15	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-	VISIT 1	1	1	VACCINIA NAIVE SUBJECTS WITH	N	2

Unique Subject Identifier	Visit name	Results for ELISA MVA Titre	Results for PRNT MVA Titre	Stratified Study Group	Per Protocol Population	Number of vaccinations
2015-012				ACTIVE ATOPIC DERMATITIS		
POX-MVA-008-2015-012	VISIT 2	1	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2015-012	VISIT 3	100	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2015-012	VISIT 4	740	223	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2015-012	VISIT 5	256	15	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2017-002	VISIT 1	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2017-002	VISIT 2	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2017-002	VISIT 3	100	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2017-002	VISIT 4	454	15	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2017-002	VISIT 5	283	15	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2017-007	VISIT 1	1	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2017-007	VISIT 2	1	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2017-007	VISIT 3	50	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-	VISIT 4	100	15	VACCINIA NAIVE SUBJECTS WITH	N	2

Unique Subject Identifier	Visit name	Results for ELISA MVA Titre	Results for PRNT MVA Titre	Stratified Study Group	Per Protocol Population	Number of vaccinations
2017-007				ACTIVE ATOPIC DERMATITIS		
POX-MVA-008-2017-007	VISIT 5	100	15	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2018-008	VISIT 1	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2018-008	VISIT 2	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2018-008	VISIT 3	100	15	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2018-008	VISIT 4	1646	286	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2018-008	VISIT 5	1260	183	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2018-009	VISIT 1	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2018-009	VISIT 2	50	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2018-009	VISIT 3	100	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2018-009	VISIT 4	1493	284	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2018-009	VISIT 5	436	15	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2018-013	VISIT 1	200	15	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-	VISIT 2	200	15	VACCINIA NAIVE SUBJECTS WITH	N	2

Unique Subject Identifier	Visit name	Results for ELISA MVA Titre	Results for PRNT MVA Titre	Stratified Study Group	Per Protocol Population	Number of vaccinations
2018-013				ACTIVE ATOPIC DERMATITIS		
POX-MVA-008-2018-013	VISIT 3	297	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2018-013	VISIT 4	279	15	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2018-013	VISIT 5	100	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2018-013	FOLLOW-UP VISIT	200	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2018-014	VISIT 1	200	15	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2018-014	VISIT 2	233	15	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2018-014	VISIT 3	326	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2018-014	VISIT 4	1179	89	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2018-014	VISIT 5	100	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2018-016	VISIT 1	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2018-016	VISIT 2	100	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2018-016	VISIT 3	228	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-	VISIT 4	1207	15	HEALTHY, VACCINIA NAIVE	N	2

Unique Subject Identifier	Visit name	Results for ELISA MVA Titre	Results for PRNT MVA Titre	Stratified Study Group	Per Protocol Population	Number of vaccinations
2018-016				SUBJECTS WITHOUT ATOPIC DISEASE		
POX-MVA-008-2018-016	VISIT 5	594	15	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2018-017	VISIT 1	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2018-017	VISIT 2	50	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2018-017	VISIT 3	50	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2018-017	VISIT 4	3500	1172	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2018-017	VISIT 5	2733	15	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2018-025	VISIT 1	100	1	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2018-025	VISIT 2	100	1	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2018-025	VISIT 3	50	1	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2018-025	VISIT 4	100	1	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2018-025	VISIT 5	100	1	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2018-028	VISIT 1	100	86	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-	VISIT 2	100	15	HEALTHY, VACCINIA NAIVE	N	2

Unique Subject Identifier	Visit name	Results for ELISA MVA Titre	Results for PRNT MVA Titre	Stratified Study Group	Per Protocol Population	Number of vaccinations
2018-028				SUBJECTS WITHOUT ATOPIC DISEASE		
POX-MVA-008-2018-028	VISIT 3	100	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2018-028	VISIT 4	525	260	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2018-028	VISIT 5	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2018-029	VISIT 1	100	15	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2018-029	VISIT 2	100	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2018-029	VISIT 3	1046	269	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2018-029	VISIT 4	806	265	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2018-029	VISIT 5	407	206	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2018-032	VISIT 1	100	15	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2018-032	VISIT 2	2372	478	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2018-032	VISIT 3	1055	445	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2018-032	VISIT 4	1086	207	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-	VISIT 5	100	1	HEALTHY, VACCINIA NAIVE	N	2

Unique Subject Identifier	Visit name	Results for ELISA MVA Titre	Results for PRNT MVA Titre	Stratified Study Group	Per Protocol Population	Number of vaccinations
2018-032				SUBJECTS WITHOUT ATOPIC DISEASE		
POX-MVA-008-2018-036	VISIT 1	50	15	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2018-036	VISIT 3	1968	252	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2018-036	VISIT 4	1024	77	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2018-036	VISIT 5	1	1	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2018-038	VISIT 1	50	1	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	1
POX-MVA-008-2018-038	VISIT 2	50	15	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	1
POX-MVA-008-2018-038	VISIT 5	936	391	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	1
POX-MVA-008-2018-050	VISIT 1	1	1	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	1
POX-MVA-008-2018-050	VISIT 2	1	1	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	1
POX-MVA-008-2018-054	VISIT 1	1	1	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	1
POX-MVA-008-2018-055	VISIT 1	1	1	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2018-055	VISIT 2	1	1	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-	VISIT 3	1	1	VACCINIA NAIVE SUBJECTS WITH	N	2

Unique Subject Identifier	Visit name	Results for ELISA MVA Titre	Results for PRNT MVA Titre	Stratified Study Group	Per Protocol Population	Number of vaccinations
2018-055				HISTORY OF ATOPIC DERMATITIS		
POX-MVA-008-2018-055	VISIT 5	50	1	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2018-062	VISIT 1	1	15	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	1
POX-MVA-008-2018-062	VISIT 5	50	1	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	1
POX-MVA-008-2018-067	VISIT 1	1	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	1
POX-MVA-008-2018-067	VISIT 2	1	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	1
POX-MVA-008-2018-067	VISIT 5	682	184	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	1
POX-MVA-008-2018-071	VISIT 1	1	1	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	1
POX-MVA-008-2018-071	VISIT 2	1	1	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	1
POX-MVA-008-2018-071	VISIT 5	50	15	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	1
POX-MVA-008-2018-076	VISIT 1	1	1	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	1
POX-MVA-008-2018-076	VISIT 2	1	1	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	1
POX-MVA-008-2018-076	VISIT 5	602	127	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	1
POX-MVA-008-	VISIT 1	1	1	VACCINIA NAIVE SUBJECTS WITH	N	2

Unique Subject Identifier	Visit name	Results for ELISA MVA Titre	Results for PRNT MVA Titre	Stratified Study Group	Per Protocol Population	Number of vaccinations
2018-084				ACTIVE ATOPIC DERMATITIS		
POX-MVA-008-2018-084	VISIT 2	1	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2018-084	VISIT 3	1	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2018-084	VISIT 4	50	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2018-084	VISIT 5	1	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2018-085	VISIT 1	1	1	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	1
POX-MVA-008-2018-085	VISIT 5	100	15	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	1
POX-MVA-008-2018-102	VISIT 1	1	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2018-102	VISIT 2	1	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2018-102	VISIT 3	50	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2018-102	VISIT 4	328	15	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2018-102	VISIT 5	211	15	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2018-103	VISIT 1	1	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-	VISIT 2	1	1	VACCINIA NAIVE SUBJECTS WITH	N	2

Unique Subject Identifier	Visit name	Results for ELISA MVA Titre	Results for PRNT MVA Titre	Stratified Study Group	Per Protocol Population	Number of vaccinations
2018-103				ACTIVE ATOPIC DERMATITIS		
POX-MVA-008-2018-103	VISIT 3	50	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2018-103	VISIT 5	1	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2018-105	VISIT 1	1	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	1
POX-MVA-008-2018-105	VISIT 5	351	129	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	1
POX-MVA-008-2018-116	VISIT 1	1	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	1
POX-MVA-008-2018-116	VISIT 2	50	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	1
POX-MVA-008-2018-116	VISIT 5	50	15	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	1
POX-MVA-008-2020-003	VISIT 1	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2020-003	VISIT 2	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2020-003	VISIT 3	50	15	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2020-003	VISIT 4	200	15	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2020-003	VISIT 5	100	15	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-	FOLLOW-	1	1	HEALTHY, VACCINIA NAIVE	N	2

Unique Subject Identifier	Visit name	Results for ELISA MVA Titre	Results for PRNT MVA Titre	Stratified Study Group	Per Protocol Population	Number of vaccinations
2020-003	UP VISIT			SUBJECTS WITHOUT ATOPIC DISEASE		
POX-MVA-008-2020-004	VISIT 1	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2020-004	VISIT 2	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2020-004	VISIT 3	50	15	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2020-004	VISIT 4	333	109	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2020-004	VISIT 5	203	15	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2020-004	FOLLOW-UP VISIT	100	15	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2020-007	VISIT 1	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2020-007	VISIT 2	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2020-007	VISIT 3	100	15	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2020-007	VISIT 4	593	158	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2020-007	VISIT 5	249	254	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2020-007	FOLLOW-UP VISIT	50	15	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-	VISIT 1	1	1	VACCINIA NAIVE SUBJECTS WITH	N	2

Unique Subject Identifier	Visit name	Results for ELISA MVA Titre	Results for PRNT MVA Titre	Stratified Study Group	Per Protocol Population	Number of vaccinations
2020-009				HISTORY OF ATOPIC DERMATITIS		
POX-MVA-008-2020-009	VISIT 2	1	1	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2020-009	VISIT 3	50	1	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2020-009	VISIT 4	251	15	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2020-009	VISIT 5	100	15	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2020-009	FOLLOW-UP VISIT	50	15	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2020-013	VISIT 1	1	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2020-013	VISIT 2	1	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2020-013	VISIT 3	50	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2020-013	VISIT 4	470	15	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2020-013	VISIT 5	261	15	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2020-013	FOLLOW-UP VISIT	50	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2020-014	VISIT 1	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-	VISIT 2	200	1	HEALTHY, VACCINIA NAIVE	N	2

Unique Subject Identifier	Visit name	Results for ELISA MVA Titre	Results for PRNT MVA Titre	Stratified Study Group	Per Protocol Population	Number of vaccinations
2020-014				SUBJECTS WITHOUT ATOPIC DISEASE		
POX-MVA-008-2020-014	VISIT 3	249	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2020-014	VISIT 4	1892	15	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2020-014	VISIT 5	890	15	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2020-015	VISIT 1	1	1	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2020-015	VISIT 2	1	1	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2020-015	VISIT 3	100	15	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2020-015	VISIT 4	379	15	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2020-015	VISIT 5	285	15	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2020-015	FOLLOW-UP VISIT	100	15	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2020-017	VISIT 1	50	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2020-017	VISIT 2	50	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2020-017	VISIT 3	267	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-	VISIT 4	378	15	HEALTHY, VACCINIA NAIVE	N	2

Unique Subject Identifier	Visit name	Results for ELISA MVA Titre	Results for PRNT MVA Titre	Stratified Study Group	Per Protocol Population	Number of vaccinations
2020-017				SUBJECTS WITHOUT ATOPIC DISEASE		
POX-MVA-008-2020-017	UNSCHEDULED VISIT 5A	322	15	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2020-017	FOLLOW-UP VISIT	100	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2020-020	VISIT 1	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2020-020	VISIT 2	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2020-020	VISIT 3	50	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2020-020	VISIT 4	236	15	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2020-020	VISIT 5	233	15	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2020-022	VISIT 1	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2020-022	VISIT 2	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2020-022	VISIT 3	100	15	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2020-022	VISIT 4	2573	259	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2020-022	VISIT 5	778	159	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2

Unique Subject Identifier	Visit name	Results for ELISA MVA Titre	Results for PRNT MVA Titre	Stratified Study Group	Per Protocol Population	Number of vaccinations
POX-MVA-008-2020-025	VISIT 1	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2020-025	VISIT 2	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2020-025	VISIT 3	200	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2020-025	VISIT 4	861	101	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2020-025	VISIT 5	315	15	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2020-025	FOLLOW-UP VISIT	100	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2020-026	VISIT 1	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2020-026	VISIT 2	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2020-026	VISIT 3	50	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2020-026	VISIT 4	273	15	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2020-026	VISIT 5	253	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2020-030	VISIT 1	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2020-030	VISIT 2	265	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2

Unique Subject Identifier	Visit name	Results for ELISA MVA Titre	Results for PRNT MVA Titre	Stratified Study Group	Per Protocol Population	Number of vaccinations
POX-MVA-008-2020-030	VISIT 3	728	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2020-030	VISIT 4	889	109	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2020-030	VISIT 5	846	15	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2020-032	VISIT 1	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	1
POX-MVA-008-2020-032	VISIT 2	100	15	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	1
POX-MVA-008-2020-036	VISIT 1	1	1	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2020-036	VISIT 2	1	1	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2020-036	VISIT 3	204	1	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2020-036	VISIT 4	370	82	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2020-036	VISIT 5	433	15	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2020-043	VISIT 1	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2020-043	VISIT 2	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2020-043	VISIT 3	200	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2

Unique Subject Identifier	Visit name	Results for ELISA MVA Titre	Results for PRNT MVA Titre	Stratified Study Group	Per Protocol Population	Number of vaccinations
POX-MVA-008-2020-043	VISIT 4	22172	239	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2020-043	VISIT 5	7052	297	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2020-047	VISIT 1	1	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2020-047	VISIT 2	1	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2020-047	VISIT 3	50	15	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2020-047	VISIT 4	1010	411	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2020-047	VISIT 5	305	161	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2020-049	VISIT 1	1	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2020-049	VISIT 2	244	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2020-049	VISIT 3	200	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2020-049	VISIT 4	391	76	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2020-049	VISIT 5	332	15	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2020-049	FOLLOW-UP VISIT	1	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2

Unique Subject Identifier	Visit name	Results for ELISA MVA Titre	Results for PRNT MVA Titre	Stratified Study Group	Per Protocol Population	Number of vaccinations
POX-MVA-008-2020-050	VISIT 1	1	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2020-050	VISIT 2	1	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2020-050	VISIT 3	371	15	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2020-050	VISIT 4	1128	139	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2020-050	VISIT 5	592	309	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2020-051	VISIT 1	1	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2020-051	VISIT 2	1	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2020-051	VISIT 3	1	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2020-051	VISIT 4	456	15	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2020-051	VISIT 5	318	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2021-010	VISIT 1	1	1	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2021-010	VISIT 2	1	1	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2021-010	VISIT 3	100	15	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2

Unique Subject Identifier	Visit name	Results for ELISA MVA Titre	Results for PRNT MVA Titre	Stratified Study Group	Per Protocol Population	Number of vaccinations
POX-MVA-008-2021-014	VISIT 1	1	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2021-014	VISIT 2	50	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2021-014	VISIT 3	221	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2021-014	VISIT 4	1175	159	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2021-014	VISIT 5	617	15	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2021-017	VISIT 1	1	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2021-017	VISIT 2	1	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2021-017	VISIT 3	100	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2021-017	VISIT 4	265	15	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2021-017	VISIT 5	294	15	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2023-030	VISIT 1	1	1	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2023-030	VISIT 2	1	1	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2023-030	VISIT 3	1	1	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2

Unique Subject Identifier	Visit name	Results for ELISA MVA Titre	Results for PRNT MVA Titre	Stratified Study Group	Per Protocol Population	Number of vaccinations
POX-MVA-008-2023-030	VISIT 4	585	100	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2023-032	VISIT 1	1	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	1
POX-MVA-008-2023-032	VISIT 2	1	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	1
POX-MVA-008-2023-032	VISIT 5	1	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	1
POX-MVA-008-2024-001	VISIT 1	1	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2024-001	VISIT 2	1	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2024-001	VISIT 3	50	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2024-001	VISIT 4	1787	558	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2024-001	VISIT 5	800	198	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2024-001	FOLLOW-UP VISIT	50	15	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2024-002	VISIT 1	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2024-002	VISIT 2	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2024-002	VISIT 3	235	15	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2

Unique Subject Identifier	Visit name	Results for ELISA MVA Titre	Results for PRNT MVA Titre	Stratified Study Group	Per Protocol Population	Number of vaccinations
POX-MVA-008-2024-002	VISIT 4	1927	109	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2024-002	VISIT 5	855	122	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2024-002	FOLLOW-UP VISIT	100	15	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2024-003	VISIT 1	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2024-003	VISIT 2	50	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2024-003	VISIT 3	200	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2024-003	VISIT 4	278	15	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2024-003	VISIT 5	200	15	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2024-003	FOLLOW-UP VISIT	50	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2024-011	VISIT 1	1	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2024-011	VISIT 2	1	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2024-011	VISIT 3	100	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2024-011	VISIT 4	1919	122	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2

Unique Subject Identifier	Visit name	Results for ELISA MVA Titre	Results for PRNT MVA Titre	Stratified Study Group	Per Protocol Population	Number of vaccinations
POX-MVA-008-2024-011	VISIT 5	704	15	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2024-011	FOLLOW-UP VISIT	50	15	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2024-015	VISIT 1	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2024-015	VISIT 2	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2024-015	VISIT 3	100	15	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2024-015	VISIT 4	1642	126	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2024-015	VISIT 5	224	15	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2024-025	VISIT 1	1	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2024-025	VISIT 2	1	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2024-025	VISIT 3	50	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2024-025	VISIT 4	241	81	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2024-025	VISIT 5	1990	225	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2025-001	VISIT 1	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2

Unique Subject Identifier	Visit name	Results for ELISA MVA Titre	Results for PRNT MVA Titre	Stratified Study Group	Per Protocol Population	Number of vaccinations
POX-MVA-008-2025-001	VISIT 2	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2025-001	VISIT 3	50	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2025-001	VISIT 4	299	15	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2025-001	VISIT 5	293	15	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2025-001	FOLLOW-UP VISIT	100	15	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2025-003	VISIT 1	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2025-003	VISIT 2	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2025-003	VISIT 3	50	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2025-003	VISIT 4	907	188	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2025-003	VISIT 5	375	15	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2025-004	VISIT 1	1	1	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2025-004	VISIT 2	1	1	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2025-004	VISIT 3	50	1	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2

Unique Subject Identifier	Visit name	Results for ELISA MVA Titre	Results for PRNT MVA Titre	Stratified Study Group	Per Protocol Population	Number of vaccinations
POX-MVA-008-2025-004	VISIT 4	275	99	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2025-004	VISIT 5	219	15	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2025-004	FOLLOW-UP VISIT	50	1	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2025-005	VISIT 1	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	1
POX-MVA-008-2025-005	VISIT 2	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	1
POX-MVA-008-2025-005	VISIT 3	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	1
POX-MVA-008-2025-005	VISIT 4	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	1
POX-MVA-008-2025-005	VISIT 5	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	1
POX-MVA-008-2025-005	FOLLOW-UP VISIT	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	1
POX-MVA-008-2025-006	VISIT 1	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2025-006	VISIT 2	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2025-006	VISIT 3	50	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2025-006	VISIT 4	436	120	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2

Unique Subject Identifier	Visit name	Results for ELISA MVA Titre	Results for PRNT MVA Titre	Stratified Study Group	Per Protocol Population	Number of vaccinations
POX-MVA-008-2025-006	VISIT 5	356	97	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2025-006	FOLLOW-UP VISIT	50	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2025-008	VISIT 1	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2025-008	VISIT 2	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2025-008	VISIT 3	50	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2025-008	VISIT 4	476	256	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2025-008	VISIT 5	393	15	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2025-009	VISIT 1	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2025-009	VISIT 2	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2025-009	VISIT 3	100	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2025-009	VISIT 4	566	183	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2025-009	VISIT 5	384	231	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2025-011	VISIT 1	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2

Unique Subject Identifier	Visit name	Results for ELISA MVA Titre	Results for PRNT MVA Titre	Stratified Study Group	Per Protocol Population	Number of vaccinations
POX-MVA-008-2025-011	VISIT 2	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2025-011	VISIT 3	100	15	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2025-011	VISIT 4	828	206	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2025-011	VISIT 5	1702	239	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2025-011	FOLLOW-UP VISIT	100	15	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2025-012	VISIT 1	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2025-012	VISIT 2	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2025-012	VISIT 3	100	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2025-012	VISIT 4	308	15	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2025-012	VISIT 5	349	15	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2025-026	VISIT 1	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2025-026	VISIT 2	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2025-026	VISIT 3	50	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2

Unique Subject Identifier	Visit name	Results for ELISA MVA Titre	Results for PRNT MVA Titre	Stratified Study Group	Per Protocol Population	Number of vaccinations
POX-MVA-008-2025-026	VISIT 4	652	15	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2025-026	VISIT 5	287	15	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2025-028	VISIT 1	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2025-028	VISIT 2	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2025-028	VISIT 3	200	15	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2025-028	VISIT 4	582	138	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2025-028	VISIT 5	547	15	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2025-029	VISIT 1	1	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2025-029	VISIT 2	1	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2025-029	VISIT 3	100	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2025-029	VISIT 4	379	124	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2025-029	VISIT 5	300	15	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2025-033	VISIT 1	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	1

Unique Subject Identifier	Visit name	Results for ELISA MVA Titre	Results for PRNT MVA Titre	Stratified Study Group	Per Protocol Population	Number of vaccinations
POX-MVA-008-2025-033	VISIT 2	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	1
POX-MVA-008-2025-033	VISIT 3	293	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	1
POX-MVA-008-2025-033	VISIT 4	224	15	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	1
POX-MVA-008-2025-033	VISIT 5	100	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	1
POX-MVA-008-2025-045	VISIT 2	1	1	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2025-045	VISIT 3	50	1	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2025-045	VISIT 4	548	102	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2025-045	VISIT 5	332	15	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2025-048	VISIT 1	50	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	1
POX-MVA-008-2025-048	VISIT 2	556	227	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	1
POX-MVA-008-2025-048	VISIT 3	1191	480	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	1
POX-MVA-008-2025-048	VISIT 4	718	393	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	1
POX-MVA-008-2025-048	VISIT 5	413	233	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	1

Unique Subject Identifier	Visit name	Results for ELISA MVA Titre	Results for PRNT MVA Titre	Stratified Study Group	Per Protocol Population	Number of vaccinations
POX-MVA-008-2026-003	VISIT 1	1	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2026-003	VISIT 2	1	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2026-003	VISIT 3	200	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2026-003	VISIT 4	7248	147	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2026-003	VISIT 5	2443	242	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2026-003	FOLLOW-UP VISIT	205	15	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2026-005	VISIT 1	50	1	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2026-005	VISIT 2	50	1	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2026-005	VISIT 3	50	1	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2026-005	VISIT 4	697	15	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2026-005	VISIT 5	386	89	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2026-005	FOLLOW-UP VISIT	50	1	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2026-006	VISIT 1	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2

Unique Subject Identifier	Visit name	Results for ELISA MVA Titre	Results for PRNT MVA Titre	Stratified Study Group	Per Protocol Population	Number of vaccinations
POX-MVA-008-2026-006	VISIT 2	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2026-006	VISIT 3	50	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2026-006	VISIT 4	413	15	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2026-006	VISIT 5	239	15	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2026-007	VISIT 1	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2026-007	VISIT 2	50	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2026-007	VISIT 3	227	15	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2026-007	VISIT 4	900	15	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2026-007	VISIT 5	501	15	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2026-008	VISIT 1	1	1	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2026-008	VISIT 2	1	1	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2026-008	VISIT 3	200	1	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2026-008	VISIT 4	929	117	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2

Unique Subject Identifier	Visit name	Results for ELISA MVA Titre	Results for PRNT MVA Titre	Stratified Study Group	Per Protocol Population	Number of vaccinations
POX-MVA-008-2026-008	VISIT 5	746	1	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2026-008	FOLLOW-UP VISIT	50	15	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2026-010	VISIT 1	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2026-010	VISIT 2	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2026-010	VISIT 3	50	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2026-010	VISIT 4	910	164	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2026-010	VISIT 5	728	99	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2026-011	VISIT 1	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2026-011	VISIT 2	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2026-011	VISIT 3	50	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2026-011	VISIT 4	426	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2026-011	VISIT 5	200	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2026-012	VISIT 1	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2

Unique Subject Identifier	Visit name	Results for ELISA MVA Titre	Results for PRNT MVA Titre	Stratified Study Group	Per Protocol Population	Number of vaccinations
POX-MVA-008-2026-012	VISIT 2	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2026-012	VISIT 3	50	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2026-012	VISIT 4	1025	96	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2026-012	VISIT 5	435	15	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2026-013	VISIT 1	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2026-013	VISIT 2	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2026-013	VISIT 3	100	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2026-013	VISIT 4	2836	245	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2026-013	VISIT 5	1312	15	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2026-014	VISIT 1	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2026-014	VISIT 2	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2026-014	VISIT 3	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2026-014	VISIT 4	50	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2

Unique Subject Identifier	Visit name	Results for ELISA MVA Titre	Results for PRNT MVA Titre	Stratified Study Group	Per Protocol Population	Number of vaccinations
POX-MVA-008-2026-014	VISIT 5	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2026-016	VISIT 1	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2026-016	VISIT 2	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2026-016	VISIT 3	100	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2026-016	VISIT 4	1656	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2026-016	VISIT 5	848	109	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2026-017	VISIT 1	1	1	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2026-017	VISIT 2	1	1	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2026-017	VISIT 3	246	1	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2026-017	VISIT 4	957	15	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2026-017	VISIT 5	576	15	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2026-017	FOLLOW-UP VISIT	50	1	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2026-018	VISIT 1	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2

Unique Subject Identifier	Visit name	Results for ELISA MVA Titre	Results for PRNT MVA Titre	Stratified Study Group	Per Protocol Population	Number of vaccinations
POX-MVA-008-2026-018	VISIT 2	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2026-018	VISIT 3	100	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2026-018	VISIT 4	935	309	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2026-018	VISIT 5	501	15	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2026-020	VISIT 1	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2026-020	VISIT 2	100	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2026-020	VISIT 3	100	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2026-020	VISIT 4	1023	162	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2026-020	VISIT 5	416	138	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2026-021	VISIT 1	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2026-021	VISIT 2	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2026-021	VISIT 4	5502	611	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2026-021	VISIT 5	1178	236	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2


Unique Subject Identifier	Visit name	Results for ELISA MVA Titre	Results for PRNT MVA Titre	Stratified Study Group	Per Protocol Population	Number of vaccinations
POX-MVA-008-2026-024	VISIT 1	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2026-024	VISIT 2	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2026-024	VISIT 3	823	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2026-024	VISIT 4	4375	250	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2026-024	VISIT 5	991	15	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2026-026	VISIT 1	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2026-026	VISIT 2	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2026-026	VISIT 3	50	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2026-026	VISIT 4	396	205	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2026-026	VISIT 5	294	15	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2026-028	VISIT 1	1	1	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	1
POX-MVA-008-2026-028	VISIT 2	1	1	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	1
POX-MVA-008-2026-029	VISIT 1	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	1

Unique Subject Identifier	Visit name	Results for ELISA MVA Titre	Results for PRNT MVA Titre	Stratified Study Group	Per Protocol Population	Number of vaccinations
POX-MVA-008-2026-029	VISIT 2	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	1
POX-MVA-008-2026-029	VISIT 3	50	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	1
POX-MVA-008-2026-029	VISIT 4	50	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	1
POX-MVA-008-2026-029	VISIT 5	50	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	1
POX-MVA-008-2026-033	VISIT 1	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	1
POX-MVA-008-2026-033	VISIT 2	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	1
POX-MVA-008-2026-033	VISIT 3	50	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	1
POX-MVA-008-2026-033	VISIT 4	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	1
POX-MVA-008-2026-033	VISIT 5	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	1
POX-MVA-008-2026-047	VISIT 1	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	1
POX-MVA-008-2026-047	VISIT 2	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	1
POX-MVA-008-2026-047	VISIT 5	100	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	1
POX-MVA-008-2026-054	VISIT 1	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2

Unique Subject Identifier	Visit name	Results for ELISA MVA Titre	Results for PRNT MVA Titre	Stratified Study Group	Per Protocol Population	Number of vaccinations
POX-MVA-008-2026-054	VISIT 2	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2026-054	VISIT 3	237	15	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	2
POX-MVA-008-2026-059	VISIT 1	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	1
POX-MVA-008-2026-059	VISIT 2	1	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	1
POX-MVA-008-2026-059	VISIT 3	50	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	1
POX-MVA-008-2026-059	VISIT 4	50	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	1
POX-MVA-008-2026-059	VISIT 5	50	1	HEALTHY, VACCINIA NAIVE SUBJECTS WITHOUT ATOPIC DISEASE	N	1
POX-MVA-008-2026-060	VISIT 1	1	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	1
POX-MVA-008-2026-060	VISIT 2	50	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	1
POX-MVA-008-2026-060	VISIT 3	222	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	1
POX-MVA-008-2026-060	VISIT 4	211	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	1
POX-MVA-008-2026-060	VISIT 5	50	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	1
POX-MVA-008-2026-066	VISIT 1	1	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2

Unique Subject Identifier	Visit name	Results for ELISA MVA Titre	Results for PRNT MVA Titre	Stratified Study Group	Per Protocol Population	Number of vaccinations
POX-MVA-008-2026-066	VISIT 2	1	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2026-066	VISIT 3	50	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2026-066	VISIT 4	806	15	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2026-066	VISIT 5	604	15	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2026-071	VISIT 1	1	1	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2026-071	VISIT 2	1	1	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2026-071	VISIT 3	100	1	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2026-071	VISIT 4	1031	149	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2026-071	VISIT 5	471	15	VACCINIA NAIVE SUBJECTS WITH HISTORY OF ATOPIC DERMATITIS	N	2
POX-MVA-008-2026-072	VISIT 1	1	1	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2026-072	VISIT 2	50	15	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2026-072	VISIT 3	200	15	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2
POX-MVA-008-2026-072	VISIT 4	264	150	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2

Unique Subject Identifier	Visit name	Results for ELISA MVA Titre	Results for PRNT MVA Titre	Stratified Study Group	Per Protocol Population	Number of vaccinations
POX-MVA-008-2026-072	VISIT 5	255	105	VACCINIA NAIVE SUBJECTS WITH ACTIVE ATOPIC DERMATITIS	N	2





UNIVERSITY OF KENTUCKY

REC'D SEP 11 2006

*Dream • Challenge • Succeed***OFFICE OF RESEARCH INTEGRITY**

Initial Review
Approval Ends
June 5, 2007

Project Ends
April 30, 2011

IRB Number
06-0402-F2L

TO: Richard N Greenberg, M.D.
Internal Medicine & Divisions
c/o Beth Plummer
Infectious Disease Clinical Trials Office
MN672 Medical Science Bldg. 0298
(859)320-6327

FROM: Chairperson/Vice Chairperson
Medical Institutional Review Board (IRB)

SUBJECT: Approval of Protocol Number 06-0402-F2L

DATE: September 7, 2006

On September 5, 2006, the Medical Institutional Review Board approved minor revisions requested at the convened meeting on June 6, 2006 for your protocol entitled:

06-ID-175: A Multicenter, Open-label, Controlled Phase II Study to Evaluate Safety and Ummunogenicity of MVA-BN (IMVAMUNE) Smallpox Vaccine in 18-40 Year Old Subjects with Diagnosed Atopic Dermatitis


Approval is effective from June 6, 2006 until June 5, 2007. This approval extends to any consent/assent document unless the IRB has waived the requirement for documentation of informed consent. If applicable, attached is the IRB approved consent/assent document(s) to be used when enrolling subjects. [Note, subjects can only be enrolled using consent/assent forms which have a valid "IRB Approval" stamp unless special waiver has been obtained from the IRB.] Prior to the end of this period, you will be sent a Continuation Review Report Form which must be completed and returned to the Office of Research Integrity so that the protocol can be reviewed and approved for the next period.

In implementing the research activities, you are responsible for complying with IRB decisions, conditions and requirements. The research procedures should be implemented as approved in the IRB protocol. It is the principal investigator's responsibility to ensure any changes planned for the research are submitted for review and approval by the IRB prior to implementation. Protocol changes made without prior IRB approval to eliminate apparent hazards to the subject(s) should be reported in writing immediately to the IRB. Furthermore, discontinuing a study or completion of a study is considered a change in the protocol's status and therefore the IRB should be promptly notified in writing.

For information describing investigator responsibilities after IRB approval has been obtained, download and read the document "PI Guidance to Responsibilities, Qualifications, Records and Documentation of Human Subjects Research" from the Office of Research Integrity's Guidance/Policy Documents web page [<http://www.research.uky.edu/ori/human/guidance.htm#PIresp>]. Additional information regarding IRB review, federal regulations, and institutional policies may be found through ORI's web site [<http://www.research.uky.edu/ori/>]. If you have questions, need additional information, or would like a paper copy of the above mentioned document, contact the Office of Research Integrity at (859) 257-9428.

Edward Dischowitz, M.D.
Chairperson/Vice Chairperson

University Veterinarian, IRB, RDRC, IACUC
315 Kinkead Hall • Lexington, Kentucky 40506-0057
(859) 257-9428 • fax (859) 257-8995
www.research.uky.edu/ori
An Equal Opportunity University



Supplemental Figures – ELISA and PRNT Seroconversion.

Seroconversion rates determined by vaccinia-specific ELISA and PRNT. Data set is PPS (per protocol set), N = 451 (for Week 28 N = 170). Error bars represent upper and lower confidence intervals. Vaccinations were given at Week 0 and Week 4. AD = atopic dermatitis.

Supplemental Figures – Antibody Titers. Geometric mean titers determined by vaccinia-specific ELISA or PRNT. Data set is PPS (per protocol set), N = 451 (for Week 28 N = 170). Error bars represent upper and lower confidence intervals. Vaccinations were given at Week 0 and Week 4. AD = atopic dermatitis.